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Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder, second only to Alzheimer’s disease (AD). It is characterized by a 
progressive loss of dopaminergic neurons along the nigrostriatal axis and the 
formation of proteinaceous inclusions of alpha-synuclein (α-syn). Secondary to 
the loss of dopaminergic neurons is a progression in motor and non-motor 
symptoms. Motor symptoms are characterized by slowness in movement, 
stiffness and tremor.  Non-motor symptoms include depression, constipation, 
sleep abnormalities and loss of sense of smell. The cause of disease remains 
incompletely understood. However, age, genetics, environment, viral infection, 
and interplay between the innate and adaptive immune system can contribute to 
disease onset and progression. Currently, treatments are palliative, and no 
known intervention to halt disease progression exists. Drug therapies employ 
dopamine or a dopamine precursor that affect neurotransmitter signaling while 
showing no effect on the neurodegenerative process. Nonetheless, the available 
	  
therapies improve walking, movement and tremor debilities. Therefore, it remains 
essential that therapies are developed to combat PD itself rather than simply 
alleviating symptoms.  
Neuroinflammation and immunity can speed nigrostriatal degeneration in 
PD. The neuroinflammatory cascade begins with aggregation of misfolded or 
post-translationally modified alpha synuclein (α-syn) resulting in the occurrence 
of neuronal cell death and the presence of chronically activated glia. Such 
changes in the glial phenotypes can affect the central nervous system (CNS) 
microenvironment by producing pro-inflammatory factors that speed nigrostriatal 
degeneration.  
To halt or slow disease progression, a change in the microenvironment of 
the brain may be necessary. One potential mechanism to achieve this goal is 
through the induction and/or enhancement of immune-modulating cells such as 
regulatory T cells (Tregs). Tregs maintain immune homeostasis by suppressing 
pro-inflammatory immune responses, such as those associated with 
neuroinflammation and PD. Furthermore, Tregs taken from PD patients 
compared to control subjects lack the capacity to suppress proliferation of other 
immune cells, suggesting a dysfunctional Treg response associated with 
disease. Previously, our laboratory utilized granulocyte-macrophage colony- 
stimulating factor (GM-CSF) to restore Treg numbers and function in animal 
models and a clinical trial. This cytokine induced a neuroprotective phenotype 
when assessed in animal models; however, in the clinical setting, some mild to 
moderately severe adverse events were identified. Thus, it remains important to 
	  
identify different means for drug delivery or other compounds with Treg-inducing 
activity and without potential untoward side effects for easy translation to human 
use. 
With this goal in mind, our lab evaluated the efficacy of vasoactive 
intestinal peptide (VIP) analogs in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine	  (MPTP) mouse model of PD.  Our data indicate that treatment 
with a stable VIP analog results in a decrease in pro-inflammatory cytokine 
production, decrease in microglial reactivity, increase in neuron survival, and 
increase in suppressive immune phenotypes. Taken together, these findings 
support the use of VIP as a potential immunotherapy for the treatment of PD.  
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1.1 immunity and T cell subsets 
Innate and Adaptive Immunity 
Both innate and adaptive immune responses are important for mounting the 
body’s defense against a pathogen or foreign microorganism (Getz, 2005). The 
innate response is the first line of defense, which is relatively rapid, recognizes a 
broad spectrum of antigen patterns, does not require immune memory, and is 
characterized by phagocytic activity mediated by resident mononuclear 
phagocytes such as macrophages, dendritic cells (DC), and microglia (Turvey 
and Broide, 2010). The adaptive immune response requires substantially greater 
time to develop, produce and utilize immunological memory, and affords narrow 
specificity for antigens based on lymphoid receptors for antigen expressed by T 
cells and B cells (Dempsey et al., 2003). The main function of the adaptive 
immune system is to recognize and destroy foreign pathogens and relieve 
pathogen-associated toxicities. However, to initially mount an immune response, 
the innate arm of the immune system must first be activated by recognition via 
broadly-specific pattern recognition receptors (PRRs) which respond to 
microorganism-associated molecular patterns (MAMPs) or damage-associated 
molecular patterns (DAMPs) (Turvey and Broide, 2010). In an innate response, 
antigens recognized by PRRs of mononuclear phagocytes are engulfed, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Figures taken from: Olson KE, Gendelman HE. Immunomodulation as a neuroprotective and 
therapeutic strategy for Parkinson’s disease. Current opinion in pharmacology. 2016;26:87-95. 
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digested, and processed to bind with molecules of the major histocompatibility 
complex (MHC). Upon maturation, mononuclear phagocytes acquire an antigen 
presenting capability whereby processed and MHC-bound antigen is expressed 
on the cell surface in a configuration necessary for T cells to recognize via the T 
cell receptor (TCR). Unlike immunoglobulins (Ig) on B cells, which recognize 
cellular- or non-cellular-bound antigen, the TCR only recognizes antigen 
presented by MHC molecules on antigen presenting cells (APCs) (Cohn, 2017). 
APCs also express co-stimulatory molecules such as CD80, CD86, CD70, CD40, 
and CD200 that are necessary to generate an effective, robust, and specific 
immune response (Stephen et al., 2005). As APCs, mononuclear phagocytes 
bridge the innate and adaptive arms of the immune system by providing the 
antigen and co-stimulation necessary for naïve T cells to become activated. 
Additionally, APCs also deliver cytokine signals, undergo polarized 
differentiation, transforming them into activated T cells with specific effector 
functions, which will be described in the next section (Effector T cells) (Turvey 
and Broide, 2010). Once activated, T cells proliferate and undergo clonal 
expansion to increase their cell number and potential to challenge invading 
pathogens (Dempsey et al., 2003). One mechanism by which effector T cells 
expand in the presence of antigen is to secrete pro-growth cytokines to the 
surrounding environment. For instance, activated T cells produce and secrete IL-
2 cytokine that binds their own IL-2R to enhance proliferation in an autocrine 
fashion, as well as enhance proliferation of surrounding T cells in a paracrine 
fashion (Ozaki et al., 2000). In addition, to achieve an efficient effector function, 
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activated T cells migrate to areas of infection and inflammation to interact with 
other immune cells, such as macrophages or microglia, ultimately, bestowing 
collaborative effector functions to rid the host of a foreign assault (Campbell, 
2015). Thus, T cells are important for the general cellular-mediated response of 
the adaptive immune arm. 
 
Effector T cells 
T cells represent the arm of the adaptive immune system responsible for 
mounting a response against foreign pathogens. T cells are derived from bone 
marrow lymphocyte progenitors that mature and are immunologically educated 
within the thymus (Romagnani, 2000) From there, they migrate to the periphery 
and reside throughout the tissues of the body, but are located mainly in spleen, 
lymph nodes, and peripheral circulation (Romagnani, 1999). T cells, acting as 
effector cells, provide the stimulus and signals for directing the cellular and 
antibody responses necessary to clear foreign pathogens and antigens, but also, 
when acting as regulatory T cells (Tregs), endow immunological tolerance to the 
individual and actively restrain the immune system from recognizing itself as 
foreign (Corthay, 2009).  
Generally, T cells are characterized by expression of the TCR-CD3 
complex on the cell surface (Romagnani, 2000). While the TCR recognizes 
presented antigen, it does not possess the cytosolic machinery necessary for 
successful signal transduction. Therefore, the CD3 complex serves as the 
signaling mechanism that bridges the antigen recognition and conveyance of 
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signal for effector function (Dempsey et al., 2003). T cells are subdivided into two 
major lineages based on the expression of either CD4 or CD8 on the cell surface. 
CD4+ T cells are considered helper T (Th) cells. With the TCR recognizing the 
antigen, the CD4 molecule acts as a co-receptor and binds the MHC II molecule 
that presents the antigen from the APC (Getz, 2005). Depending on the 
cytokines generated by the APC, activated CD4+ T cells develop into specific 
effector T cell (Teff) subsets that include type-1, -2, -17, -22, or -9 Th cells 
designated as Th1, Th2, Th17, Th22, or Th9 cells, respectively (Romagnani, 
2000). Th subsets secrete a variety of cytokines that act as either pro- or anti-
inflammatory mediators.  
Classically, Th1 cells are important for mounting immune responses 
against intracellular pathogens and are characterized by secretion of 
predominately IFN-γ, TNF-α, and IL-2 (Romagnani, 2000). IFN-γ from Th1 cells 
enhances macrophage activation necessary for immunity to pathogens. In 
addition, Th1 cells produce IL-2 and IL-21 to promote and maintain antigen-
specific CD8+ cytotoxic T lymphocytes (CTLs) that lyse virally-infected cells 
(Hiroishi et al., 2010). CTLs are primarily responsible for ridding the host of 
intracellular pathogens and virus-infected cells, by recognizing antigen presented 
by MHC class I, which is expressed in all nucleated cells. When activated and 
expanded, CTL effectors produce perforins and granzymes to induce cell-
mediated cytolysis in infected cells (Fan and Zhang, 2005). On the other hand, 
Th2 cells preferentially assist antibody-mediated responses through the secretion 
of IL-4, IL-10, IL-13, and IL-5, which act on B cells for antibody production 
	   5	  
(Romagnani, 2000). Because the prototypical cytokines from Th1 and Th2 cells 
regulate the expression of each other’s master-controlling transcription factors, 
this preferentially selects T cells to differentiate into either Th1 or Th2 effector cell 
types in response to pathogens (Romagnani, 1999).  
Th17 cells are a more recently discovered subset of Teffs. They 
predominantly secrete IL-17, as well as TNF-α, and are thought to be important 
for protection against extracellular infections (Korn et al., 2009). In addition to the 
Th17 effectors, another subset expresses IL-9 and is thought also to be 
important in resolution of extracellular infections (Li and Rostami, 2010). The Th9 
subset has been implicated in promoting the migration of Th17 cells to the central 
nervous system (CNS) (Zhou et al., 2011) and potentiation of Th17 effectors via 
the ability to increase Th17-produced IL-17. Moreover, recent evidence indicates 
that other T cell types such as Tregs, Th1, and Th17 can also secrete IL-9 with 
pleiotropic effects that may ultimately alter the predominant proinflammatory 
response (Li and Rostami, 2010). Along the same lines, Th22 cells are a 
separate lineage of CD4+ Teffs that primarily secrete proinflammatory cytokines 
such as IL-22, IL-13 and TNF-α, and express the skin homing-associated 
chemokine receptors CCR4, CCR6 and CCR10 (Zhang et al., 2011). Th22 cells 
differentiate from naïve T cells in the presence of IL-6 and TNF-α under control of 
the transcription factors aryl hydrocarbon receptor and GATA3 (Azizi et al., 
2015). These Teffs are recruited to the skin and thought to be involved in 
microbial immunity and tissue repair and remodeling. Skin disorders such as 
psoriasis, eczema, and contact dermatitis may be due to dysregulation of Th22 
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migration or function.  
Each of these T cell subsets plays crucial, yet independent roles in 
mounting a robust and effective adaptive immune response. As these effector 
cells provide potent weapons toward immunity to foreign invaders, they also 
serve equally as potential liabilities due to increased pro-inflammatory cytokines, 
antibody-mediated cytotoxicity to cells, or hyperactivation of innate immune cells. 
Thus, regulation of the Teffs is necessary to prevent untoward pathological 
sequelae. CD4+CD25+ regulatory T cells (Tregs) provide that regulation, 
seemingly via expression and control of a master regulatory transcription factor, 
forkhead box 3 (FoxP3). 
 
Regulatory T cells 
Tregs are a subset of T cells that regulate and suppress the activities of Teffs 
and myeloid lineage cells such as DCs, microglia, and macrophages that 
comprise innate immunity. Tregs can be further subdivided into natural Tregs 
(nTregs) that are derived from the thymus and induced Tregs (iTregs) that arise 
from naïve T cells in the periphery (Corthay, 2009). Moreover, a primary function 
of Tregs is the maintenance of immunological tolerance to self and thus, 
inhibition of initial autoimmune responses and suppression of auto-reactive T 
cells that may arise in peripheral tissues. As such, individuals that do not produce 
functional nTregs due to mutated FOXP3, develop immunodysregulation 
polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a systemic, multi-
organ autoimmune disorder (Wildin et al., 2002). 
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Treg-mediated regulatory functions are achieved at many levels. First, 
Tregs inhibit initiation of immune responses by diminishing antigen processing 
and antigen presentation by MHC molecules as well as regulating 2nd and 3rd 
signals from APCs (Sakaguchi et al., 2008). This is achieved through interaction 
with cytotoxic T-lymphocyte-associated protein 4 (CTLA4) on the Treg cell 
surface and CD80 or CD86 on the APC cell surface. This interaction acts as an 
“off” switch for the APC. Second, Tregs secrete anti-inflammatory cytokines such 
as IL-10, IL-35, and TGF-β that suppress activated mononuclear phagocytes and 
Teffs (Dasgupta and Saxena, 2012). Third, Tregs have the capacity to elicit 
metabolic disruption in effector cell types through cytokine deprivation or cell-
mediated apoptosis. To maintain this function, Tregs express CD39 and the IL-
2R, also known as CD25. CD39 is an ATPase, which phosphohydrolyzes 
ADP/ATP to AMP, and CD25 binds extracellular IL-2 (Antonioli et al., 2013). 
Upregulation of these receptors results in a decrease in surrounding IL-2, a 
cytokine needed for cellular proliferation, and a decrease in available ATP, which 
is needed for cellular energy.  Finally, Tregs also possess the ability to mediate 
cytolysis through the secretion of granzymes and perforins, ultimately leading to 
apoptosis of the target cell (Dasgupta and Saxena, 2012). However, unlike the 
Th2 subset, which also elicits anti-inflammatory and protective effects, Tregs do 
not traditionally interact with B cells to elicit a response. Therefore, Tregs 
generally regulate the immune response independently rather than via the 
activation of other cell types.  
The interplay between the innate and adaptive arms of the immune 
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system is essential to the relationship between neuroinflammation, 
neuroprotection, and neurodegeneration. While neuroinflammation and 
neurodegeneration are associated with the pathobiology of neurodegenerative 
diseases, they are also responsible for the overall neuroprotective homeostasis 
of the host CNS in infectious disease surveillance. Similarities between multiple 
neurological disorders have provided common mechanisms of immune 
interactions that lead to protective or destructive effects within the CNS and 
peripheral nervous system (PNS). Although neuroinflammation and T cell 
interactions play a prominent role in disease progression, it should be noted that 
the immune response can vary from a very prominent primary T cell response, as 
in multiple sclerosis (MS), to seemingly less intense T cell responses as in the 
cases of amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) (Town et al., 2005, Holmoy, 2008, Fletcher et al., 2010, 
Mosley and Gendelman, 2017). Recent findings in human neurodegenerative 
disorders, specifically in PD and in corresponding animal models, have shown 
the involvement and putative mechanisms of T cells and subsequent secondary 
responses in disease initiation and progression, which will be discussed in the 
following section. 
 
1.2 Parkinson’s disease and neuroinflammation 
Clinical features, diagnosis, and treatment  
PD is the second most common neurodegenerative disorder, but it is the most 
prevalent neurodegenerative movement disorder (Kalia and Lang, 2015). The 
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first clinical description of PD was originally described as a “shaking palsy” by 
James Parkinson in 1817 (Donaldson, 2015). It is a neurological disease that is 
characterized by two disease hallmarks, the progressive loss of dopaminergic 
neurons that originate within the substantia nigra (SN) and innervate into the 
striatum and the presence of proteinaceous inclusions called Lewy bodies (LB) 
and Lewy neurites (LN). LB and LN are intracellular inclusions consisting of 
modified and misfolded α-syn accompanied by ubiquitin (Carrithers et al., 2000, 
Scanlon et al., 2008).  Dopaminergic neurons are the main producers of 
dopamine, the key neurotransmitter needed for proper movement. Thus, the loss 
of this neuron population causes the majority of the motor symptoms associated 
with PD (Maiti et al., 2017).  
The classical motor symptoms of PD are recognized as prominent 
features for disease diagnosis, but only appear after ~50-60% neuronal loss 
(Olanow et al., 2009). These motor symptoms include bradykinesia, rigidity, 
resting tremor, postural instability, and gait dysfunctions. However, the severity 
and degree of these motor features remains heterogeneous within the diseased 
population. Apart from prevalent motor dysfunction, patients with PD display 
many non-motor symptoms as well including olfactory deficits, sleep 
disturbances, cognitive impairments, pain, fatigue, constipation, and some 
psychiatric disorders (Titova et al., 2017). Frequently, these non-motor features 
arise well before the onset of motor dysfunction, indicating that the pathogenic 
cause of the disease occurs years prior to noticeable disease onset. One 
hypothesis for the onset of non-motor dysfunctions prior to motor dysfunction lies 
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with Braak and colleagues (Rietdijk et al., 2017). They hypothesize that 
symptoms start in the periphery before entering the CNS via a nasal or gastric 
route, eventually contributing to neuronal loss. Thus, continued evaluation of 
biomarkers for early diagnosis remains essential for combating the disease. To 
date, a variety of biomarkers are being evaluated using clinical, pathological, 
biochemical, genetic, and bioimaging techniques (Kalia and Lang, 2015). These 
include, but are not limited to, detection of olfactory impairments, neuronal 
imaging using PET/SPECT, skin biopsies, changes in biochemical makeup of the 
CSF, saliva, or blood, and genetic sequencing.  
Without easily defined and detectable diagnostics, clinicians focus on 
treating patients after diagnosis based on motor symptoms. Initially, motor 
dysfunctions are managed symptomatically. Currently, the readily available 
therapies for PD are palliative; however, there is no known cure or intervention to 
slow or halt disease progression (Olanow et al., 2009). In general, drug therapies 
employ dopamine agonists or the dopamine precursor, L-DOPA, to assist with 
normal dopaminergic neurotransmission (Kalia and Lang, 2015). A second 
therapeutic avenue is through deep brain stimulation (DBS), a surgical approach 
aimed at stimulating either the subthalamic nucleus or globus pallidus internus to 
counteract the motor disturbances (Follett and Torres-Russotto, 2012, Hamani et 
al., 2017). However, each of these therapies only targets the symptoms and 
shows no effect on the progressive nature of the disease. Also, as the disease 
progresses, it is not as easily managed, and is characterized by the worsening of 
motor disturbances, resulting in freezing, falls, dysphagia, and slurred speech 
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(Kalia and Lang, 2015). Thus, it remains essential that therapies are developed 
for combating PD progression rather than simply alleviating symptoms. 
These disease hallmarks and symptoms can present themselves in both 
sporadic and familial cases of PD. Familial PD is genetically-linked and accounts 
for approximately 10% of all PD cases. Likewise, several genes have been 
identified in patients with a family history of disease, including SNCA, LRRK2, 
PINK1, DJ-1, and Parkin (Olanow et al., 2009). Apart from genetics, other risk 
factors include increased age, male gender, Hispanic ethnicity, and exposure to 
environmental toxins (Kalia and Lang, 2015). In accordance with known genetic 
links and risk factors, both sporadic and familial cases are linked to dysfunctions 
in common cellular networks. These include dysregulation of protein 
homeostasis, such as abnormalities in protein aggregation, intracellular protein 
trafficking, and ubiquitin-based protein disposal, and dysfunctional mitochondrial 
processes (Good et al., 1998, Moon and Paek, 2015).  
The importance of the mitochondrial function for parkinsonism was verified 
by Dr. Langston in “The Case of the Frozen Addicts (Langston et al., 1983).”  
Men and women had ingested heroin containing an impurity called 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). After ingestion, they suddenly became 
immobile, as if they had instantly acquired PD.  Some continued to experience 
effects years after the fact (Langston et al., 1999). It was discovered that the 
impurity resulted in motor dysfunction and is now utilized as a model for inducing 
PD-like symptoms and hallmarks in rodent and primate models (Przedborski et 
al., 2001). When MPTP is administered peripherally, it rapidly crosses the blood-
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brain barrier (BBB) where it is metabolized into its toxic form, MPP+. This toxin 
accumulates within dopaminergic neurons via uptake by the dopamine 
transporter (DAT), due to the similar structure to dopamine itself.  Once inside 
the neuron, MPP+ inhibits complex I of the electron transport chain within the 
mitochondria, ultimately inhibiting ATP production and generating the formation 
of superoxide radicals. Superoxide radicals react with nitric oxide (NO) and 
produce peroxynitrite, causing cellular damage. In turn, tyrosine hydroxylase 
(TH), the rate-limiting enzyme for dopamine production, is oxidized and nitrated 
causing it to become inactive. This inactivation leads to decreased dopamine 
production, resulting in Parkinson-like motor symptoms (Przedborski et al., 
2000).  
However, even with the known risk factors and known associations with 
cellular dysfunction, the underlying driving force behind the progression of PD is 
still unknown. It is hypothesized that the overall cause and pathogenesis of 
disease is multi-factorial and results in an elaborate interplay between multiple 
insults. For instance, genetics, environment, age and interplay between innate 
and adaptive immune systems contribute to disease onset and progression. 
Recently, neuroinflammation and immune dysfunction have been shown to be a 
characteristic feature of PD, but whether or not neuroinflammation is a cause or 
effect of the disease is not yet known. However, while the pathobiology of PD 
remains in study, neuroinflammation and immunity are thought to speed 
nigrostriatal degeneration (Mosley et al., 2012, Anderson et al., 2014). The 
neuroinflammatory cascade associated with PD begins with the aggregation of 
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misfolded or post-translationally modified α-syn. Such aggregation results in 
neuronal cell death and the presence of chronically activated microglia and 
astrocytes, leading to the production of tumor necrosis factor alpha (TNFα), 
interleukin-1 beta (IL-1β), IL-6, reactive oxygen species (ROS), and enzymes 
such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Liu and 
Hong, 2003). These changes in the microglial phenotype can affect the CNS 
microenvironment by producing a pro-inflammatory milieu that speeds PD 
pathogenesis (Figure 1). Compelling evidence in both animal and human studies 
helps to support the idea of an overactive inflammatory state and lack of immune 
regulation within the PD population.  
 
Disease-associated immune dysfunction  
Initial studies of peripheral lymphocyte populations from PD patients show 
decreased frequencies and total numbers of CD4+ T lymphocytes compared to 
controls (Bas et al., 2001, Baba et al., 2005, Saunders et al., 2012, Stevens et 
al., 2012). However, due to conflicting reports on T cell phenotypes, a firm 
consensus of other T cell subset changes in PD patients has proven difficult. For 
instance, the diminution of CD4+ T cell numbers in PD patients was found chiefly 
from decreased numbers of CD4+CD45RA+  naïve T cells and to a lesser extent 
from CD4+CD29+ memory subsets (Saunders et al., 2012). On the other hand, 
Stevens and colleagues reported decreased levels of CD4+CD45R0+  memory T 
cells (Stevens et al., 2012). A recent study by Saunders and colleagues showed 
slight, yet significant increases in frequencies of CD4+CD45R0+ memory/effector 
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T cells with a parallel diminution of CD4+CD45RA+  resting/naïve T cell levels 
(Saunders et al., 2012). Additionally, frequencies of peripheral CD4+ T cells with 
effector-associated phenotypes expressing FAS were increased in patients, 
whereas those expressing α4β7 integrins and CD31 were diminished. Notably, 
these changes in CD4+ T cell phenotypes were correlated with severity of motor 
function as quantified by the Unified Parkinson’s Disease Rating Scale, part III 
(UPDRS III) (Saunders et al., 2012). Differences in modulation of T cell 
immunology profiles may be the consequence of disease heterogeneity and 
severity, but clearly require further investigation. 
Post-mortem studies of PD patient brain tissues show both CD4+ and 
CD8+ T cells in close proximity to dopaminergic neurons within the SN at levels 
exceeding 10-fold those found in controls (Brochard et al., 2009). Moreover, 
these levels of T cells were not detected in non-lesioned brain regions. 
Microarray analysis of peripheral blood leukocytes and SN brain tissue showed 
many genes expressed were in common with those expressed by Th17-mediated 
immune reactions and suggest that idiopathic parkinsonism is a Th17 dominant 
autoimmune disease (Qian et al., 2010). However, whether T cell infiltration is 
primary or secondary to PD progression is unknown at this time. Similarly, 
conflicting reports of Tregs in PD also produced variances in levels detected 
ranging from increased frequencies in PD patients to little or no differences 
among groups (Fiszer et al., 1994a, Baba et al., 2005, Saunders et al., 2012, 
Stevens et al., 2012). However, one study demonstrated the diminished capacity 
of Tregs from PD patients compared to those of controls to inhibit the 
	   15	  
proliferation of responder T cells from healthy donors (Saunders et al., 2012). 
This suggests that a dysfunction in Tregs leads to a hyper-activated immune 
state and increased disease progression. The notion that hyper-activated 
immune responses support increased dopaminergic loss is provided by use of 
animal studies.  
Multiple studies in animal models demonstrate the involvement of the 
adaptive immune system in dopaminergic neurodegeneration using both active 
and passive transfer of immunity (Kurkowska-Jastrzebska et al., 1999b, Brochard 
et al., 2009, Kosloski et al., 2013). In the MPTP mouse model, numbers of T cells 
in the SN are increased after intoxication, and interestingly, numbers of CD8+ T 
cells predominate those of CD4+ T cells (Brochard et al., 2009). While in 
agreement of the relative proportions of T cell subsets within the SN of MPTP-
treated mice, the total numbers of CD4+ T cells vary widely between studies. The 
importance of T cells for mediating MPTP-induced neurodegeneration was found 
initially in adoptive transfer and reconstitution studies of functional T cells to 
immunodeficient mice (Benner et al., 2008, Brochard et al., 2009). While both 
studies confirm that immune deficient mice were not susceptible to MPTP 
intoxication, reconstitution of those mice with functional naïve lymphocytes partly 
restored MPTP susceptibility (Benner et al., 2008) and CD4+ T cells were found 
to be chiefly responsible for MPTP susceptibility (Brochard et al., 2009). These 
studies point to a deleterious role of CD4+ T cells in PD. The phenotypes of 
CD4+ populations required for increased degeneration were determined to be 
Th1 and Th17 cell lineages. Similarly, T cells isolated from mice immunized with 
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a modified self-antigen, nitrated α-synuclein (N-α-syn) recognized only N-α-syn, 
but not unmodified α-syn in in vitro challenge assays. Moreover, N-α-syn specific 
Teffs exacerbated neuroinflammation and increased neuronal injury and 
subsequent neurodegeneration of dopaminergic neurons within the SN of MPTP 
mice (Benner et al., 2008). These findings indicate that N-α-syn, a modified self-
protein, either evades or breaks immunological tolerance to self α-syn and 
induces N-α-syn specific T cells. Likewise, another second study showed that 
Th17 Teffs possess a significantly greater capacity to exacerbate dopaminergic 
neurodegeneration than the same number of Th1 Teffs (Reynolds et al., 2010). 
Together, these data indicate that CD4+ T cells play an important role in the 
neuroinflammation and subsequent neurodegeneration in models of PD. It also 
indicates that Th17 Teffs are more potent at direct killing of neurons or 
alternatively, enhancing neurotoxic microglia than Th1 Teffs. These data also 
support the idea that increased peripherally circulating Teffs, as found in PD 
patients, are capable of migrating to the sites of neuroinflammation and can 
exacerbate and accelerate PD disease progression. 
Activated microglia and Teffs are thought to be key mediators of 
neuroinflammatory processes in PD progression. If left uncontrolled, these 
mediators support an inflammatory cascade that affects the tempo of the disease 
(Reynolds et al., 2007a). Initially, studies directed to harness the inflammatory 
cascade using an anti-inflammatory agent demonstrated that adoptive transfer of 
CD4+ T cells from copolymer-1 (Cop-1) immunized donor mice protected 
dopaminergic neurons and striatal termini in MPTP-treated mice (Laurie et al., 
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2007). These observations supported the hypothesis that subpopulations of T 
cells potentiate neurodegeneration in the MPTP animal model of PD. These 
findings are consistent with known mechanisms by which Cop-1 regulates 
proliferative and inflammatory responses by preferentially inducing Th2, Th3, and 
Tregs that secrete anti-inflammatory cytokines (Benner et al., 2004, Laurie et al., 
2007, Reynolds et al., 2007b, Lalive et al., 2011). In a separate line of study, 
researchers found that CD4+CD25+ Tregs were most capable of suppressing 
neuroinflammation and neurodegeneration in the MPTP model with as few as 3.5 
× 106 Tregs being sufficient to provide virtually complete neuroprotection to 
dopaminergic neurons along the nigrostriatal axis (Reynolds et al., 2007b). 
Moreover, the degree of protection afforded by Tregs seems to increase with 
increasing inflammatory responses as evidenced by increased neuroprotection 
with Treg co-transfer with N-α-syn specific Th17 cells in the MPTP model 
(Reynolds et al., 2010). Also, use of VIP, a known inducer of Treg activity 
(Gonzalez-Rey and Delgado, 2007), increased the neuroprotective capability of 
Tregs from VIP-treated donors in the MPTP model (Reynolds et al., 2010). Along 
those same lines, studies using GM-CSF showed that pretreatment with GM-
CSF prior to MPTP-intoxication increased Treg activity in a dose-dependent 
fashion and diminished the neuroinflammatory response, affording significant 
dopaminergic neuroprotection (Kosloski et al., 2013). Based on these findings, 
our lab carried out an investigator-initiated phase I clinical trial to target the 
dysregulated Treg population in PD using sargramostim, also known as GM-
CSF. In theory, treatment would upregulate Treg numbers and function to 
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suppress the neuroinflammatory cascade in the PD population, with the hopes 
that treatment would afford a neuroprotective outcome to inhibit or slow disease 
progression (Gendelman et al., 2017). Prolonged treatment with GM-CSF in PD 
patients resulted in decreased motor severity, as determined by the UPDRS III, 
and these changes were linked to increases in Treg function. Treatment was also 
associated with increased adverse events, such as injection site reactions, 
eosinophilia, increased white cell counts, bone pain, urticarial reaction, vasculitis, 
and stroke. However, some of these adverse events are known to be associated 
with the drug due to its ability to rapidly reconstitute all parts of the immune 
system (Vial and Descotes, 1995a). Thus, we now aim to utilize an analog of 
another potent immune modulator, VIP, in the hopes that it would result in a 
neuroprotective phenotype with a lower likelihood of the development of 
untoward side effects.  
 
Influence of viral infection on Parkinson’s disease  
Apart from neuroinflammation and immune dysfunction, there has also been a 
potential association between viral infection and PD. Besides the overlapping 
symptomology and generation of movement disorders, a number of viruses have 
already been associated with parkinsonism development. These include, but are 
not limited to, influenza viruses, herpes simplex viruses, Epstein-barr virus, 
cytomegalovirus, polio virus, human immunodeficiency virus (HIV), West Nile 
virus, and Japanese encephalitis B virus (Jang et al., 2009). Findings suggest 
that viruses, such as these, possess neurotropism, have the ability to enter the 
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brain, cause cell death, and elevate pro-inflammatory cytokine production 
responses, resulting in a neurodegenerative response (Karim et al., 2014).  
 These findings help support the idea that viral infection could participate in 
the development of neurologic disease such as PD. However, other studies have 
generated opposing findings, suggesting that some viral infections such as 
hepatitis or HIV show no significant associations with development of PD (Boyd 
et al., 2016, Pakpoor et al., 2017).  Thus, past epidemiologic studies have 
yielded conflicting reports, and there is a lack of experimental findings utilizing 
animal models to determine the resulting effects of viral infection on neurologic 
deficits and degeneration. Therefore, amidst testing immunotherapies in PD 
models, we also aim to identify a potential relationship between viral infection 
and a Parkinson-like state.  
 
1.3 Current Immunotherapies in Parkinson’s Disease 
While immunosuppression is associated with nigrostriatal neuroprotection for PD, 
the direct cause and effect relationships have not yet been realized. Thus, 
modulating the immune system for therapeutic gain has been openly debated. 
Currently, researchers are revealing how innate and adaptive immunity can affect 
neurodegenerative disease pathology, and similarly, how the immune response 
can be harnessed for successful treatments. The overarching idea is to employ 
immune modulating agents as a neuroprotective strategy for disease treatment. 
To date, many disease-modifying treatments have been or are currently being 
developed as neuroprotective strategies for PD in both experimental animal 
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models and for human disease translation, as discussed below. Overall, the long-
term goal of this research is to effectively harness the immune system to slow or 
prevent PD pathobiology.  
Upon observational evaluation of large cohorts of individuals, those who 
use non-steroidal anti-inflammatory drugs (NSAIDs), specifically ibuprofen, 
exhibit a lower risk of developing PD, and treatment with NSAIDs is protective in 
both 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP) and 6-
hydroxydopamine (6-OHDA)- induced neuronal lesions (Rees et al., 2011). 
Ultimately, this suggests that there is an association with anti-inflammatory use 
and a decrease in the potential of developing PD. One of the first anti-
inflammatory treatments to be investigated was minocycline. Minocycline 
possesses potent neuroprotective and anti-inflammatory activity in various 
inflammatory rodent models of PD, and has been carried into clinical trials as 
well. Its mechanisms of action are mediated by blocking activation of NADPH 
oxidase, decreasing microglial activation, and decreasing the production of iNOS, 
IL-1β, and TNFα (Du et al., 2001, He et al., 2001, Tikka et al., 2001, Kim and 
Suh, 2009, Lu et al., 2010). In both the MPTP and 6-OHDA models, minocycline 
reduced the numbers of reactive microglia and spared nigral dopaminergic 
neurons along with their projections into the striatum in a dose-dependent 
manner. However, in the clinical setting, neuroimaging analysis of PD patients 
following minocycline treatment suggests that microglial activation is perturbed, 
but motor assessments failed to show any clinical benefit (2006, 2008, Dodel et 
al., 2010). In conclusion, anti-inflammatory agents, while having been extensively 
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studied, have failed to provide improved clinical outcomes.  
Many natural and/or endogenous compounds have recently been shown 
to be effective in rodent models of PD as well, such as resveratrol (Lin et al., 
2014), tanshinone (Ren et al., 2015), silymarin (Borah et al., 2013), resolvins 
(Tian et al., 2015), daidzein (Chinta et al., 2013), and apocynin derivatives (t Hart 
et al., 2014). The majority of these compounds act as both anti-inflammatory 
agents and anti-oxidants. Collectively, they mediate their actions by down-
regulating glial activation, decreasing pro-inflammatory cytokine production, 
suppressing M1 microglial phenotypes, and reducing NF-κB activation. 
Specifically, resveratrol and tanshinone treatment both show decreases in IL-1β, 
IL-6, and TNFα (Zhang et al., 2010, Lofrumento et al., 2014, Wang et al., 2015). 
Also, resveratrol causes an upregulation of suppressor of cytokine signaling 
(SOCS-1), and tanshinone treatment inhibited nitric oxide (NO) production, as 
well as NADPH and iNOS expression. In the MPTP model, silymarin treatment 
stabilizes mitochondrial membrane potential, decreases levels of TNFα, iNOS, 
and IL-1β, and ultimately, decreases striatal levels of caspase-3 and NF-κB 
indicating an anti-apoptotic and anti-inflammatory function (Geed et al., 2014, 
Jung et al., 2014, Lee et al., 2015). Taken together, these findings help to justify 
the potential beneficial use of natural anti-inflammatory agents for the treatment 
of PD. However, these agents have yet to be translated into clinical investigation 
for efficacy in PD patients. 
To date, there have also been many recent investigations into the role of 
peroxisome proliferator-activated receptor (PPAR) agonists and their 
	   22	  
neuroprotective mechanisms within the CNS. PPAR is a receptor super family of 
transcription factors that is activated by small molecules such as hormones and 
steroids, and its activation plays an important role in mediating the inflammatory 
response. PPAR agonists, such as pioglitazone and rosiglitazone, are shown to 
possess neuroprotective and anti-inflammatory activity both in vitro and in vivo by 
selectively targeting neurotoxic factors within reactive microglia (Carta and 
Pisanu, 2013, Pisanu et al., 2014). Their use in the MPTP model of PD led to 
decreases in microglial activation, iNOS production, NF-κB activation, and ROS 
production (Garrido-Gil et al., 2012, Pisanu et al., 2014). Along with a decrease 
in pro-inflammatory mediators, it is associated with increases in anti-inflammatory 
mediators such as IL-10 and transforming growth factor-β (TGF-β), as well as 
restored levels of CD206, a marker for anti-inflammatory M2 microglial responses 
(Pisanu et al., 2014). These findings suggest a shift from a pro-inflammatory 
response to an anti-inflammatory one, perhaps resulting in a more protective and 
neurotrophic environment. To further confirm neuroprotective effects and the 
ability to modulate the inflammatory response, pioglitazone was tested in 
parkinsonian monkeys. Oral administration led to higher stereological counts of 
tyrosine hydroxylase-positive neurons and modulated CD68+ inflammatory cells 
in a dose-dependent manner (Swanson et al., 2011). To this end, these findings 
prompted translation of PPAR agonists, specifically pioglitazone, into a multi-
center, double-blind phase 2 clinical trial (2015). This trial also attempted to find 
peripheral biomarkers for PD that included leukocyte PGC-1α, IL-6, and urine 8-
hydroxydeoxyguanosine (Simon et al., 2015). There were no changes in 
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peripheral biomarkers observed. Additionally, the agonist failed to show benefit 
as indicated by UPDRS III scores.  
Explanations for why PPAR agonists failed in human PD studies likely 
reflect the fact that the neurotoxin-inducing neuroinflammatory models 
incompletely reflect human disease. In addition, multiple inflammatory response 
targets are likely needed, along with secondary drug-induced neuroprotective 
activities. The UPDRS III scores may show other limitations. Indeed, there is the 
potential that using motor tests as an singular end point may not preclude other 
disease events that could be influenced by PD-modifying treatments. The span of 
time for the assessment was also relatively short. This would not allow evaluation 
as to whether the treatment had long-term beneficial effects. Potentially, the anti-
inflammatory activities of PPAR agonists may slow the rate of progression in the 
long term. However, the lack of observed efficacy in treating motor dysfunction 
should prompt researchers to continue to explore other therapeutic alternatives.  
Due to the lack of clinical efficacy using anti-inflammatory agents, potential 
therapies aimed at directly modulating immune aberrancies are actively being 
studied and investigated in the clinical setting. Currently, two main therapeutic 
avenues are being explored and have shown promise in both rodent models of 
disease and PD itself. These two methods are based on the specific targeting of 
aberrantly misfolded proteins and peripheral immune modulation to elicit immune 
transformation into a protective phenotype.  
The therapeutic strategy of targeting alpha-synuclein is aimed at 
ameliorating PD-associated neuroinflammation and disease progression via 
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targeting misfolded α-syn. In recent years, it has been shown that toxic versions 
of α-syn can accumulate within neurons and be secreted into the extracellular 
environment where the misfolded, oligomeric protein can cause a neurotoxic, 
inflammatory immune response (Benner et al., 2008). Thus, immunotherapeutic 
approaches are being developed to target and enhance clearing of misfolded or 
post-translationally modified α-syn. There is potential benefit in targeting both the 
N-terminal and/or C-terminal region of the protein. A recent study using an AAV-
α-syn rat model of PD indicates that anti-human α-syn N-terminal peptide 
antibodies can protect against dopaminergic neuron loss and decrease microglial 
activation to some extent (Shahaduzzaman et al., 2015). Treatment with the 
vaccine also lead to altered IgG production, enhanced MHCII expression, and 
increased CD4+ T cell infiltration into the CNS. Recently, it has also been shown 
that use of monoclonal antibodies against the C-terminal region of α-syn or 
misfolded α-syn reduces levels of protein propagation and improves PD-like 
pathologies, ameliorates dopaminergic neuronal cell loss, and attenuates motor 
deficits in mouse models of the disease (Fagerqvist et al., 2013, Games et al., 
2014, Lindstrom et al., 2014, Tran et al., 2014). Based on these findings, in 2013, 
Roche and Prothena further developed and commercialized PRX002 to 
specifically target α-syn.  A phase I clinical trial was initiated with the finding that 
the vaccine was safe and well-tolerated, prompting a second phase I trial to 
assess dose response, tolerability, pharmacokinetics, exploratory biomarkers, 
and immunogenicity (NCT02095171 and NCT02157714).  
With a similar directive in mind, a current study using a vaccine against α-
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syn demonstrated that vaccination prevented Parkinson-like inclusions, as well 
as increased Treg recruitment, increased glial cell-derived neurotrophic factor 
(GDNF) production, and increased antibody formation (Sanchez-Guajardo et al., 
2013). Excitingly, another vaccine that has been developed to produce 
antibodies that are specific for α-syn while sparing neuroprotective beta-
synuclein, AFFITOPE PD01A, has entered clinical trials (Schneeberger et al., 
2012, Mandler et al., 2014).  PD01 targets the phosphorylated form of α-syn that 
is responsible for induction of a neurotoxic proinflammatory cascade through 
microglial activation. The first phase is completed and has indicated that the 
vaccine is safe and tolerable in two doses, 15 and 75 µg (NCT01568099). Half of 
the patients developed α-syn antibodies suggesting that the vaccine is effective 
as well. However, further investigations are underway to test PDO1A’s clinical 
benefit in PD, as well as other parkinsonian-associated diseases (Mandler et al., 
2015) (NCT02216188 and NCT02270489).  
Collectively, these studies show that α-syn-targeted immunotherapies may 
have the potential to attenuate neuroinflammatory-associated neurotoxicities and 
as such, delay dopaminergic neurodegeneration associated with PD. 
Alternatively, targeting α-syn may have some potential pitfalls. Vaccination and 
antibody-mediated therapies are associated with antigen-specific T cell 
responses that may contribute to an inflammatory state operative during PD. This 
concern was realized in studies of immunotherapies for AD. Here, extensive T 
cell reactivity and an autoimmune meningoencephalitis followed immune-
stimulating strategies for amyloid beta (Aβ) clearance (Orgogozo et al., 2003). 
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This, coupled with the presence of intracellular misfolded proteins, makes it 
imperative to generate vaccination designs that are long-lasting and highly 
specific for α-syn. The robustness of the immune response generated needs to 
be evaluated together with any potential cross-reactivity of common 
nonpathogenic forms of α-syn or members of its protein families.  
 Lastly, since there has been little success in anti-inflammatory therapy 
translation into the clinic, therapeutic strategies aimed at modulating the aberrant 
immune response during disease progression may be more appropriate. The 
majority of immunotherapies are designed to protect the host from something 
foreign; however, in neurodegenerative diseases, the target is a self-protein, 
making the type and duration of the peripheral immune response elicited 
extremely important. In the acute MPTP model of PD, nitrated α-syn enhances 
the neurotoxic element of microglia activation, ultimately leading to neuronal cell 
loss (Reynolds et al., 2008). In PD, our data supports that with inflammation and 
chronic immune stimulation in the brain, there is an increase in effector and 
memory T cell populations that can secrete pro-inflammatory and neurotoxic 
cytokines (Mosley et al., 2012, Anderson et al., 2014). This can drive microglial 
reactivity, producing even greater levels of pro-inflammatory mediators (Figure 
1). Thus, inhibiting Teff subsets, along with microglial activation may be of clinical 
benefit (Benner et al., 2004). One such strategy utilizes the immune suppressing 
capabilities of Tregs to target neuroinflammation (Figure 2). In the MPTP mouse 
model, our lab has shown that Tregs can attenuate microgliosis, protect against 
dopaminergic neuronal death, and spare striatal termini (Kosloski et al., 2013)(. 
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Tregs can elicit a down-regulation of pro-inflammatory mediators such as iNOS, 
TNFα, IL-1β, and IFN-γ, as well as decrease levels of ROS production and NF-
κB activation (Lan et al., 2012, Lowther and Hafler, 2012). Through these 
mechanisms, they may also have the ability to mediate their protective actions by 
switching microglial responses from a neurotoxic M1 response to a neurotrophic 
M2 response (Reynolds et al., 2007b). However, it should be noted that even 
resting microglia can exist in a spectrum of phenotypic states rather than solely 
existing in an M1 and M2 condition that are exclusively pro- or anti-inflammatory 
(Cherry et al., 2014). Rather, microglia may simply be shifted into a more or less 
anti-inflammatory state. Nonetheless, these findings indicate a phenotypic 
transition during Teff or Treg interactions with microglia or peripheral monocyte-
macrophages. Furthermore, as discussed previously, Tregs can act directly on 
activated Teff populations and antigen presenting cells by cytolysis, metabolic 
disruption, inhibiting maturation, and/or secreting suppressive cytokines 
(Dasgupta and Saxena, 2012). However, in the overall PD population, there is a 
Treg deficit and an increase in Teff populations that are associated with 
increased movement dysfunction and disease severity (Saunders et al., 2012), 
indicating a need for a therapy that may induce or enhance Treg functions. One 
appropriate therapeutic avenue would be to enhance Treg numbers or function 
through the use of potent immune modulating agents such as VIP, pituitary 
adenylate cyclase-activating polypeptide (PACAP), and GM-CSF, or through the 
use of vaccine strategies that induce Treg populations. Notably, the use of 
PACAP, VIP, GM-CSF, and a Bacillus Calmette-Guerin vaccination have shown 
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promising results in PD models. Such therapeutic interventions have also shown 
effectiveness in the treatments of other chronic inflammatory conditions and as 
such, support their ability to restore immune homeostasis and repair tissue 
injuries (Schabitz et al., 2008, Reynolds et al., 2010, Delgado and Ganea, 2013, 
Kosloski et al., 2013, Lacan et al., 2013, Waschek, 2013, Shivers et al., 2014, 
Fraccaroli et al., 2015, Kelso et al., 2015).  
For instance, adoptive transfer of VIP- or GM-CSF-induced Tregs 
following MPTP intoxication leads to enhanced neuronal survival of nearly 100%, 
and a decrease in microglia activation (Reynolds et al., 2010, Kosloski et al., 
2013). The potential use of this therapeutic strategy, along with clearance of 
aberrant protein, could possibly lead to induction of Tregs that will induce a 
phenotypic shift in effector subsets and microglia, ultimately ameliorating 
disease. Although, there remains the possibility that the neuroinflammatory 
response that is occurring with progressed PD will not be ameliorated simply 
through the induction of Tregs. Tregs may not have the ability to suppress the 
detrimental immune response to a point in which protection is observed. 
However, pre-clinical studies have already shown potential promise and the 
ability of effector to regulatory cell transformation.  Thus, here, we report the 
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Figure 1. Neuroinflammation in Parkinson’s disease. The pathogenesis of PD is 
affected by modified α-syn released extracellularly when dopaminergic neurons 
become damaged or die. The modified aggregated protein elicits microglial 
immune responses leading to a neurotoxic cascade within the substantia nigra 
pars compacta. Reactive microglia secrete neurotoxic factors that include 
proinflammatory mediators further accelerating neuronal cell death. Drainage of 
modified α-syn across the blood-brain barrier and into secondary lymphoid 
tissues causes an aberrant activation of the adaptive immune system. In 
response to α-syn, infiltrating effector T cells exacerbate neurodegeneration by 
contributing to the inflammatory neurotoxic cascade through the secretion of 
factors that include TNF-α and IFN-γ. 
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Figure 2. Modulating the neuroinflammatory response. The use of agents that 
induce Treg promote neurotrophic support and ultimately, neuronal cell survival 
by suppressing effector T cell activation, proliferation, secretion of neurotoxic 
mediators, and infiltration into the brain. These events modulate microglial 
reactivity by secreting immune suppressive factors such as IL-10, IL-4, and FASL 
(Fas ligand).  The immune events temper neurotoxic innate and adaptive 
immune responses associated with disease progression, ultimately leading to a 
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CHAPTER TWO 
2SELECTIVE VIP RECEPTOR AGONISTS FACILITATE 
NIGROSTRIATAL NEUROPROTECTION 
2.1 Abstract 
Vasoactive intestinal peptide (VIP) mediates a broad range of biological 
responses by activating two related receptors, VIP receptors 1 and 2 (VIPR1 and 
VIPR2). Although use of native VIP facilitates neuroprotection, clinical application 
of the hormone is limited due to VIP's rapid metabolism and inability to 
distinguish between VIPR1 and VIPR2 receptors. In addition, activation of both 
receptors by therapeutics may increase adverse secondary toxicities. Thus, we 
developed two metabolically stable and receptor-selective agonists, one for 
VIPR1 and one for VIPR2 in order to improve the pharmacokinetic and 
pharmacodynamic therapeutic endpoints.  These two selective agonists were 
investigated for their abilities to protect mice against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced nigrostriatal degeneration used to model 
Parkinson’s disease (PD). Survival of tyrosine hydroxylase (TH+) neurons in the 
substantia nigra was quantified by stereological tests after MPTP intoxication in 
mice pretreated with VIPR1 or VIPR2 agonist, or following adoptive transfer of 
splenic cell populations from agonist-treated mice administered into MPTP-
intoxicated animals. Treatment with VIPR2 agonist or splenocytes from those 
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  Data previously published: Olson KE, Kosloski-Bilek LM, Anderson KM, et al. Selective VIP 
receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-
intoxicated mice. J Neurosci. 2015;35(50):16463–16478. doi: 10.1523/JNEUROSCI.2131-
15.2015.	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mice resulted in increased neuronal sparing when compared to native VIP or 
VIPR1 agonist. Immunohistochemical tests showed that agonist-treated mice 
displayed reductions in microglial responses, with the most pronounced effects in 
VIPR2 agonist-treated, MPTP-intoxicated mice. In parallel studies, we observed 
changes in pro-inflammatory cytokine release that included decreases in IL-17A, 
IL-6, and IFN-γ and increases in GM-CSF transcripts in CD4+ T cells recovered 
from VIPR1 or VIPR2 agonist-treated animals. Moreover, a phenotypic shift of 
effector to regulatory T cells was observed. These results support the use of 
VIPR2-selective agonists for PD treatment. 
 
2.2 Introduction 
Aberrant innate and adaptive immune responses are known disease initiators for 
PD (Ha et al., 2012, Mosley et al., 2012, Kosloski et al., 2013). These result in 
chronic immune activation perpetuated by the extracellular accumulation of 
aggregated and post-translationally modified α-syn (Benner et al., 2008). Prion-
like aggregated α-syn induces an inflammatory neurotoxic cascade affecting 
nigrostriatal degeneration (Anderson et al., 2014). Infiltrating CD4+ and CD8+ T 
cells, microglial activation, and dopaminergic cell loss are linked to human 
disease and are observed in PD mouse models and post-mortem human brain 
tissues (McGeer et al., 1988, Fiszer et al., 1994b, Kurkowska-Jastrzebska et al., 
1999a, Bas et al., 2001, McLaughlin et al., 2006, Brochard et al., 2009). PD 
patients present higher frequencies of Teff phenotypes with reduced Treg 
function, and T cell changes relative to controls without disease correlate with 
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increased PD-associated movement disorder scores (Saunders et al., 2012). 
Other clinical studies have shown altered frequencies in peripheral CD4+ T cells 
and phenotype changes within the PD population, substantiating the possible 
role changes in T cells in PD progression (Romero-Ramos et al., 2014). 
Work performed in animal models demonstrates that adoptive transfer of 
Teff exacerbates neurodegeneration (Benner et al., 2008, Kroenke et al., 2008), 
whereas transfer of Tregs elicits neuroprotective responses (Reynolds et al., 
2007b, Huang et al., 2009, Kosloski et al., 2013). Treg-mediated protection from 
dopaminergic cell death is complemented by decreased microglial reactivity. Our 
work and the work of others have shown that GM-CSF, which modulates Teff 
immunity, is neuroprotective in MPTP-treated mice and in traumatic brain injury 
models (Schabitz et al., 2008, Kosloski et al., 2013, Kelso et al., 2015). GM-CSF 
induces an immune transformation from a neurotoxic response to a protective 
regulatory response (Kosloski et al., 2013). Nonetheless, extended use of GM-
CSF is associated with secondary toxicities including bone pain, fatigue and 
nausea (Vial and Descotes, 1995a). Therefore, a search for alternative immune-
modulating treatment strategies that restore regulatory capacity to a system 
imbalanced by disease pathobiology or means for the achievement of improved 
drug delivery is warranted.  
One agent that could improve PD outcomes is vasoactive intestinal 
peptide (VIP). VIP is the natural 28-residue agonist of the G protein-coupled 
receptors, VIPR1 and VIPR2 (Reubi and Waser, 2003). It acts as a cytokine and 
neuropeptide by positively affecting immune responses (Delgado and Ganea, 
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2001, Delgado et al., 2004, Dickson and Finlayson, 2009). The 
immunomodulatory capabilities of VIP support its potential to transform T cell 
phenotypes, leading to protection in models of inflammatory and autoimmune 
conditions (Delgado et al., 2000, Delgado and Ganea, 2001, Abad et al., 2003, 
Abad et al., 2005, Chen et al., 2008, Abad et al., 2010, Deng et al., 2010). These 
conditions include rheumatoid arthritis, inflammatory bowel disease, endotoxic 
shock, multiple sclerosis, and Crohn’s disease. Thus, we reasoned that VIP 
could also transform adaptive immune responses in PD. Indeed, prior works 
show that VIP protects against neurotoxicity by attenuating microglial activation 
and degradation of neuronal cell bodies and termini in both MPTP- and 6-OHDA-
induced injuries (Offen et al., 2000, Delgado and Ganea, 2003b, Reynolds et al., 
2010, Korkmaz et al., 2012, Tuncel et al., 2012). The protective mechanism 
arises from altering the cytokine response into an anti-inflammatory profile (Vial 
and Descotes, 1995b, Delgado et al., 1999, Chen et al., 2008, Reynolds et al., 
2010). 
Based on these findings, we hypothesize that VIP-induced neuroprotective 
responses can be harnessed for clinical benefit if the rapid proteolytic 
degradation and lack of VIPR selectivity of the native hormone itself can be 
overcome (Domschke et al., 1978). To this end, we developed backbone-
modified analogues of VIP that resist protease degradation and display selective 
agonism of VIPR1 or VIPR2. Both VIPR1 and VIPR2 agonists caused reductions 
in the release of pro-inflammatory cytokines, IL-17A, IL-6, and IFN-γ from 
stimulated CD4+ T cells. Transformation of Teff responses into an anti-
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inflammatory T cell phenotype was observed. Likewise, VIPR2-selective agonist 
elicited a neuroprotective response, which provides evidence for its potential to 
ameliorate PD.  
 
2.3 Materials and Methods 
Peptide synthesis and purification.  
Protected α-amino acids, resins, and 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophostphate (HBTU) were purchased from GL 
Biochem. Protected β-homoamino acids were purchased from PepTech. ACPC 
was acquired from Chemimpex and Polypeptide and APC was purchased from 
the organic chemistry facility at Fox Chase Cancer Center (Lee et al., 2001). 
Native VIP and [D-p-Cl-Phe6, Leu17]-VIP were purchased from Genway Biotech 
and Tocris Bioscience, respectively. All other reagents and solvents were 
purchased from Airgas, ChemImpex, Fisher Scientific, PharmcoAaper or Sigma 
Aldrich and used as received. Reverse-phase high performance liquid 
chromatography (RP-HPLC) was carried out on Supelco and Phenomenex 
analytical or preparative scale C18 columns using gradients between 0.1% 
trifluoracetic acid (TFA) in water or in acetonitrile using Agilent 1260 and Varian 
Prostar systems.  
Peptides were synthesized by standard Fmoc-solid phase synthesis on 
Rink amide 4-methylbenzhydrylamine hydrochloride (MBHA) resin with 
norleucine. Microwave irradiation was used as previously described for peptide 
syntheses (Korendovych et al., 2010, Shandler et al., 2011). Briefly, protected 
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amino acids were activated with HBTU and N-hydroxybenzotriazole (HOBt) in the 
presence of N,N-diisopropylethylamine (DIEA) in N-methyl-2-pyrrolidone (NMP) 
for coupling reactions. Deprotection was achieved with 20% piperidine in 
dimethylformamide (DMF). After the final deprotection, peptides were capped 
using acetic anhydride/DIEA in DMF. After synthesis was complete, peptides 
were cleaved from the resin using a solution of 95% TFA, 2.5% H2O, and 2.5% 
triisopropylsilane. Excess TFA was removed under a stream of nitrogen, and 
crude peptide was precipitated by addition of cold ether. Crude peptide solutions 
were purified using reverse-phase HPLC on preparative scale using C18 
columns. The identity and purity of peptides were confirmed by mass 
spectrometry. After lyophilization, peptides were dissolved in TFE. An Agilent 
diode array, model 8453, was used to determine concentrations, with an 
extinction coefficient of 2980 M-1 cm-1 was applied. Aliquots for assays were dried 
under vacuum, resuspended in 20% acetonitrile, 0.1% HCl and lyophilized to 
exchange the counter ion. Dried peptide was resuspended in either DMSO or 1% 
DMSO in PBS.   
 
Cell-based assays.  
EC50 values for both VIPR1 and VIPR2 were determined in triplicate for each 
time point by monitoring intracellular cAMP concentrations of DiscoveRX’s 
PathHunter CHO-K1 VIPR1 β-arrestin or CHO-K1 VIPR2 β-arrestin cell lines, 
respectively. Both cell lines were used between 2 and 5 passages. To initiate 
assays, 2000 cells per well were plated into a 384-well plate and incubated 16 
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hours in F-12K medium supplemented with 10% FBS. The following day, each 
reconstituted compound was diluted by twelve 3-fold serial dilutions and added to 
the plated cells. The final concentrations for each compound in the assay wells 
ranged between 5.6 pM and 1 µM in 1% DMSO/PBS. After a 90-minute 
incubation period the medium and compound were removed and intracellular 
cAMP concentrations were determined using the cAMP HiRange Kit available 
from Cisbio. All kit components were used at concentrations according to the 
manufactures recommendation. In brief, this kit functions by lysing the activated 
cells to release the intracellular cAMP, which is then available to disrupt a FRET 
pair. Homogenous time-resolved fluorescence signals were monitored using a 
Tecan M1000 Pro in TR-FRET mode. All TR-FRET parameters including 
excitation, emission, delay, and integration times were set according to the kits 
recommendations and 100 flashes were used per well. The fluorescence 
intensity of each well at both 620 nm and 665 nm was measured and the ratio of 
these values was used to determine delta F%, which is defined as [(standard or 
sample ratio - ratio of the negative control) / ratio of the negative control] x 100. 
The resulting data were calibrated against a negative control, baseline corrected 
then normalized using the average VIP response for each cell line as boundaries. 
This normalized log inhibitor response curve was fit to a four-parameter 
sigmoidal dose-response curve using least squares fitting in the GraphPad Prism 
software package with a boundary constraint that each EC50 fit was less than 1e-
6M.  
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Proteinase and pepsin assays.   
The degradation rate of the peptide agonists was measured in the context of 
multiple aggressive proteases. All data were analyzed using analytical HPLC in 
triplicate for each time point. Pepsin Assay proteinase stock was prepared fresh 
using 185 nM pepsin, 34 mM NaCl and 84 mM HCl in deionized water.  At time 
zero either 2.8 nmol of VIP or 7.0 nmol of Hybridtide was rapidly diluted into 350 
µL of proteinase stock. Hybridtides were run at slightly higher concentrations to 
account for HPLC line broadening during detection. At specified times, 50 µl 
aliquots were removed and quenched with 10 µL of 1 M Tris pH 9.5. Quenched 
samples were evaluated by HPLC. Peak integrals were determined using 
Chemstation software and normalized to the average integral value for the first 
time-point for each dataset independently.  These data were then fitted to a 
single exponential decay using least squares fitting through GraphPad Prism. 
Chymotrypsin and proteinase K assays were performed similarly to the pepsin 
assay with the following exceptions: all solutions were made in phosphate 
buffered saline, chymotrypsin was used at 40 nM, Proteinase K was used at 35 
nM, and all time points were quenched with 10 µL of 99% acetonitrile/1% TFA. 
 
Pharmacokinetic Analysis  
Doses of LBT-3627 at 250 nmol/kg in 50 µL of 1% DMSO in PBS was prepared 
and dosed subcutaneously into the neck scruff of six 25-week-old C57BL/6 mice 
across two cohorts, which were used to minimize the amount of blood taken from 
each mouse according to IACUC approved protocols. Group 1 was sampled at 0, 
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30, 75 and 180 minutes, and Group 2 was sampled at 15, 45, 120 and 300 
minutes.  At each time point, 20 µL of blood was sampled from the tail vein using 
heparin-coated glass capillaries. Collected whole blood was mixed with broad-
spectrum protease inhibitors (ThermoScientific) and sodium heparin (Sagent 
Pharmaceuticals) at 1X and 1 IU/mL, respectively.  Whole blood samples were 
centrifuged for 10 min at 5000 x g to isolate plasma, which was flash-frozen in 
liquid nitrogen and stored at -20°C until further processing. To prepare samples 
for LC-MS/MS analysis an acetonitrile precipitation was performed by mixing 5 
µL of thawed blood plasma with 15 µL of acetonitrile containing 1% formic acid 
and 13.3 nM LBT-3393 which was used as an internal standard. This mixture 
was vortexed at room temperature for 5 minutes at maximum speed on a Vortex 
Genie 2 and then centrifuged at room temperature for 5 minutes to remove the 
precipitated proteins. Supernatant was removed and transferred to an HPLC 
autosampler vial, and 23 µL of H2O containing 5% formic acid was added to 
dilute the supernate prior to analysis.  
For LC-MS/MS analysis, samples were transferred to an Agilent 1260 
autosampler and held at 25°C until injection. Thirteen microleters of the sample 
was injected onto a Phenomenex Kinetex 2.6 µm C18 (50 x 3.0 mm) column 
heated to 50°C. An acetonitrile gradient of 20-35% over 2.5 minutes at 
400µL/min was used to isolate LBT-3627 along with the internal standard. 
Compound elution was detected with an AB Sciex 4000 mass spectrometer 
equipped with a Turbo V ion source. Standard ionization parameters, as defined 
by the manufacturer, were used for drying and ionization.  The two most intense 
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MS/MS transitions were collected, summed for quantification, and subsequently 
integrated with Analyst version 1.6 using default parameters. Integral intensities 
were normalized to the internal standard and compared to the linear range of a 
10-point standard curve to determine plasma drug concentrations. The plasma 
exposure data were fitted to a single-compartment model for absorption and 
clearance using nonlinear regression within GraphPad Prism version 6.0f. 
 
Animals, drug treatment and MPTP intoxication 
Male C57BL/6 mice, six to eight weeks old (The Jackson Laboratory) were used 
as donor and recipient mice in all studies. Donor and pretreated mice were 
administered either VIP (VIP, human ovine porcine rat, Genway Biotech), LBT-
3393, LBT-3627, or scrambled peptide, all of which, were reconstituted using 
Dulbecco’s PBS (DPBS) and given at a dosage of 15 µg, i.p., daily for 5 days 
prior to MPTP intoxication. For antagonist treatment, mice were administered 
with [D-p-Cl-Phe6,Leu17]-VIP at 8 µg i.p. daily for 5 days. Recipient mice 
received 4 s.c. injections of vehicle (DPBS, 10 ml/kg body weight) or MPTP-HCl 
(Sigma-Aldrich) at 16 mg MPTP (free base)/kg body weight in DPBS; each 
injection was given at 2-hour intervals. Twelve hours after MPTP intoxication, 
splenocytes were harvested from donors and adoptively transferred to MPTP-
intoxicated recipient mice (n = 5-8 mice per group per time point). On days 2 and 
7 following administration of MPTP, mice were sacrificed, and brains were 
harvested and processed for analysis. MPTP safety precautions were followed in 
accordance with the determined safety and handling protocols (Jackson-Lewis 
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and Przedborski, 2007), and all animal procedures were in agreement with 
National Institutes of Health guidelines and approved by the Institutional Animal 
Care and Use Committee of the University of Nebraska Medical Center.   
 
Isolation and adoptive transfer of CD4+ T cells 
After 5 days of peptide administration, donor mice were sacrificed and single-cell 
suspensions were obtained from spleen and lymph nodes (brachial, axillary, 
cervical, and inguinal), and resuspended to 50 x 106 cells/0.25 ml for adoptive 
transfer. Recipient mice received 0.25 ml of cell suspension i.v. via the tail vein 
within 12 hours of the final MPTP injection. CD4+ T cells and CD4+CD25+ T 
cells were negatively selected using CD4+ T cell isolation kit II for mouse as per 
manufacturer’s instructions (Miltenyi Biotech) or CD4+CD25+ Treg isolation kit 
for mouse, with purity ranging from 65% to 90% depending on assay. Isolated 
CD4+ T cell populations were used for RNA isolation, genomic analysis, and 
cytometric bead assays (CBA). Freshly isolated CD4+CD25+ Treg were used for 
carboxyfluorescein succinimidyl ester (CFSE) inhibition assays (Quah and 
Parish, 2010).  
 
CD11b+ microglia isolation 
Following either MPTP-intoxication or 5 days of pretreatment with peptides, mice 
(n=8) were sacrificed and perfused with cold PBS to remove circulating immune 
cells. Ventral midbrains were collected from each mouse and dissociated into 
single-cell suspensions using the Neural Tissue Dissociation kit, as per 
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manufacturer’s instructions (Miltenyi Biotech). Myelin was removed using a 30% 
Percoll in DPBS solution. CD11b+ cells were magnetically isolated using PE-
conjugated anti-CD11b antibodies followed by a magnetic bead-conjugated 
secondary antibody. The labeled cells were passed through a magnetic MS 
column (Miltenyi Biotech) according to protocol and as previously described 
(Nikodemova and Watters, 2012). 
 
Perfusions and immunohistochemistry 
Under terminal anesthesia (Fatal Plus, pentobarbital), mice were transcardially 
perfused with DPBS followed by 4% paraformaldehyde/DPBS (Sigma-Aldrich). 
Whole brains were harvested post-perfusion in order to assess dopaminergic 
neurons in the substantia nigra (SN) and termini in the striatum. Frozen midbrain 
sections (30 µm) were immunostained for tyrosine hydroxylase (TH) (anti-TH, 
1:2000, EMD Millipore) and counterstained for Nissl substance (Benner et al., 
2004). To assess microglial reactivity, midbrain sections (30 µm) were 
immunostained for Mac-1 (anti-CD11b, 1:1000, AbD Serotech). To assess 
dopaminergic termini, striatal sections (30 µm) were labeled with anti-TH (1:1000, 
EMD MIllipore). To visualize antibody-labeled tissues, sections were incubated in 
streptavidin-HRP solution (ABC Elite Vector Kit, Vector Laboratories) and color 
was developed using an H2O2 generation system and diaminobenzidine (DAB) 
chromogen (Sigma-Aldrich). Within the SN, total numbers of Mac-1+ cells, 
TH+Nissl+ (dopaminergic neurons), and TH-Nissl+ (non-dopaminergic neurons) 
were quantified by stereological analysis using Stereo Investigator software with 
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the optical fractionator module (MBF Bioscicence). Density of dopaminergic 
neuronal termini in the striatum was determined by digital densitometry using 
Image J software (National Institutes of Health), as previously described 
(Kosloski et al., 2013).  
 
MPTP metabolism and reverse phase-high performance liquid chromatography 
(RP-HPLC)  
Mice (n=5) were intoxicated with MPTP alone or pretreated for 5 days with either 
VIP, LBT-3393, or LBT-3627 followed by MPTP intoxication. Within 90 minutes 
post-MPTP, striatum and ventral midbrain were isolated and processed for MPTP 
and MPP+ levels (Jackson-Lewis and Przedborski, 2007). MPTP and MPP+ 
levels were determined using RP-HPLC analysis, using UV illumination and 
detection at 245 and 295 nm, respectively.  
 
RNA isolations and polymerase chain reaction  
Mice were pretreated with PBS, VIP, LBT-3393, or LBT-3627. CD4+ T cells or 
CD11b+ microglia were harvested and total RNA was isolated using an RNeasy 
Mini Kit (Qiagen). All procedures were performed under RNAse-free conditions. 
cDNA was generated from RNA using the RevertAid First Strand cDNA 
Synthesis kit (Thermo Scientific) and pre-amplification was performed using the 
appropriate primer mixes for RT2 PCR arrays for Mouse T Helper Cell 
Differentiation or Mouse Proinflammatory Response and Autoimmunity (Qiagen). 
Quantitative RT-PCR was performed on an Eppendorf Mastercycler Realplex Ep 
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as per the manufacturer’s instructions (Eppendorf). Data analysis was performed 
using RT2 Profiler PCR Array web-based data analysis software, version 3.5 
(Qiagen). Gene networks were generated using Ingenuity Pathway Analysis 
(IPA, Qiagen) and were designed using the Pathway Designer Tool.  
 
Flow cytometric tests and cytokine assessments 
Cell fractions were isolated from total splenocytes following peptide treatment. 
Samples were permeabilized using the FoxP3 staining buffer set kit 
(eBioscience) and fluorescently labeled with monoclonal antibodies to CD4, 
CD25, CD8, and FoxP3 (eBioscience) to assess T cell frequencies within the 
total population and analyzed using a FACSCalibur flow cytometer. To assess 
cytokine production, CD4+ T cells were isolated, stimulated using anti-CD3/CD28 
beads, and cell supernatant was collected at 12 hours. Supernatants were 
assessed for cytokine levels using a multianalyte Th1/Th2/Th17 cytometric bead 
array (BD Biosciences) and with data acquired using a BD FACSArray 
bioanalyzer (Reynolds et al., 2010).  
 
Statistical Analyses 
All values are expressed as means ± SEM. Differences in between-group means 
were analyzed using ANOVA followed by Fisher’s least significant difference 
(LSD) post hoc test (GraphPad Software, Inc.). Comparisons of slope and 
elevation for CFSE inhibition assays were evaluated using linear regression. 
Slopes for all lines were significantly non-zero (P < 0.0005), and no line deviated 
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from linearity as determined by runs test (P ≥ 0.6667). 
 
2.4 Results 
Peptide Stability.  
VIP exerts strong neuroimmunomodulatory effects (Delgado and Ganea, 2003a, 
Reynolds et al., 2010, Waschek, 2013). However, two features of VIP are 
potentially problematic for its pharmaceutical development. First, as is the case 
for all peptide hormones, VIP has a short half-life in vivo because of rapid 
proteolysis (Domschke et al., 1978). Second, VIP activates two widely-distributed 
receptors, VIPR1 and VIPR2, both members of the B-family of GPCRs (Reubi 
and Waser, 2003). Currently, it is not clear which of the two receptors is most 
relevant to its neuroprotective capabilities. Therefore, we developed analogs of 
VIP to resist protease degradation and display selectivity for either VIPR1 or 
VIPR2. 
 Our design strategy centers on replacing some of the original α-amino 
acid residues with β-amino acid residues (Horne et al., 2008, Boersma et al., 
2012, Cheloha et al., 2014, Johnson et al., 2014). These αàβ substitutions alter 
the covalent spacing between amide groups along the peptidic backbone, which 
disrupts protease recognition, while largely retaining native side chains and α-
helix propensity (Johnson and Gellman, 2013).  Recent studies show that 
periodic αàβ replacements in the C-terminal portions of two other peptide 
hormones that act on B-family GPCRs, glucagon-like peptide-1 (GLP-1) (7-37) 
and parathyroid hormone (PTH) (1-34), yield potent agonists that display 
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prolonged activity in vivo relative to the native hormones (Boersma et al., 2012, 
Cheloha et al., 2014). 
 These precedents prompted us to explore the impact of periodic αàβ 
substitution in the C-terminal portion of VIP. These efforts led to LBT-3393 (Table 
1), an analog that contains five αàβ replacements, at residues Thr11, Lys15, 
Val19, Leu23 and Leu27. At each replacement site, the β residue bears the 
native side chain. In addition, LBT-3393 contains 2 α residue changes that are 
known to be well-tolerated in VIP, Met17àLeu and Ser25àAla (Nicole et al., 
2000, Igarashi et al., 2002a, Igarashi et al., 2002b). LBT-3393 is a full agonist of 
VIPR1, although ~10-fold less potent than VIP itself. LBT-3393 is highly selective 
for VIPR1 relative to VIPR2 (Figure 1), exhibiting only minimal VIPR2 activity at 
the highest concentrations tested. 
 Exploration of αàβ substitutions based on the sequence of VIP did not 
deliver a VIPR2-selective agonist; therefore, the highly VIPR2-selective peptide 
Ro 25-1553 (Table 1) was utilized as a starting point (O'Donnell et al., 1994a, 
O'Donnell et al., 1994b). Analogue LBT-3627 contains nine αàβ substitutions 
(Table 1), some bearing the native side chains (Tyr10, Gln16, Lys28 and Gly30) 
and others having a cyclic structure. Dose response assays showed that LBT-
3627 is a potent agonist of VIPR2 and highly selective for VIPR2 vs. VIPR1 
(Figure 1). LBT-3627 is superior to LBT-3393 in terms of resistance to proteinase 
activities (Figure 2A-C) which translates to an improved in vivo pharmacokinetic 
profile (t½ = 24.33min, Figure 2D) of the unformulated peptide when compared to 
previous human studies at a value of t½ <1min (Domschke et al., 1978). 
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VIPR agonists induce neuroprotective responses in MPTP-intoxication. 
Our prior work demonstrated immune modulatory and neuroprotective activities 
for VIP (Reynolds et al., 2010). Indeed, previous work showed VIP induction of 
Treg with concomitant anti-inflammatory and neuroprotective responses in 
MPTP-intoxicated mice as well as a broad number of animal models of 
inflammatory and neurodegenerative diseases (Delgado et al., 2002, Delgado 
and Ganea, 2003b, Chen et al., 2008, Reynolds et al., 2010). To extend such 
observations, with an eye towards clinical translation, we assessed the abilities of 
the designed VIPR agonists to promote dopaminergic neuronal survival in our 
mouse model of PD. Mice were treated for 5 days with VIP, VIPR1 agonist (LBT-
3393), or VIPR2 agonist (LBT-3627) and then intoxicated with MPTP. Following 
MPTP treatment, total numbers of surviving dopaminergic neurons (TH+Nissl+) 
were observed in the SN (Figure 3A). Numbers of dopaminergic neurons were 
determined by investigator-blinded stereological analysis. Immunohistochemical 
observations of dopaminergic neurons showed a significant increase in surviving 
neuron numbers associated with LBT-3627 treatment compared to PBS control 
(Figure 3B). Following MPTP intoxication, dopaminergic neuron numbers 
decreased from 9789 ± 1061 to 4411 ± 1228 without or with MPTP intoxication, 
respectively (Figure 3B). No differences in numbers of non-dopaminergic 
neurons (TH-Nissl+) were observed because this neuronal type is not susceptible 
to MPTP intoxication (Otto and Unsicker, 1993, Jackson-Lewis and Przedborski, 
2007, Choi et al., 2008). Following VIPR agonist pretreatments, MPTP-induced 
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TH+ neuronal loss was attenuated for all treatment arms. Compared to MPTP 
alone, VIP, LBT-3393 and LBT-3627 pretreatment increased dopaminergic 
neuronal numbers to 5264 ± 1441, 4600 ± 945, and 7339 ± 2115, respectively. 
However, only LBT-3627 pretreatment showed significant protective effects. In 
contrast, striatal termini were not significantly spared by the peptide 
pretreatments (Figure 3C). To determine whether the observed neuroprotective 
effects are linked to specific peptide-receptor interactions, a scrambled peptide 
(LBT-SCR) as a negative peptide control and a specific VIPR antagonist ([D-p-
Cl-Phe6,Leu17]-VIP) were employed. These experiments were designed to 
competitively inhibit binding of VIP, LBT-3393 or LBT-3627 to VIP receptors 
(Figure 4A). Co-administration of the VIP receptor antagonist, [D-p-Cl-
Phe6,Leu17]-VIP, with VIP, LBT-3393, or LBT-3627 decreased previously 
observed VIP- or VIPR2 agonist-mediated neuroprotection. Under these 
conditions, numbers of TH+ neurons were not significantly different compared to 
those from mice treated with MPTP alone, or with MPTP and scrambled peptide. 
Additionally, striatal termini in MPTP-treated mice were not spared by any 
treatment (Figure 4B). To determine the neuroprotective efficacy with the current 
dose, we next addressed treatment using escalating doses of LBT-3627 (1.5 µg, 
5 µg, 15 µg, 45 µg, 90 µg) (Fig 5A). When compared to MPTP alone, the lowest 
dose did not elicit a protective response, but the other four higher doses were 
effective. Linear regression analysis suggests that there is a dose-dependent 
effect in TH+ neuronal sparing with treatment (R2 = 0.4614, P = 0.001) (Fig 5B). 
The lack of increased protection observed at the 90 µg dose and the high 
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variation observed at 45 µg may indicate that these doses are approaching a 
non-efficacious and/or toxic effect. Thus, the 15-µg dose seemed to be adequate 
for eliciting a strong neuroprotective response without generating any toxicity.     
In a next series of experiments to assess the VIP-induced cellular 
response, donor mice were treated with VIP, LBT-3393 or LBT-3627 for 5 days, 
splenocytes were isolated from donor mice and adoptively transferred into 
recipient mice 12 hours after MPTP-intoxication. Dopaminergic neurons and 
striatal termini density were assessed 7 days after MPTP intoxication by 
immunohistochemical assessment of TH+ neurons in the midbrain and termini in 
the sriatum (Figure 6A). MPTP diminished TH+Nissl+ counts from 13011 ± 1025 
to 3414 ± 382 (Figure 6B). MPTP-induced neuronal loss was attenuated by 
adoptive transfer of splenocytes from non-intoxicated donor mice treated with 
any of the VIPR agonists showing significantly increased numbers of surviving 
dopaminergic neurons of 6896 ± 707 and 11094 ± 1233 TH+Nissl+ neurons in 
mice receiving spleen cells from donors treated with LBT-3393 or LBT-3627, 
respectively, compared to those treated with MPTP alone. Transfer of 
splenocytes from VIP-treated donors increased dopaminergic neuronal survival 
by 14%. Numbers of non-dopaminergic TH-Nissl+ neurons were not significantly 
different in any group treated with MPTP regardless of adoptive transfer. 
Compared to treatment with VIPR agonists prior to MPTP (Figure 3), striatal 
density analysis showed similar, non-significant effects for striatal sparing 
following adoptive transfer of splenocytes from mice treated with VIP or LBT-
3393; however, adoptive transfer of splenocytes from LBT-3627-treated donors 
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showed significant sparing of striatal termini (Figure 6C).  
 
Microglial reactivity is decreased with VIPR2 agonism.  
As previously discussed, microglial activation is associated with neuronal cell 
death in human PD and in mouse models of disease (Kurkowska-Jastrzebska et 
al., 1999a, McLaughlin et al., 2006). Whether the neuroprotective effects upon 
either adoptive transfer from agonist-treated mice or agonist pretreatment of mice 
prior to MPTP intoxication were associated with changes in microglial 
morphology and pro-inflammatory responses were investigated. As before, 
MPTP intoxication was performed directly in mice receiving peptide pretreatment 
(Figure 7), or alternatively, donor animals were treated for 5 days prior to splenic 
cell isolation and adoptive transfer into recipient MPTP-intoxicated mice (Figure 
8). Microglial responses were evaluated 2 days following MPTP-intoxication, at 
the peak of the MPTP-induced neuroinflammatory response (Kurkowska-
Jastrzebska et al., 1999a). The SN was immunostained with macrophage antigen 
complex-1 (Mac-1) antibody, and reactive microglia were quantified. Both Mac-1 
staining magnitude and microglial morphological changes, consisting of 
intensely-stained, amoeboid shaped microglia and reduced stained, ramified 
structures, were observed; the former as activated microglia, the latter as 
quiescent microglia (Figure 7). Stereological analysis showed numbers of 
activated microglia increased from 2.8 ± 1.1 cells/mm2 in PBS-treated mice to 
44.5 ± 6.9 cells/mm2 following MPTP intoxication (Figure 7). VIP pretreatment 
decreased microglial reactivity to 25.1 ± 2.2 cells/mm2 and VIPR1 agonism (LBT-
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3393) showed similar numbers of activated microglia, 28.9 ± 3.3 cells/mm2. The 
largest reduction in MPTP-induced microglial reactivity was seen following 
pretreatment with the VIPR2 agonist (LBT-3627) which significantly decreased 
the activated cell numbers to 18.1 ± 7.4 cells/mm2. Moreover, treatment with 
LBT-3627 diminished numbers of activated microglia not only from mice treated 
with MPTP alone, but also from those treated with VIP or LBT-3393 and MPTP.  
 Adoptive transfer of splenic cells from agonist-treated donors was 
performed twelve hours following MPTP intoxication of recipient animals. 
Replicate data sets revealed reduced microglial reactivity in the SN after transfer 
of splenocytes from donors treated with VIP or either VIPR agonist (Figure 8). 
Compared to PBS-treated animals, MPTP intoxication increased the number of 
reactive microglia from 2.2 ± 0.5 cells/mm2 to 29.6 ± 6.9 cells/mm2 (Figure 8). 
Adoptive transfer of cells from animals treated with VIP significantly reduced the 
numbers of activated microglia to 18.7 ± 7.6 cells/mm2. Comparable transfers 
from animals treated with either LBT-3393 or LBT-3627 scored at 23.9 ± 5.7 
cells/mm2, and 18.3 ± 2.9 cells/mm2. However, only VIP or LBT-3627 treatment 
elicited significant decreases in activated microglial numbers when compared to 
MPTP alone. Together, these findings indicate that VIPR agonism can reduce 
reactive microgliosis associated with MPTP intoxication in each of two different 
treatment schemes. These favorable effects are likely to be associated with 
reduced inflammatory responses induced by VIP and VIPR agonists that in turn 
result in neuroprotection.  
 
	   54	  
Neuroprotective mechanisms for VIPR agonists.  
We showed that VIP treatment expands Treg numbers and elicits anti-
inflammatory and immune-suppressive responses by modulating immune cell 
profiles and phenotypes (Reynolds et al., 2010). Thus, to understand the 
immune-modulating potential of VIPR agonism, we assessed the ability of VIPR 
agonists to affect levels of CD4+ T cell populations, the function CD4+CD25+ 
Treg, and/or modulate cytokine production. Flow cytometric analysis of total 
lymphocyte populations recovered from animals after five days of peptide 
treatment revealed no significant changes in either CD4+ (Figure 9A) or 
CD4+CD25+ T cell frequencies within the total lymphocyte population (Figure 
9B). Next, Treg function was evaluated after peptide treatment as the capacity to 
inhibit CD3/CD28-stimulated proliferation of CD4+ T responder cells (Tresp) 
using a CFSE proliferation assay (Quah and Parish, 2010, Saunders et al., 
2012). Tregs isolated from animals treated with LBT-3627 showed an increased 
functional capacity when compared to Tregs isolated from animals treated with 
PBS, VIP, or LBT-3393 (Figure 10). LBT-3627 treatment resulted in Tregs that 
caused a 74% inhibition of proliferation at a 1:1 Tresp:Treg ratio while the 
inhibition was 29% for Tregs from animals treated with PBS, 41.5% for Tregs 
from animals treated with VIP, and 47.5% for Tregs from animals treated with 
LBT-3393. The inhibitory capacity of isolated Tregs decreased in a dose 
dependent manner (R2 > 0.88, P < 0.0005, for all treatments); however, LBT-
3627 Tregs maintained enhanced suppressive capabilities even at the lowest 
dose when compared to all other treatment arms. Linear regression analyses of 
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Treg-mediated inhibition indicated that Treg dose responses from LBT-3627-
treated mice were significantly enhanced (P < 0.03) over those from mice treated 
with PBS, VIP, or LBT-3393. Dose responses of Tregs from mice treated with 
LBT-3393 were significantly larger than those from PBS-treated controls (P = 
0.016), whereas Treg responses from VIP-treated mice compared to PBS 
controls did not reach significance (P = 0.0788). Collectively, these data suggest 
that Treg frequencies are not affected by treatment with VIPR agonists, but 
functional properties of Tregs are enhanced upon these treatments, with the 
most pronounced enhancement resulting from the VIPR2-selective agonist.  
Next, to determine mechanism(s) by which VIPR agonists could enhance 
Tresp suppression and diminish inflammation with neuroprotective effects, the 
effects of VIPR agonists on cytokine production were investigated after T cell 
stimulation. For these studies, mice were treated with PBS, VIP, LBT-3393, or 
LBT-3627 for 5 days. CD4+ spleen cells from each treatment arm were isolated, 
stimulated with anti-CD3/CD28, cultured and assessed for cytokine production by 
cytokine bead array. Relative to cytokine levels of stimulated CD4+ T cells from 
PBS-treated controls, LBT-3393 and LBT-3627 treatment significantly 
suppressed production of the proinflammatory cytokines IL-17A, IFN-γ, and IL-6, 
but not tumor necrosis factor-α (TNF-α) (Figure 11). Interestingly, VIP 
administration resulted in an opposite effect, with a significant upregulation of 
pro-inflammatory cytokines. This may be due to the fact that VIP is about 10-fold 
more potent than the selective VIPR agonists, suggesting that increased potency 
may yield an undesirable effect on pro-inflammatory cytokine production. Taken 
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together, these data demonstrated that selective agonism of either VIPR1 or 
VIPR2 induces downregulation of pro-inflammatory T cell phenotypes, and 
results in the enhanced immunosuppressive properties observed by Tregs. 
Observation of such T cell shifts in phenotype within 12 hours of stimulation also 
suggested that this VIPR agonist-mediated shift may occur prior to stimulation via 
CD3/CD28.     
Because Treg numbers or cytokine production alone could not readily 
explain differences in the preferential effects on Treg function and 
neuroprotection mediated by VIPR2 versus VIPR1 agonism, we next examined 
potential phenotypic shifts elicited by VIPR agonists. We investigated T helper 
differentiation gene expression changes within the total CD4+ T cell population. 
CD4+ T cells were isolated from animals treated with 5 days with PBS, VIP, LBT-
3393, or LBT-3627, RNA was isolated, and gene expression evaluated by RT-
PCR array for genes associated with T helper cell differentiation. Gene 
expression levels of T cells from mice treated with VIP, LBT-3393, or LBT-3627 
were compared to those from animals treated with PBS alone. Significant fold 
changes in mRNA expression were observed for each pretreatment (Figure 12); 
each of the three VIPR agonists produces a distinct profile change. For VIP 
pretreatment, transmembrane emp24 protein transport domain containing 1 
(Tmed1) was significantly upregulated, whereas Fas ligand (FasL), IL-18 
receptor accessory protein (Il-18rap), IL-21, interferon regulatory factor 4 (Irf-4), 
Rel, and suppressor of cytokine signaling 5 (Socs5) were significantly down-
regulated. VIPR1 agonist pretreatment yielded a down-regulation in Irf-4, Rel, 
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and Tmed1. VIPR2 agonist pretreatment elicited a robust and significant increase 
in Gm-csf, as well as parallel increases in IL-17 receptor E (Il-17re), IL-18 
receptor 1 (Il-18r1), RAR-related orphan receptor C (Rorc), Toll-like receptor 4 
(Tlr4), and Tmed1. Il-21, inhibitor of DNA 2 (Id2) and Socs5 were increased as 
well, but these increases did not reach statistical significance. VIPR2 agonism 
did not lead to significant downregulation of any genes associated with T cell 
differentiation.  
Because the majority of the detected neuroprotective and anti-
inflammatory responses were associated with VIPR2 agonism, we focused on 
relationships among genes for which mRNA expression increased upon 
pretreatment with the VIPR2-selective agonist, LBT-3627. Mapping the 
relationships by Ingenuity Pathway Analysis (IPA) among genes for which mRNA 
increased suggests that changes in two overlapping networks are induced by 
VIPR2 agonism (Figure 13). IPA-mapped changes implicate immunological 
disease and inflammatory response networks and cell-to-cell signaling and 
interaction networks. Changes in Gm-csf (CSF2) are central to these networks. 
Changes linked to both anti- and pro-inflammatory genes as well as innate and 
adaptive immunity were observed, along with changes in T cell transcription 
factors associated with T cell differentiation. 
 Futhermore, since T cells readily interact with microglial populations to 
elicit an immune response, we next sought to examine the effect of VIPR2 
agonism on CD11b+ cell populations isolated from the ventral midbrain of MPTP 
intoxicated mice. To do so, we investigated the inflammatory response mediated 
	   58	  
by CD11b+ populations following both pre-treatment with LBT-3627 alone (Figure 
14) or in combination with MPTP (Figure 15). The results suggest a down-
regulation in multiple innate and adaptive immune mediators with LBT-3627 
treatment. Specifically, with LBT-3627 treatment alone, mRNA transcripts for 
genes associated with a pro-inflammatory and/or oxidative immune response 
such as Il-1β, Il-23a, Ifn-γ, Ptgs2 (prostaglandin-endoperoxide synthase 2, also 
known as cyclooxygenase), Ltb (lymphotoxin B also known as TNF-C), Tnf, and 
Il-7 were profoundly decreased with a fold decrease of more than 10 when 
compared to the inflammatory response associated with MPTP treatment alone 
(Figure 14).  Also, in combination with MPTP intoxication, LBT-3627 pretreatment 
yielded similar decreases in the pro-inflammatory response, showing moderate 
decreases in Ptgs2 and Ltb with at least a 2 fold decrease, as well as greater 
decreases in Tnf, Il-7, and NFκB expression at more than 10 fold decreases 
when compared to MPTP intoxication alone. Thus, the genomic analyses 
revealed that VIPR agonists, especially the agonist specific for VIPR2, can 
positively affect both innate and adaptive immune responses through modulation 
of gene expression in CD4+ T cells and CD11b+ microglial populations, with a 
coincident down-regulation of pro-inflammatory cytokine production in vitro. 
 
VIPR agonists do not affect MPTP metabolism.  
VIP can cross the BBB (Dogrukol-Ak et al., 2003), and possibly inhibit 
metabolism of the MPTP protoxin to the 1-methyl-4-phenylpyridinium (MPP+) 
toxin with putative neuroprotection due to diminished intoxication. To rule out that 
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possibility, we analyzed levels of MPTP and MPP+ by RP-HPLC within the 
midbrain and striatum of intoxicated mice and compared those to levels in 
intoxicated mice that received VIP, LBT-3393, or LBT-3627 before MPTP. 
Treatment with VIP or either VIPR agonist did not reduce the levels of MPP+ 
intoxicant in either the midbrain (Figure 16A) or the striatum (Figure 16B). Thus, 
conversion from MPTP into MPP+ was achieved in all treatment arms and, in 
fact, MPP+ levels were greater in mice treated with either VIPR agonist prior to 
MPTP. Thus, these data and the adoptive transfer data support the idea that 
VIPR2 agonist-mediated neuroprotective responses do not arise from effects on 
MPTP metabolism, which is consistent with a more direct immunomodulatory 
mechanism of action for these agonists. 
 
Treatment with VIPR agonist following MPTP intoxication is not neuroprotective.  
Because PD is a chronic and progressive disease, we wanted to evaluate the 
treatment efficacy of LBT-3627 after administration of MPTP. This treatment 
scheme would, in theory, be more similar to human disease onset and resulting 
treatment. To evaluate this testing paradigm, mice were treated with MPTP, and 
after 12 hours, five days of consecutive treatment with LBT-3627 was started.  
After 7 days, mice were sacrificed and surviving dopaminergic cell bodies and 
striatal termini were quantified (Figure 17). With both MPTP intoxication alone 
and MPTP intoxication followed by LBT-3627 treatment, there was a significant 
decrease in both surviving cell bodies (Figure 17A) and termini (Figure 17B). 
Treatment with LBT-3627 did not lead to the neuroprotective response that was 
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observed in adoptive transfer and pretreatment studies. The lack of protective 
response may be attributed to the rapid inflammatory cascade that ensues 
following MPTP intoxication and the slow induction of protective T cell 
phenotypes following initial LBT-3627 treatment (Kurkowska-Jastrzebska et al., 
1999a). Perhaps this treatment scheme would be more effective in a more 
chronic and less inflammatory model, such as the chronic MPTP model or an α-
syn overexpressing model.  
 
2.5 Discussion 
VIP has potential for the treatment of neuroinflammatory conditions based on its 
ability to transform T cells (Gonzalez-Rey et al., 2007). One obstacle to the 
clinical use of VIP is the hormone's lack of specificity for VIPR1 and VIPR2 
(Usdin et al., 1994, Reubi and Waser, 2003). A second obstacle is the rapid 
proteolytic degradation of VIP in vivo. Our work aimed to better define 
therapeutic potential in this arena by developing protease-resistant VIPR 
agonists that target each receptor independently. We hypothesized that targeting 
specific VIP receptors individually with physiologically stable agonists would elicit 
a robust neuroprotective response connected to changes in innate and adaptive 
immunity. It was demonstrated that the metabolically stable and VIPR2-specific 
agonist LBT-3627 is an effective immunomodulatory agent in the mouse model of 
PD. Treatment of MPTP-intoxicated mice with LBT-3627 significantly spared 
dopaminergic neuronal cell bodies within the nigrostriatal lesion, decreased the 
amount of reactive microgliosis associated with MPTP insult, decreased levels 
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pro-inflammatory gene expression associated with the inflammatory response in 
CD11b+ microglia populations, down-regulated pro-inflammatory cytokine 
production, and modulated T cell phenotypes with treatment. In contrast, 
treatment with the stable, VIPR1-selective agonist LBT-3393 yielded lesser 
neuroprotective responses. Thus, in this model of PD, VIPR2 agonism elicits a 
link between neuroprotection and modulation of the immune response with 
systemic treatment.  Interestingly, significant sparing of striatal termini was only 
observed following adoptive transfer not during pretreatment. It’s suggested that 
the lack of termini survival may be due to the increased MPP+ levels associated 
with VIPR pretreatment, whereas the increased MPTP conversion would not 
have been observed with adoptive transfer because no drug interaction would 
have been possible.  
Similar anti-inflammatory and protective responses associated with the 
VIPR2 have been studied previously. For instance, specific targeting of VIPR2 
has been shown to mediate anti-inflammatory and therapeutic effects in 
rheumatoid arthritis (Juarranz et al., 2008) and models of spinal muscular 
atrophy (Hadwen et al., 2014), ultimately leading to enhanced production of Th2-
type transcription factors like c-Maf and JunB, anti-inflammatory cytokines such 
as IL-4 and IL-5 (Voice et al., 2004) and IL-10 (Larocca et al., 2007), and 
decreased macrophage-derived pro-inflammatory cytokine production (Gomariz 
et al., 2000). Also, the loss of VIPR2 receptor leads to enhanced and 
exacerbated disease states in experimental autoimmune encephalitis (EAE) and 
experimental colitis, suggesting that VIPR2 activity is important for mediating 
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disease processes (Yadav et al., 2011, Tan et al., 2015). This loss was 
associated with increased Th1/Th17 responses and decreased Th2/Treg 
responses (Tan et al., 2015). These previous findings are consistent with the 
observation of enhanced neuroprotective activity of a degradation-resistant and 
selective VIPR2 agonist relative to a selective VIPR1 agonist or the non-selective 
native hormone VIP. Together, these studies highlight the potential of a VIPR2-
selective agonist to modulate the adaptive immune response in therapeutically 
favorable ways.  
Initially, it was hypothesized that VIPR2 agonism would yield an increase 
in CD4+CD25+ Treg population, resulting in increased neuroprotection. Even 
though prior work has shown VIP-mediated increases in frequencies of Tregs 
(Fernandez-Martin et al., 2006, Gonzalez-Rey et al., 2006b, Reynolds et al., 
2010), we were unable to demonstrate this response at the dosages we used, so 
we began to assess other avenues of regulatory and anti-inflammatory function 
that promote dopaminergic neuron survival upon MPTP-intoxication. Thus, we 
assessed the ability of Tregs isolated from VIPR agonist-treated mice to 
suppress the proliferation of Tresp in vitro. It was found that co-culture of Tresp 
with Tregs from animals treated with the VIPR2-selective agonist, LBT-3627, 
elicited an enhanced suppressive effect when compared to Tregs from animals 
subjected to other treatments. This suppressive effect corresponded with down-
regulation of pro-inflammatory cytokine production associated with Th1/Th17 T 
cell phenotypes. Thus, the regulatory and immune-suppressive roles of LBT-
3627 are likely a result of T cell phenotype modulation that leads to a change in 
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the adaptive immune response associated with inflammation.  
The impact of VIPR agonists on MPTP-intoxicated mice led us to employ 
gene expression analysis for further exploration of T cell differentiation and 
possible phenotypic shifts induced by agonist treatment. Observed increases in 
genes associated with both pro- and anti-inflammatory responses following LBT-
3627 treatment were found. The most abundant change was a 45-fold 
upregulation of the Gm-csf transcript. Previous studies have demonstrated the 
potent and robust neuroprotective responses associated with GM-CSF treatment, 
such as increased neuronal survival, decreased microglial reactivity, induction of 
Tregs, and changes in innate and adaptive immune responses associated with 
inflammation (Schabitz et al., 2008, Kosloski et al., 2013). Although genes 
associated with multiple T cell subsets were altered upon LBT-3627 treatment, 
many were associated with anti-inflammatory subsets including Tregs and Th2 
populations. For instance, Id2 was upregulated 10-fold with treatment. This gene 
has been associated with maintaining Treg populations in inflammatory disease 
in order to enhance suppressive capabilities (Miyazaki et al., 2014). These 
changes were not observed for VIP or LBT-3393 treatment. Likewise, Tmed1 
was upregulated 3.3-fold when compared to PBS treatment. Tmed1 has been 
shown to be involved in IL-33 signaling (Connolly et al., 2013); IL-33 is an IL-1-
like cytokine that induces Th2 type cytokines such as IL-4, IL-5, and IL-13 
(Schmitz et al., 2005). While mRNA levels for these Th2-associated cytokines 
were upregulated >2-fold with LBT-3627, the modest changes were not 
significant for the current sample size. Small changes in cytokine levels can 
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ultimately affect T cell subsets depending on the microenvironment at the sites of 
inflammation. The expression level changes we observed may suggest that LBT-
3627 induces a shift toward an anti-inflammatory response associated with 
regulatory or Th2 subsets rather than a pro-inflammatory Th1/Th17-mediated 
response. This possibility is supported by the down-regulation of Th1/Th17 
cytokine production following treatment with LBT-3627. Upon cytometric bead 
analysis, we observed a significant down-regulation of IFN-γ, IL-6, and IL-17A 
with LBT-3627 treatment. The VIPR2-selective agonist also generated a >2-fold 
decrease in IFN-γ gene transcript, although, the effect did not reach significance. 
Collectively, alterations in the inflammatory disease response and cell-cell 
signaling pathways following VIPR2 agonism were demonstrated. Gm-csf is a 
central component for both networks, and its upregulation can elicit changes 
linked to both innate and adaptive immunity (Kelso et al., 2015, Gendelman et 
al., 2017). This ability to modulate the immune response was strengthened with 
the observed changes in inflammatory response transcripts in microglial 
populations isolated from the ventral midbrain. Treatment with LBT-3627 alone 
elicited profound down-regulation of mRNA levels of potent pro-inflammatory 
mediators such as IL-1β, TNF-α, TNF-C, COX, and IFN-γ. Given the enhanced 
inflammatory cascade that occurs during MPTP intoxication, it is important to 
note that pre-treatment with LBT-3627 followed by MPTP intoxication was also 
able to elicit changes in some of the same detrimental mediators, such as 
decreased COX, TNF-c, and TNF-a. Collectively, these findings could be 
indicative of cross-talk between CD4+ T cell populations and their interactions 
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with CD11b+ microglia populations, creating a shift in the inflammatory response, 
ultimately leading to enhanced anti-inflammatory function and neuroprotective 
capabilities.  
VIP can cross the BBB (Dogrukol-Ak et al., 2003), which may allow direct 
interaction with resident immune cells and neurons within the CNS. Both glia 
cells and neurons express VIP receptors (Chneiweiss et al., 1985, Hosli et al., 
1989), and both VIPR1 and VIPR2 are expressed within the SN, as well as in 
many other parts of the brain (Joo et al., 2004). Activation of VIPR1 and/or 
VIPR2 within the CNS could lead to many other protective effects that are not 
directly associated with the modulation of T cell responses and/or phenotypes. 
VIP binding to its receptors on microglia and other antigen-presenting cells has 
been associated with down-regulation of co-stimulatory molecules, possibly 
resulting in desensitization of an inflammatory response (Ganea et al., 2003), as 
well as inhibition of pro-inflammatory cytokine production by microglia (Kim et al., 
2000). VIP interaction with astrocytes results in increased neurotrophin 
production such as activity-dependent neurotrophic factor (ADNF), leading to 
decreased cellular toxicities and increased neuronal survival (Gozes and 
Brenneman, 1996). VIP interaction with neurons has been documented as well, 
causing VIP to be widely accepted as a neuropeptide for neuronal signaling and 
regulation of reactive gliosis (Brenneman et al., 1987, Waschek, 2013).  
It has not been determined whether LBT-3393 or LBT-3627 can cross the 
BBB. It is possible that these VIPR1- and VIPR2-specific agonists share the 
ability of VIP to cross the BBB and act directly on microglia, astrocytes, and 
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neurons. Further exploration of the effects of LBT-3393 and LBT-3627 on cell 
types within and outside the CNS will be necessary to elucidate the 
immunomodulatory and neuroprotective effects manifested by these compounds 
in the MPTP mouse model of PD. Such insight would enhance the prospects for 
clinical translation. Ultimately, the pleiotropic functions of VIP and this hormone's 
ability to act broadly within the immune system, and possibly the central nervous 
system, suggest that targeting VIPR1 and/or VIPR2 provides a good strategy for 
identifying therapeutic candidates. The results reported here show that systemic 
administration of a VIPR2-selective agonist elicited profound neuroprotective and 
anti-inflammatory responses, supporting further exploration from a clinical 
perspective. Our evaluation of LBT-3393 and LBT-3627 to date has been limited 
to an animal model, but based on the results, we hypothesize that such agents 
would elicit similar anti-inflammatory responses and T cell phenotypic shifts in 
humans. Thus, such agonists might counteract the imbalanced 
neuroinflammatory response associated with neurodegeneration in PD. By 
enhancing the suppressive function of Tregs and down-regulating pro-
inflammatory cytokine production, a long-acting VIPR2-selective agonist might 
restore pro-inflammatory and anti-inflammatory responses to a homeostatic state 
within the substantia nigra, ultimately sparing dopaminergic neurons, along with 
the possibility of direct neuronal stimulation. Overall, our studies support the 
likelihood that VIPR2 agonism has the potential to slow the pathogenesis of PD 
through modulation of the aberrant adaptive immune response. 
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2.6 Tables and figures  
Table 1. Amino acid sequences for the peptides evaluated in these studies. 
VIP      HSDAV FTDNY TRLRK QMAVK KYLNS ILN-NH2 
LBT-3393   aAc-HSDAV FTDNY tRLRk QLAvK KYlNA IlN-NH2 
Ro 25-1553 b,cAc-HSDAV FTENY TKLRK QnLAAK K*YLND* LKKGG T-NH2 
LBT-3627 a,cAc-HXDAX FTEXy TKLRK qLAAZ  KYXND   LKkGg T-NH2 
LBT-SCR Ac-TyXTX EgLKX GFKTK RHZKA qYLXL ANADkD 
aβ3-amino acids are in blue lowercase font, cyclic β-amino acids are indicated in 
red capital font. 
bA lactam bridge between K* and D* exists in Ro25-1553 along with a single 
norleucine, indicated by nL. 
cBoth Ro 25-1553 and LBT-3627 are alkanoylated at the N-terminus.   
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Figure 1.  LBT-3393 and LBT-3627 peptides are VIPR1 and VIPR2 agonists. 
cAMP dose response assays comparing native VIP to LBT-3393 and LBT-3627, 
top and bottom, respectively. Data were generated by activating engineered 
CHO cells that over express either VIPR1 or VIPR2 with increasing 
concentrations of peptide and detecting intracellular cAMP activation using a two-
component HTRF pair. The data was reported as normalized ΔF%  (a measure 
of cAMP HTRF ratios that is quenched at higher cAMP concentrations).    Higher 
concentrations of VIP (>10e-8M) were excluded from analysis as appropriate 
since they began to increase in relative value, likely a result of receptor 
internalization (data not shown). 
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Figure 2. LBT-3627 is resistant to protease activities. A-C. Relative stabilities of 
three peptides, VIP (solid line & circles), LBT-3393 (dotted lines and open circle) 
and LBT-3627 (dotted lines and open triangles) after exposures up to 120 
minutes to different aggressive protease environments of pepsin (A), proteinase 
K (B), and chymotrypsin (C). Percentages of non-degraded peptide 
concentrations remaining from time zero were determined by RP-HPLC. D. 
Pharmacokinetic (PK) profile of 250 nmol/kg unformulated LBT-3627 drug 
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Figure 3. LBT-3627 pretreatment is neuroprotective. A. Photomicrographs of 
TH+Nissl+ neurons in the SN and TH+ striatal termini (STR) in mice treated with 
PBS, MPTP, or pretreated with VIP, LBT-3393, or LBT-3627 prior to MPTP 
intoxication (40x image, scale bar, 200 µm). Sections were immunostained with 
anti-TH and HRP-conjugated secondary antibody and visualized with DAB. SN 
sections were counterstained with thionin. B. Total numbers of surviving 
dopaminergic neurons (TH+Nissl+) and nondopaminergic neurons (TH-Nissl+) in 
the SN following MPTP treatment alone or pretreatment with VIP, LBT-3393, or 
LBT-3627. Percentages of spared dopaminergic neurons are included for each 
treatment (10x image, scale bar, 1000 µm). C. Relative TH densitometry of 
striatal dopaminergic termini following pretreatment. A-C. Differences in means 
(± SEM, n=8) were determined where P<0.05 compared with groups treated with 
PBS (a), MPTP (b), VIP (c), or LBT-3393 (d). 
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Figure 4. Administration of a VIPR antagonist blocks the neuroprotective effects 
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Figure 4. Administration of a VIPR antagonist blocks the neuroprotective effects 
of LBT-3627. A. Total number of TH+Nissl+ and TH-Nissl+ neurons within the SN 
following MPTP intoxication alone or with pretreatment of [D-p-Cl-Phe6,Leu17]-
VIP (Antag), scrambled peptide (LBT-SCR), or co-administration of VIP, LBT-
3393, or LBT-3627 with antagonist. B. Relative TH densitometry of striatal 
dopaminergic termini following pretreatment. C. Differences in means (± SEM, 
n=8) were determined where P<0.05 compared with groups treated with PBS (a) 
or MPTP (b). 
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Figure 5. The neuroprotective effect of LBT-3627 is dose-dependent. A. Dose 
response for LBT-3627 at varying pretreatment doses of 1.5 µg, 5 µg, 15 µg, 45 
µg, and 90 µg followed by MPTP intoxication. B. Linear regression analysis of 
dose response, R2 = 0.4614 P = 0.001. Differences in means (± SEM, n=8) were 
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Figure 6. Adoptive transfer of splenocytes from mice treated with VIPR agonists 
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Figure 6. Adoptive transfer of splenocytes from mice treated with VIPR agonists 
is neuroprotective. A. Photomicrographs of TH+Nissl+ neurons in the SN and 
STR in mice treated with PBS, MPTP, or MPTP followed by adoptive transfer of 
spleen cells from mice treated with VIP, LBT-3393, or LBT-3627 (40x image, 
scale bar, 200 µm). Sections were immunostained with anti-TH and HRP-
conjugated secondary antibody and visualized with DAB. SN sections were 
counterstained with thionin. B. Total numbers of surviving dopaminergic neurons 
(TH+Nissl+) and non-dopaminergic neurons (TH-Nissl+) in the SN following 
MPTP treatment and adoptive transfer (10x image, scale bar, 1000 µm). C. 
Relative TH densitometry of striatal dopaminergic termini. B and C. Differences 
in means (± SEM, n=8) were determined where P<0.05 compared with groups 
treated with PBS (a), MPTP (b), VIP (c), LBT-3393 (d). 
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Figure 7. Pretreatment with VIPR agonists decreases reactive microglia levels 
during MPTP-induced inflammation.  
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Figure 7. Pretreatment with VIPR agonists decreases reactive microglia levels 
during MPTP-induced inflammation. A. Photomicrographs of Mac-1+ microglia in 
the SN of PBS or MPTP treated mice pretreated with VIP, LBT-3393, or LBT-
3627 (scale bars: top panel, 40x image, 200 µm and bottom panel, 400x image, 
20 µm). B. Quantification of reactive microglia taken from midbrains 2 days post 
MPTP treatment. Sections were stained for Mac-1+ microglia using an anti-Mac-
1 antibody, HRP-conjugated secondary antibody, and DAB for color visualization. 
Numbers of reactive microglia (amoeboid Mac-1+) were determined by 
stereological analysis. Differences in means (± SEM, n = 6) were determined 
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Figure 8. Adoptive transfer of splenocytes from VIPR agonist-treated mice 
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Figure 8. Adoptive transfer of splenocytes from VIPR agonist-treated mice 
diminishes microgliosis during MPTP intoxication. A. Representative 
photomicrographs of Mac-1+ microglia within the SN of mice treated with PBS 
alone, MPTP alone, or MPTP-treated mice receiving splenocytes from donors 
treated with VIP, LBT-3393, or LBT-3627 (scale bars: top panel, 40x image, 200 
µm and bottom panel, 400x image, 20 µm). B. Quantification of reactive microglia 
within midbrains, visualized as described in Figure 6. Differences in means (± 
SEM, n = 5) were determined where P < 0.05 compared with groups treated with 
PBS (a), or MPTP alone (b). 
	   84	  
 
Figure 9. VIPR agonist pretreatment does not affect CD4+ and CD4+CD25+ T 
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Figure 9. VIPR agonist pretreatment does not affect CD4+ and CD4+CD25+ T 
cell frequencies. Mice were treated with PBS, VIP, LBT-3393, or LBT-3627 for 5 
days, and splenocytes assessed using flow cytometric analysis for frequencies of 
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Figure 10. LBT-3627 treatment elicits changes in Treg function.  Assessment of 
Treg-mediated inhibition (± SEM) of CFSE-stained CD4+ Tresps stimulated for 
proliferation with anti-CD3/CD28. Tregs were isolated from PBS-, VIP-, LBT-
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Figure 11. LBT-3627 treatment decreases proinflammatory cytokine release in 












	   89	  
Figure 11. LBT-3627 treatment decreases proinflammatory cytokine release in 
CD4+ T cell subsets. Mice were treated with PBS, VIP, LBT-3393, or LBT-3627 
for 5 days. Relative concentration of pro-inflammatory cytokines in cell culture 
supernatants of anti-CD3/CD28 stimulated CD4+ T cells following pretreatment 
(±SEM, n=3). Cytokine concentrations were determined by cytokine bead array 
for pro- and anti-inflammatory cytokines. Differences in means were determined 
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Figure 12. VIPR2 agonism induces dysregulation of genes associated with 
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Figure 12. VIPR2 agonism induces dysregulation of genes associated with 
inflammatory responses and cell-to-cell signaling. PBS controls received no 
treatment, whereas VIP, LBT-3393, and LBT-3627 treatment groups were 
pretreated for 5 days followed by negative selection of the CD4+ T cell subset. 
qRT-PCR data shows gene expression changes by CD4+ T cells of mice 
pretreated with VIPR agonists (n = 3). Fold changes and p values were 
determined using SABioscience RT2 Profiler PCR Array Data Analysis software, 
version 3.5. Fold changes and p values for differentially regulated mRNA levels 
with VIP (A), LBT-3627 (B), or LBT-3393 (C) treatment, normalized to PBS 
controls. Differences in fold change (n=3) were determined where p < 0.05. 
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Figure 13. VIPR2 agonism elicits changes in immune pathways. Shown are 
direct and indirect pathways utilizing T cell gene modulations that were 
significantly dysregulated with LBT-3627 treatment compared to PBS treatment 
group. Resulting gene networks from each treatment group were analyzed using 
Qiagen Ingenuity Pathway Analysis. Pink coloration indicates a modest increase 
in expression as compared to PBS control, and red indicates a profound increase 
in expression. Nodes lacking color indicate a molecule involved in the pathway, 
but not identified in the PCR data set. The central node, CSF-2 or GM-CSF is 
indicated in yellow color.  
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Figure 14. Targeting VIPR2 with LBT-3627 changes inflammation-associated 
gene expression in microglial populations.  
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Figure 14. Targeting VIPR2 with LBT-3627 changes inflammation-associated 
gene expression in microglial populations. CD11b+ microglial populations from 
the ventral midbrain of 8 mice were collected following treatment with MPTP 
alone, LBT-3627 pretreatment + MPTP, or LBT-3627 treatment only. Gene 
expression changes within the CD11b-enriched population were assessed using 
qRT-PCR (Inflammatory Response and Autoimmunity PCR profiler array) in each 
experimental group. Fold changes were determined using MPTP alone as the 
control. Fold changes for differentially regulated mRNA levels in response to 
LBT-3627 treatment only are displayed in the above table. Dark red coloration 
indicates a profound increase compared to MPTP, pink indicates a modest 
increase, light green indicates a modest decrease, and dark green indicates a 
profound decrease in expression.  
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Figure 15. Targeting VIPR2 with LBT-3627 prior to MPTP intoxication elicits 
changes in the inflammatory response pathway.  
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Figure 15. Targeting VIPR2 with LBT-3627 prior to MPTP intoxication elicits 
changes in the inflammatory response pathway. CD11b+ microglial populations 
from the ventral midbrain of 8 mice were collected following treatment with MPTP 
alone, LBT-3627 pretreatment + MPTP, or LBT-3627 treatment only. Gene 
expression changes within the CD11b+ enriched population were assessed using 
qRT-PCR (Inflammatory Response and Autoimmunity PCR profiler array) in each 
experimental group. Fold changes were determined using MPTP alone as the 
control. Fold changes for mRNA levels in response to LBT-3627 pretreatment 
followed by MPTP intoxication, normalized to MPTP alone. Dark red coloration 
indicates a profound increase compared to MPTP, pink indicates a modest 
increase, light green indicates a modest decrease, and dark green indicates a 
profound decrease in expression.  
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Figure 16. MPTP metabolism in the midbrain and striatum is not inhibited by 
pretreatment with VIPR agonists.  
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Figure 16. MPTP metabolism in the midbrain and striatum is not inhibited by 
pretreatment with VIPR agonists. Quantification of total MPTP and MPP+ levels 
in µg/g tissue in the midbrain (A) and striatum (B) of mice pretreated with VIP, 
LBT-3393, or LBT-3627 followed by MPTP intoxication. Tissues were collected at 
90 minutes after the final MPTP injection. Differences in means (± SEM, n=5) 
were determined where P < 0.05 compared with groups treated with MPTP only 












Figure 17. LBT-3627 treatment following MPTP intoxication does not attenuate 
neurodegeneration. Mice were intoxicated by MPTP and, after 12 hours, mice 
were then treated with LBT-3627 for 5 consecutive days. A. Total numbers of 
surviving dopaminergic neurons (TH+Nissl+) and non-dopaminergic neurons 
(TH-Nissl+) in the SN following MPTP treatment and post-MPTP intoxication 
treatment of LBT-3627. B. Relative TH densitometry of striatal dopaminergic 
termini following MPTP intoxication or MPTP intoxication followed by LBT-3627 
treatment. A and B. Differences in means (± SEM, n = 5) were determined where 

















3UTILIZATION OF BIOIMAGING TO EVALUATE THERAPEUTIC POTENTIAL 
FOLLOWING VIPR TREATMENT IN VIVO 
3.1 Abstract 
Neuroprotective immunity is defined by transformation of T cell polarity for 
therapeutic gain. For neurodegenerative disorders and specifically for PD, GM-
CSF or VIPR2-agonists elicit robust anti-inflammatory microglial responses 
leading to neuronal sparing in MPTP-intoxicated mice. While the 
neurotherapeutic potential of immune modulation was demonstrated for PD, 
there remain inherent limitations in translating these inventions from the 
laboratory to patients. One obstacle in translating such novel neurotherapeutics 
is limited to the availability of suitable noninvasive methods to track disease 
progression and therapeutic efficacy. To this end, manganese-enhanced 
magnetic resonance imaging (MEMRI) assays were developed as a way to track 
a linkage between glial activation and VIPR2 agonist (LBT-3627)-induced 
neuroprotective immunity for MPTP-induced nigrostriatal degeneration. Notably, 
LBT-3627-treated, MPTP-intoxicated mice showed reduced MEMRI brain signal 
intensities. These changes were associated with reduced astrogliosis and 
sparing of nigral tyrosine hydroxylase neurons. Most importantly, the data 
suggest that MEMRI can be developed as a biomarker tool to monitor 
neurotherapeutic responses following treatment. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  Data previously published: Olson, K.E., Bade, A.N., Schutt, C.R. et al. Neurotherapeutics (2016) 




Progressive nigrostriatal degeneration and its associated neuroinflammation 
contribute to the pathogenesis of PD. Although the cause of PD remains 
unknown, aberrant innate and adaptive immune responses direct the time course 
of nigral neuronal loss (Kosloski et al., 2010, Ha et al., 2012). Associated 
immune activation is propagated through the accumulation and extracellular 
release of α-syn, a self-protein (Benner et al., 2008). Extracellular release of 
aggregated and post-translationally modified α-syn results in glial activation that, 
in turn, affects the breakdown of immune tolerance. These pathological events 
underlie progressive dopaminergic neuronal loss and microglial activation. 
Indeed, neuronal loss is accompanied by robust microgliosis, astrocytosis and 
release of pro-inflammatory neurotoxic mediators (Mosley et al., 2012). Recent 
work from our own laboratories has served to highlight the role of Teff and Treg 
in attenuating such neuroinflammatory response cascades (Reynolds et al., 
2010, Kosloski et al., 2013). The balance between Teff and Treg activities leads 
to degenerative or protective effects in the brain, respectively, depending on 
defined T cell polarity and cell phenotype (Kosloski et al., 2010). Immune profiles 
analyzed in PD patients support a functional balance between the cells becasue 
circulating immunocyte profiles demonstrate increased pro-inflammatory profiles 
and decreased Treg function (Saunders et al., 2012). Such aberrations serve to 
change the brain’s microenvironment such that a pro-inflammatory dominance 
ensues. These notions are further supported by pre-clinical studies performed in 
	  104	  
an MPTP model of PD where intervention by immune modulation serves to 
protect dopaminergic neurons within the nigrostriatal pathway (Schabitz et al., 
2008, Kosloski et al., 2013).  
Mobilizing specific Treg adaptive immune responses affects microglial 
reactivity and protects against nigrostriatal degeneration (Reynolds et al., 2010, 
Kosloski et al., 2013, Olson et al., 2015). The use of immunomodulatory 
compounds shifts immune phenotypes and functions from neurotoxic to 
neuroprotective regulatory responses (Reynolds et al., 2010, Kosloski et al., 
2013, Olson et al., 2015). Specifically targeting VIP receptor 2 (VIPR2) with a 
modified VIP analog (referred to as LBT-3627) showed robust neuroprotective 
activities in MPTP-intoxicated mice (Olson et al., 2015). LBT-3627 attenuates 
microglial activation and induces endogenous GM-CSF mRNA transcripts 
leading to increased Treg functional activities and potentiation of dopaminergic 
neuronal sparing. This has clinical relevance as recently shown in a randomized 
phase I clinical trial of Sargramostim where improvements in motor skills were 
observed as a consequence of immune modulation (Gendelman et al., 2017). 
LBT-3627 is a receptor-selective and metabolically stable agonist and a potent 
inducer of Treg. Moreover, it should not be associated with untoward adverse 
events, such as those observed with GM-CSF (Vial and Descotes, 1995a, 
Gendelman et al., 2017). Thus, further assessment of the neurotherapeutic 
capacities of LBT-3627 in a preclinically relevant model using bioimaging 
techniques was utilized. Manganese (Mn)-enhanced magnetic resonance 
imaging (MEMRI) was used as a noninvasive imaging biomarker assay to follow 
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disease progression and to assess the abilities of LBT-3627 therapies to slow 
neurodegenerative activities. However, even with promising results, a potential 
downside of its use rests in the fact that Mn exposure can be linked parkinsonism 
in humans (Olanow, 2004, Kwakye et al., 2015). Thus, owing to the toxicity of 
Mn, MEMRI has only been utilized in animal studies. The feasibility of using 
MEMRI in humans is still under investigation. Nonetheless, we now show that 
MEMRI is an effective noninvasive tool that can be developed as a means to 
follow immune-modulatory neurotherapies in experimental models for preclinical 
testing. 
 
3.3 Materials and methods 
Animals, Drug treatment, and MPTP Intoxications 
Male C57BL/6J mice, 6–8 weeks old (The Jackson Laboratory, Bar Harbor, ME, 
USA) were used in all studies. Mice were pretreated with LBT-3627 (Longevity 
Biotech, Inc., Philadelphia, PA, USA), a VIPR2 agonist, at intraperitoneal 
dosages of 15 µg or 45 µg daily for 5 days prior to MPTP intoxication. On the 
sixth day, mice received 4 subcutaneous injections of vehicle [Dulbecco’s 
phosphate-buffered saline (DPBS), 10 ml/kg body weight] or MPTP –HCl 
(SigmaAldrich, St. Louis, MO, USA) at 16 mg MPTP (free base)/ kg body weight 
in DPBS, with each injection given every 2h. MPTP safety precautions were 
followed according to published safety and handling protocol (Przedborski et al., 
2000, Jackson-Lewis and Przedborski, 2007). All animal procedures used in this 
report were approved by the Institutional Animal Care and Use Committee of the 
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University of Nebraska Medical Center and were in agreement with the 
guidelines set by the National Institutes of Health. 
 
Manganese-enhanced MRI (MEMRI) 
A 50 mM solution of MnCl2 ·4H 2O (Sigma-Aldrich) in 0.9 % w/v NaCl (Hospira, 
Lake Forest, IL, USA) was used for MEMRI. For MEMRI examinations, 
60mg(0.3mmol)/kg MnCl2 solution was administered intraperitoneally at 48 and 
24 h prior to initiation of examination. The fractioned MnCl2 administration 
scheme (1 i.p. dose per day for 2 days) were used to control uneven Mn2+ 
distribution caused by a variety reasons, including differences in extracellular and 
intracellular Mn2+ concentrations, anterograde transport through neurons, and 
injection variability. This design allows Mn2+ to reach a stable distribution as 
previously published by others and our laboratory (Grunecker et al., 2010, 
Grunecker et al., 2013). The period of stable distribution allows for reproducible 
and even distribution of signal during MRI (Silva et al., 2004, Silva and Bock, 
2008, Grunecker et al., 2010, Massaad and Pautler, 2011, Grunecker et al., 
2013). For studies performed 2 days post-MPTP treatment, the first MnCl2 was 
injected 4 h after MPTP/DPBS administration. After lesion formation (day 5), 
MEMRI examinations were performed on a staggered basis for days 7–16 post 
MPTP/DPBS treatment and were binned together (hereafter designated as day-7 
examinations). As only 4 MEMRI examinations could be completed in 1 day, 
staggering examinations using 1 subject from each of 4 treatment groups (4 
total/day) were necessary to minimize between group variability. For both day-2 
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and day-7 examinations, mice were scanned in a 7T/21 cm MRI scanner (Bruker, 
Billerica, MA, USA). Animals were anesthetized by inhalation of isoflurane in 100 
% oxygen and maintained at 40–80 breaths/minute. Anesthetized mice were 
scanned using a T1 mapping sequence (fast spin echo with variable repetition 
time from 0.4 s to 10 s, 12 slices, slice thickness 0.5 mm, in-plane resolution 0.1 
× 0.1 mm2) and T1-weighted (T1-wt) MRI (FLASH, repetition time 20 ms, flip 
angle 20°, 3-dimensional isotropic resolution 0.1 × 0.1 × 0.1 mm3). After data 
acquisition, the mice were euthanized and tissues removed for 
immunohistological studies. T1 and T1-wt scans were performed prior to MPTP 
treatment, and the acquired image served as baseline data for the calculation of 
Mn-mediated signal enhancement. 
 
MRI Data Processing 
Brain volumes in the T1-wt images were first extracted using an in-house 
MATLAB program based on the level sets method. The brain images were then 
registered to the MRI-based mouse brain atlas (Laboratory of Neuro Imaging, 
University of California Los Angeles) using affine transformation first, and then 
nonlinear transformation (DiffeoMap; John Hopkins University, Baltimore, MD, 
USA). The baseline and postMnCl2 injection, T1-wt images were calibrated using 
T1 values to minimize the MRI system variations between the baselines and 
post-MnCl2 injection scans as described (Bock et al., 2008). Signal enhancement 
maps were calculated as follows: (SMn – Sbl) / Sbl, where SMn and Sbl are T1-
wt signal intensity of post- and pre-MnCl2 injection, respectively. The MEMRI 
	  108	  
enhancement maps were segmented automatically into 16 brain 
regions/subregions using the atlas. The enhancements in the regions were 
measured, and 1-way analysis of variance (ANOVA) performed to examine the 
significance of enhancement change among groups. A pixel-by-pixel comparison 
was also performed among groups using one-way ANOVA. A pixel on a brain 
image was compared with corresponding pixels on the same locus on other brain 
images. 
 
Tissue Acquisitions and Immunohistochemistry 
Following MEMRI scanning, mice were terminally anesthetized and transcardially 
perfused with DPBS followed by 4 % paraformaldehyde/DPBS (Sigma-Aldrich) at 
day 2 or days 7– 16 post-MPTP intoxication (referred to as day 7). Whole brains 
were harvested, processed, and flash-frozen to assess dopaminergic neuronal 
survival and glial reactivity in the substantia nigra (SN) as previously described 
[36]. Frozen midbrain sections (30 µm) were immunostained for either tyrosine 
hydroxylase (TH) (anti-TH, 1:2000; EMD Millipore, Billerica, MA, USA), Mac-1 
(anti-CD11b, 1:1000; AbD Serotech, Raleigh, NC, USA), or glial fibrillary acidic 
protein (anti-GFAP, 1:1000; Dako, Carpinteria, CA, USA). Within the SN, 
numbers of GFAP+ cells/mm2, Mac1+ cells/mm2, total numbers of TH+Nissl+ 
(dopaminergic neurons), and total numbers of TH-Nissl+ (nondopaminergic 
neurons) were estimated using stereological analysis via Stereo Investigator 
software with the optical fractionator module (MBF Bioscience, Williston, VT, 




All immunohistochemical values are expressed as mean ± SEM. Differences in 
between-group means were analyzed using ANOVA followed by Fisher’s least 
significant difference post hoc test (GraphPad Software, Inc., La Jolla, CA, USA). 
 
3.4 Results 
Detection of LBT-3627 therapy using MEMRI signal enhancement. 
Peak neuroinflammation and rate of neuronal death as measured by reactive 
microglia occurs 2 days post-MPTP intoxication (Kurkowska-Jastrzebska et al., 
1999b, a). We chose to examine the ability of MEMRI to detect changes between 
MPTP and DPBS controls during this time. MEMRI provides information relevant 
to assessments of neural anatomy, function, and connectivity (Eschenko et al., 
2010, Inoue et al., 2011). Mn2+ enters neurons through voltage-gated calcium 
Ca2+ channels, owing to its similarities with Ca2+, linking Mn2+ accumulation to 
MEMRI signal intensity (Massaad and Pautler, 2011). Additionally, in prior 
studies, we demonstrated that MEMRI signals are increased during 
neuroinflammation due to elevated neuronal Mn2+ uptake and accumulation 
through astrocyte activation (Bade et al., 2013, Bade et al., 2016). Thus, 
comparisons of pretreatment scans and day-2 or day-7 DPBS post-treatment 
scans demonstrated that MnCl2 administration yielded enhanced signal 
intensities (hereafter designated as MEMRI signal) (Figure 1 and 2). Previous 
reports of Mn enhanced T1-wt signaling confirm these results (Bade et al., 2013, 
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Bade et al., 2016). To minimize between-group by day variability, one subject 
from each of 4 treatment groups were assessed every day on days 7–16; a time 
after MPTP-induced lesion forms (Jackson-Lewis et al., 1995). Linear regression 
of all dependent experimental parameters for an effect of day showed no 
significant effects on any dependent variable except for MEMRI signal intensities 
and changes in intensities for mice treated with MPTP and 15 µg LBT-3627 (r2 
=0.64, p=0.0176). However, comparison of signal levels obtained on days 7–10 
with those obtained on days 11–14 showed no significant differences by t test (p 
=0.1091). Thus, data acquired on days 7–16 were binned as 1 time point and are 
hereafter designated as day-7 data. Using baseline T1-wt images, we prepared 
mean MEMRI signal enhancement maps for day 2 and day 7 acquisitions (Figure 
1A and 2A). Following bioimaging, results indicate that on day 2 following MPTP 
intoxication (Figure 1A), the MEMRI signal in the SN was diminished (column 3, 
row 4), while that in the striatum was increased (column 3, rows 1 and 2). Pixels 
with significant signal changes (p<0.05) were superimposed on anatomical 
structures to form a p-value map (Figure 1B). Significantly decreased MEMRI 
signals were found primarily within the SN (row 4). Striatum contained the most 
pixels of significantly increased signals (rows 1 and 2). A region-by-region 
comparison facilitated by the MRI-based atlas indicated the same findings (data 
not shown). A number of pixels on cerebral cortex and hippocampus also 
showed significant enhancement increases. However, the comparison did not 
find enhancement differences between the 2 groups. Comparison of subregions 
of hippocampus and cortex was not performed because the MRI-based mouse 
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brain atlas employed for enhancement map segmentation does not identify these 
subregions.  
Next, we assessed MEMRI signal after lesion formation in mice pretreated 
with LBT-3627. By day 7, the major inflammatory condition associated with 
reactive microglia in MPTP is essentially resolved, leaving only astrogliosis and 
the nigrostriatal lesion to be observed (Jackson-Lewis et al., 1995). In contrast to 
day 2, by day 7 MEMRI signals for DPBS controls and MPTP intoxicated mice 
were similar in most brain regions, including SN (column 3, rows 3 and 4). Signal 
intensity within the SN was significantly decreased in low-dose LBT-3627-treated 
mice compared with MPTP-intoxicated mice (columns 4 and 5, rows 3 and 4). 
The pixel-wise p-value map also showed the most pixels on 15 µg-treated with 
lower signal compared with MPTP-treated mice (Figure 2B). Mice treated with 
the higher dose of LBT-3627 also had lower MEMRI signal when compared with 
MPTP; however, it did not reach significance. The lack of significance is 
potentially due to the high variation of signal intensity and low number of animals. 
In accordance with our previous dose–response findings, a 45-µg dose appears 
to elicit an extremely variable response, indicating that we may be approaching a 
therapeutic threshold (Olson et al., 2015). In addition, both cerebral cortex and 
hippocampus included pixels that had significantly lower signal (Figure 2B). 
However, the brain atlas-based regional comparison did not find a significant 
difference between 15-µg-treated and MPTP mice in these 2 regions. 
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Changes in neuron numbers and glial reactivity following treatment with LBT-
3627. 
In order to assess the ability of MEMRI to detect neuronal loss and/or 
inflammation during MPTP, we carried out immunohistological evaluations to 
determine dopaminergic neuron numbers, microglial reactivity, and astrogliosis. 
As expected, TH+Nissl+ dopaminergic neurons were lost following MPTP 
intoxication (Figure 3A), whereas TH-Nissl+ neurons remained unchanged. At 
day 2, neuron numbers significantly dropped from 8020 ± 379 to 3938 ± 317, 
equivalent to a 51% loss (Figure 3B). At day 7, MPTP intoxication markedly 
reduced neuron levels to 42 %, with an increased loss compared with day 2 
(Figure 4A and 4B). Both the low and high dose of LBT-3627 significantly spared 
dopaminergic neurons, resulting in 62% and 64% neuron survival compared with 
DPBS alone. At 2 and 7 days post MPTP, reactive microglial populations were 
also assessed (Figure 5 and 6). When compared with day 2 DPBS controls, 
MPTP significantly increased reactive microglial cell numbers from 2.8 ± 0.3 
cells/mm2 to 46 ± 5 cells/mm2, Indicating an inflammatory response associated 
with MPTP intoxication (Figure 5). By day 7, there was a significant decrease in 
observed microglial reactivity, when compared with MPTP-treated mice (Figure 
6). The number of reactive microglia decreased by 48% from day 2 to day 7, 
indicating a resolution of inflammation. LBT-3627 treatment also led to a small 
decrease in reactive microglial numbers, standing at 15.18 ± 3 cells/mm2 and 
14.96 ± 2.7 cells/mm2 with both a low and high dose, respectively. However, the 
magnitude of changes in microglial activation at day 7 is small, which is expected 
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in this model. With the acute MPTP model of PD, the reactive microglial 
response generally subsides by day 7; thus, the minute differences observed 
between groups is in accordance with what has been previously demonstrated in 
the literature (Kohutnicka et al., 1998, Kurkowska-Jastrzebska et al., 1999a).  
In addition, GFAP-immunoreactive cells were assessed following MPTP 
intoxication at both time points, as well as following low- and high-dose LBT-3627 
pretreatment (Figure 7 and Figure 8). At day 2, MPTP intoxication led to an 
unremarkable increase in astroglial response (Figure 7). However, by day 7, the 
increase was highly significant (Figure 8A). Compared with DPBS, MPTP 
intoxication noticeably increased GFAP reactivity by nearly 6-fold from 12 ± 2 
cells/mm2 to 61 ± 8 cells/mm2 (Figure 8B). Both doses of LBT-3627 pretreatment 
attenuated astroglial response by significantly decreasing GFAP reactivity by 
~50% when compared with MPTP treatment alone (Figure 8B). In developing 
MEMRI as a potential therapeutic biomarker, we sought to correlate signal 
intensity change with the immunohistological findings (Figure 9). When 
comparing dopaminergic neuron (Th+Nissl+) number and signal intensity, data 
was found to be associated in all treatment arms except for MPTP-treated mice 
at day 7 that did not receive LBT-3627 treatment (Figure 9A). Microglial reactivity 
seemed to be inversely related to signal enhancement, indicating that microglial 
response over time does not contribute to the MEMRI signal strength (Figure 
9B). As expected, correlation analysis of combined day 2 and day 7 data points 
revealed a positive relationship between signal intensity and TH+ neuronal 
number (r=0.36, p=0.0208), and a negative relationship between signal intensity 
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and Mac-1+ microglia cell numbers (r=−0.42, p=0.0066), indicating that increases 
in signal intensity correlate with increased neuron number and decreased 
microglial response. Interestingly, for GFAP+ staining, there was not a significant 
correlation observed when including all data points. Conversely, when comparing 
data on day 2 alone, changes in GFAP+ staining was negatively related to 
changes in signal intensity in MPTP-treated groups (r =−0.74, p=0.0092), as 
shown in Figure 9C. At day 2, when MEMRI signal intensity was significantly 
decreased from DPBS control levels, GFAP+ astrocyte numbers were also low, 
with no significant change observed between DPBS and MPTP treatment. 
However, by day 7, MEMRI signal intensity corresponded with significantly higher 
GFAP+ reactivity, indicating that the increased signal may be due to an activation 
of astrocytes, which outweighed the expected decreased signal due to the 
significant neuronal loss seen 7 days after the formation of an MPTP-mediated 
lesion. Likewise, in the mice pretreated with LBT-3627, the decrease in MEMRI 
signal was likely due to the loss of neurons from MPTP. Also, there was an 




Progressive neuronal degeneration underlies the pathobiology of a broad range 
of neurodegenerative diseases that include PD (Kalia and Lang, 2015). While the 
causes of most neurodegenerative diseases are not known, the relationship 
between neurodegeneration and immune system activation is clear. Therapies 
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are constantly being developed and tested to modulate or transform the immune 
system with the intention to clear misfolded, aggregated, and nitrosylated 
proteins, as well as to restore the damaged central nervous system 
microenvironment (Olanow et al., 2009). Amongst these therapies, there are 
agents that can change a dominant effector phenotype to one that promotes 
immune tolerance and is regulatory, anti-inflammatory, and neuroprotective. One 
such candidate is LBT-3627. This drug has shown robust neuroprotective 
potential in MPTP-intoxicated animals to attenuate neuroinflammatory responses 
while affecting Treg function (Olson et al., 2015). Despite such effects, broad 
obstacles still lie ahead in bringing the treatments to human use. With this in 
mind, our laboratory has pioneered preclinical development of these agents and 
entered into randomized clinical evaluations (Gendelman et al., 2017). All such 
efforts have shown promise but with known limitations. One such limitation rests 
in uncovering suitable biomarkers to track disease and therapeutic effectiveness. 
While immune monitoring of circulating T cell numbers and functions have 
proven helpful, these tests are cumbersome, time consuming, and require 
multiple technical arms for evaluation and confirmatory assessments. Thus, the 
need for suitable biomarkers to track disease and therapeutic efficacy are real 
and timely.  
Here, we report that MEMRI can be used to assess inflammatory activities 
related to neuronal loss and astrocyte activation. With a neurotherapeutic 
directive in mind, our imaging results suggest the ability of MEMRI to detect 
immune modulation following MPTP treatment and LBT-3627 pretreatment. In 
	  116	  
this case, inflammation reduction seemed to outweigh the neuronal protection 
effect, possibly leading to lower MEMRI enhancement in LBT-3627-treated mice 
compared with MPTP mice. Mn2+ serves as a surrogate measure of calcium 
influx linking MEMRI signal to the accumulation of the ion in neurons in an 
activity-dependent manner. As such, MEMRI signal is directly related to neural 
viability and activity (Takeda et al., 1998, Pautler and Koretsky, 2002). To date, 
some studies have utilized MEMRI for studying pathobiology of 
neurodegenerative diseases, such as PD (Kondoh et al., 2005, Pelled et al., 
2007, Soria et al., 2011, Weng et al., 2016). However, neurodegeneration is a 
dynamic process rather than a static event. Immune responses, neuronal 
impairment, and other pathological events are involved in neurodegenerative 
diseases, which can ultimately affect MEMRI signal intensity output. Delineation 
of the cellular basis of MEMRI is critical if it is harnessed as an imaging 
biomarker to gauge disease progression in experimental models.  
Previously, MEMRI signal change following a neuroinflammatory lesion 
was explored in a prior study from our laboratory (Bade et al., 2013). MEMRI's 
ability to detect astrocyte, microglia and neuronal activation were measured 
following treatment with lipopolysaccharide or proinflammatory cytokines, both in 
vitro and in vivo. We were able to distinguish differences in MEMRI signal from 
either activated glia or neuronal injury. As such, we used the agent as a marker 
for neural activity in inflammatory and degenerative disease states. We also 
found axonal loss detected by traditional neurofilament staining coupled with 
MEMRI signal loss (Bade et al., 2016). These findings support the notion that 
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MEMRI reflects neuronal excitotoxicity and impairment that can occur through a 
range of insults including neuroinflammation. We concluded that the MEMRI 
signal enhancement is induced by inflammation stimulating neuronal Mn2+ 
uptake. As previously stated, Mn2+ ions enter neurons through Ca2+ channels, 
and brain function depends on complex metabolic interactions amongst only a 
few different cell types, with astrocytes providing critical support for neuron 
function and survival. Astrocyte functions include buffering toxins in its 
extracellular environment, providing support to neurons, modulating glutamate 
and glutamine levels, and affecting neuronal synaptic transmission (Kimelberg 
and Nedergaard, 2010, Khakh and Sofroniew, 2015). Neurons undergo 
extremely oxidative metabolism making them highly susceptible to injury, 
whereas astrocytes are affected by glycolytic metabolism and are much less 
susceptible to oxygen deprivation. These differences in metabolism provide 
therapeutic opportunities to address Mn2+ sensitivity. Interactions between both 
cell types changes the metabolism of neurons through a range of mechanisms, 
including active glycolysis, lactate extrusion, and glutamate uptake by 
dysregulation of transporters (Araque, 2006, Ricci et al., 2009). Thus, activated 
astrocytes have a profound influence on neuronal metabolic susceptibilities and 
are changed by environment, disease, and therapeutic interventions that can 
alter function and lead to enhanced proliferation and cell surface receptor 
expression. In turn, the astrocyte phenotypic shift affects neuronal function. In 
support of this idea, in our prior study, we observed elevated Mn2+ uptake by 
neurons caused by astrogliosis (Bade et al., 2013). Thus, we also posit that 
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reactive astrocytes release cytokines stimulating neuronal Ca2+ channel activity 
and, ultimately, Mn2+ uptake.  
We demonstrated that MEMRI signals are increased during 
neuroinflammation owing to elevated neuronal Mn2+ uptake and accumulation 
through astrocyte activation through calcium channels (Bade et al., 2013, Bade 
et al., 2016). Likewise, as Mn2+ is rapidly taken up into both neurons and 
astrocytes, neuronal death leads to the release of Mn2+, and leads to decreased 
MEMRI signal (Massaad and Pautler, 2011). Similarly, in a model of traumatic 
brain injury, regions of MEMRI hyper-intensity are seen at lesion sites and are 
associated with increased accumulation and infiltration of astrocytes to the lesion 
(Talley Watts et al., 2015). Similar effects can be observed in the current study at 
2 days following MPTP intoxication, a time of peak neuronal loss and peak 
microglial response within the SN. Neuronal injury often leads to proliferation and 
migration of activated microglia to assist with cellular debris cleanup (Neumann 
et al., 2009). It could be hypothesized that activated microglia are ingesting 
released Mn2+ during this period, potentially leading to an increase in signal. 
However, we have previously found that macrophage uptake of Mn2+ using 
inductively coupled plasma mass spectrometry is not operative in these 
conditions (unpublished data). In accordance with this previous finding, increased 
early microgliosis appears to have a minimal effect on MEMRI enhancement at 
day 2, even with peak reactivity. Yet, there is the possibility that enhanced 
microglial reactivity could potentially be inhibiting neuronal uptake of Mn2+ due to 
elevated inflammatory states and neuronal degeneration, adding to a decrease in 
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MEMRI signal. Interestingly, there was a significant signal enhancement found in 
the striatum of mice treated with MPTP rather than a decrease like that observed 
in the SN. This finding was not confirmed by immunohistology, but may be owing 
to the fact that striatal termini begin to degenerate prior to the loss of 
dopaminergic cell bodies (Burke and O'Malley, 2013). Early degeneration of 
termini may induce astroglial reactivity more quickly than is seen in the SN, 
resulting in an increased signal enhancement. 
 By 7 days after initial MPTP intoxication, TH+ neuronal death is dominant, 
with limited microgliosis and a robust astroglial response. Treatment with LBT-
3627 significantly attenuates the astroglial response, paralleled by a coincident 
decrease in signal enhancement. The results suggest that MEMRI signal 
enhancements can reflect both neuronal loss and reduced astrogliosis seen 
following therapeutic activities. Nonetheless, at day 7, MEMRI signal shows no 
differences between saline-treated controls and MPTP-intoxicated mice. This 
seemingly discordant result can be explained by the astrocyte signal. As shown 
previously, astrocyte activation elicits MEMRI signal enhancement (Bade et al., 
2013). Moreover, astrogliosis and neurodegeneration can occur at the same time 
but have opposite effects on the MEMRI signal. That is, neuronal death elicits a 
signal decrease, while astrocytic activation enhances the signal. Interestingly, 
certain areas within the hippocampus and cerebral cortex were found to be 
significantly increased in MEMRI enhancement in MPTP-treated mice on day 2, 
and lower enhancement in 15-µg LBT-3627-treated mice compared with MPTP-
treated mice on day 7. In future studies, we will identify these areas and 
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investigate the pathology underlying the MEMRI signal changes. Relationships 
between MEMRI signal enhancement and glial interactions has been shown in a 
range of neurological disease models (Haapanen et al., 2007, Immonen et al., 
2008, Soria et al., 2011, Talley Watts et al., 2015). However, results have been 
conflicting. This has suggested that only astrocyte responses affect signal 
enhancement. Others have found that both activated microglia and astrocytes 
elicit signal change (Haapanen et al., 2007, Wideroe et al., 2009, Kawai et al., 
2010), or that astrocyte activation may play no role at all (Immonen et al., 2008). 
Thus, we chose to utilize an inflammatory model of disease that would allow us 
to evaluate longitudinally and independently microgliosis and astrocytic 
engagement in the MEMRI responses (Kohutnicka et al., 1998).  
By assessing early events (2 days after MPTP intoxication), a time of peak 
inflammation and microglial reactivity coincident with a peak rate of neuronal 
death, we could assess signal decreases primarily linked to neuronal loss. Here, 
astrocyte involvement was not observed. However, after 7 days, when microglial 
activation is diminished and nervous tissue repair is operative, coincident with 
astrocyte activation and facilitated Mn2+ uptake, MEMRI signal enhancement 
appears to be associated with changes in GFAP+ reactivity. Such events are 
observed during treatment of MPTP intoxication. Indeed, we demonstrate that 
inflammation-induced astrocyte activation can stimulate Mn2+ uptake, potentially 
leading to MEMRI signal enhancement. However, the sensitivity of the MEMRI 
signal changes in relation to the changes in immunohistology is relatively low. 
The moderately low spatial resolution of MEMRI (100 µm3 pixel size) compared 
	  121	  
with histological slices is one potential cause of the low sensitivity observed. 
Another reason can be attributed to the calculated T1wt signal enhancement as 
the measure of tissue Mn2+ concentration. For accurate calculation of MEMRI 
enhancement, scanner system variations among imaging sessions must be 
corrected, as described in a previous study (Bade et al., 2016). Currently, we are 
developing 3-dimensional high-resolution (<100 µm3 pixel size) T1 mapping 
methods for future use, potentially providing improved assessment of underlying 
histopathology. Nonetheless, MEMRI is a valuable tool as it provides in vivo 
















3.6 Figures  
 
Figure 1. Comparison of MEMRI signal enhancement between controls and 










Figure 1. Comparison of MEMRI signal enhancement between controls and 
MPTP-intoxicated mice at day 2 post-MPTP. A MEMRI enhancement maps. 
The first column (from left) shows coronal slices of the averaged MEMRI of 
control mice (n=5) as an anatomical reference. The sagittal slice (upper left) 
shows respective coronal slices (red lines from rostral to caudal) that correspond 
to images in rows 1-4 showing sections with striatum (rows 1-2) or midbrain 
(rows 3-4). The second column shows the average enhancement in control mice 
on the coronal slices. The third column represents the average enhancement of 
MPTP-intoxicated mice (n=6). The color bar for the enhancement maps is at the 
top of the figure. Dark blue color (0%) means no change in enhancement from 
Mn2+ compared to pre-injection signal intensity. Dark red color represents 90% 
signal increase compared to pre-injection signal intensity. B Statistical 
comparison of MEMRI enhancement between control and MPTP-intoxicated 
mice. The left column shows the pixels (red color) with significant decrease 
(p  <  0.05) in signal intensity overlaid onto the averaged brain image. The right 
column shows the pixels (red color) with significant increase (p  <  0.05) in signal 
intensity overlaid onto the averaged brain image.  
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Figure 2. Comparison of MEMRI enhancement between controls and MPTP-
intoxicated mice at day 7.  
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Figure 2. Comparison of MEMRI enhancement between controls and MPTP-
intoxicated mice at day 7.  A MEMRI enhancement maps. The first 
column (from left) shows coronal slices of the averaged MEMRI of control mice 
(n=5) as an anatomical reference. The sagittal slice (upper left) shows respective 
coronal positions (red lines). The second column shows the average 
enhancement in control mice on the coronal slices. The third column represents 
the average enhancement of MPTP-intoxicated mice (n=6). The forth column 
represents the average enhancement of MPTP-intoxicated mice treated with 15 
µg LBT-3627. The forth column represents the average enhancement of MPTP-
intoxicated mice treated with 45 µg LBT-3627. The color bar for the enhancement 
maps is at the top of the figure. Dark blue color (0 %) means no change in 
enhancement from Mn2+ compared to pre-injection signal intensity. Dark 
red color represents 90 % signal increase compared to pre-injection signal 
intensity. B Statistical comparison of MEMRI enhancement between MPTP-
intoxicated mice and MPTP-intoxicated mice treated with 15 µg LBT-3627. 
It shows the pixels (red color) with significant decrease (p  <  0.05) in signal 
intensity overlaid onto the averaged brain image. 
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Figure 3.  Assessment of neuronal survival at day 2 following MPTP intoxication 




Figure 3.  Assessment of neuronal survival at day 2 following MPTP intoxication 
and LBT-3627 pretreatment. A. Photomicrographs of TH+Nissl+ neurons in the 
substantia nigra (4x) in mice treated with PBS or MPTP, followed by 
quantification of TH+Nissl+ and TH-Nissl+ neuronal counts. B. Quantification of 
surviving TH+ dopaminergic neurons within the substantia nigra at 2 days post 
MPTP Intoxication.  All sections were immunostained with anti-TH, color was 
generated with DAB, and sections were counterstained with thionin. Differences 
in means (± SEM, n=5-8) were determined ANOVA followed by Fisher’s least 
significant difference (LSD) post hoc test where P<0.05 compared with PBS (a). 
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Figure 4. Quantification of dopaminergic neuronal survival following pretreatment 




Figure 4. Quantification of dopaminergic neuronal survival following pretreatment 
with 2 different doses of LBT-3627. A. Photomicrographs of surviving TH+Nissl+ 
neurons after 7 days within the SN following treatment with MPTP or LBT-3627 
pretreatment of 15 µg or 45 µg doses. B. Quantification of TH+Nissl+ and TH-
Nissl+ neurons following treatment. Sections were stained as described in Figure 
3. Differences in means (± SEM, n=5-8) were determined ANOVA followed by 
Fisher’s least significant difference (LSD) post hoc test where P<0.05 compared 














Figure 5. Assessment of microglial reactivity after 2 days following MPTP 

















Figure 5. Assessment of microglial reactivity after 2 days following MPTP 
intoxication and LBT-3627 pretreatment. Representative photomicrographs of 
Mac-1+ microglia within the SN of mice treated with PBS alone or at day 2 after 
MPTP intoxication (4x with 40x inset). The right panel depicts number of reactive 
microglia taken from midbrains 2 days following MPTP treatment. Differences in 
means (± SEM, n=5-8) were determined by ANOVA followed by Fisher’s least 
significant difference (LSD) post hoc test where P<0.05 compared with groups 
treated with PBS (a). 
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Figure 6. Assessment of microglial reactivity after 7 days post MPTP intoxication 





Figure 6. Assessment of microglial reactivity after 7 days post MPTP intoxication 
and LBT-3627 pretreatment. Nigral sections were immunostained for Mac-1+ 
microglia using an anti-Mac-1 antibody, HRP-conjugated secondary antibody, 
and DAB. Numbers of reactive microglia were assessed by stereological 
analysis. A. Photomicrographs of reactive microglia at day 7 after MPTP 
intoxication, followed by quantification of Mac-1+ cells/mm2 (B).  Differences in 
means (± SEM, n = 5-8) were determined by ANOVA followed by Fisher’s least 
significant difference (LSD) post hoc test where P<0.05 compared with groups 




Figure 7. GFAP reactivity at 2 days post MPTP intoxication and LBT-3627 
pretreatment.  
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Figure 7. GFAP reactivity at 2 days post MPTP intoxication and LBT-3627 
pretreatment. Representative photomicrographs of GFAP immunoreactive cells 2 
days post MPTP intoxication within the SN of mice (10x with 40x inset) treated 
with PBS or MPTP are displayed. Quantification was assessed using 
stereological analysis and was reported as GFAP+ cells/mm2, as indicated in the 


























Figure 8. GFAP reactivity is increased after MPTP-intoxication.  A. 
Photomicrographs of GFAP+ cells following MPTP intoxication and LBT-3627 
pretreatment at day 7. B. Quantification of day 7 reactive astrocytes. Serial 
sections were stained with a primary antibody against GFAP, followed by a 
biotinylated secondary antibody, and DAB color development. Sections were 
counterstained with thionin, and quantification was assessed using stereological 
analysis. Differences in means (± SEM, n=5-8) were determined by ANOVA 
followed by Fisher’s least significant difference (LSD) post hoc test where P<0.05 




Figure 9.  Time comparison of immunohistology and signal enhancement.  
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Figure 9.  Time comparison of immunohistology and signal enhancement. 
Change in signal intensity ± SEM was determined from PBS controls and was 
compared to total number of TH+ neuron (A), numbers of Mac-1+ microglia/mm2 
(B), and numbers of GFAP+ astrocytes/mm2 (C) at days 2 and 7. Change in 
signal intensity is labeled in blue and cells numbers in red. Differences in means 
(± SEM, n=5-8) were determined by ANOVA followed by Fisher’s least significant 
difference (LSD) post hoc test where P<0.05 compared with groups treated with 


















INTERPLAY BETWEEN VIRAL INFECTION AND PARKINSON’S DISEASE 
4.1 Abstract  
Recent advances in human immunodeficiency virus (HIV) treatment have 
dramatically prolonged the life expectancy of individuals living with the disease. 
Increased aging is associated with the likelihood of developing age-related 
disease, such as Parkinson’s disease. Interestingly, it has been shown that 
viruses can enter the central nervous system and potentially lead to 
neuropathologies themselves. HIV infection is associated with motor dysfunction 
and postural and gait abnormalities similar to the late stages of Parkinson’s 
disease, and it has also been associated with other disease hallmarks such as 
dopaminergic cell loss and neuroinflammation. Thus, we address whether viral 
infection itself can induce Parkinson-like neurodegeneration or whether it can 
speed or exacerbate MPTP-induced neurodegeneration using two models of viral 
infection, HIV and EcoHIV. Findings suggest that there is a synergistic 
mechanism of immune dysfunction during chronic periods of infection that 
causes increased dopaminergic cell loss. Likewise, EcoHIV appears to play a 
direct role in dopaminergic cell death, indicating that the virus itself is neurotoxic, 
even in the absence of an inflammatory stimulus.  
 
4.2 Introduction 
Since the advent of highly active anti-retroviral therapies for the treatment of HIV 
infection, persons living with the disease are aging at a rate similar to the normal 
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population. Infected individuals are living longer and the number of patients over 
the age of 50 is increasing (Wing, 2016). Consequently, these patients are now 
prone to suffer from age-related neurodegenerative diseases such as PD, a 
disease characterized by motor dysfunction due to the loss of dopaminergic 
neurons along the nigrostriatal system and the formation of Lewy bodies resulting 
from the accumulation of misfolded or modified α-syn (Olanow et al., 2009, Kalia 
and Lang, 2015). Past studies indicate that the CNS is highly susceptible to HIV 
infection, with increased susceptibility in dopamine-rich areas, such as those 
affected by PD itself (Ellis et al., 2009, Kumar et al., 2009). Along the same lines, 
post-mortem brain tissues isolated from individuals living with HIV display 
increased α-syn within the substantia nigra (Khanlou et al., 2009). Patients also 
suffer from other overlapping disease characteristics such as neuroinflammation, 
lymphocyte infiltration into the CNS, impaired mitochondrial function, increased 
peripheral pro-inflammatory cytokine levels, and increased oxidative stress 
(Jones et al., 1998, Hong and Banks, 2015, Moulignier et al., 2015).  
Interestingly, HIV patients also display many key motor and non-motor 
features observed in advanced PD such as bradykinesia, altered posture, 
impaired dexterity, altered gait, and cognitive impairments (Navia et al., 1986, 
Sheppard et al., 2015). Parkinsonism and Parkinson-like symptoms are also 
present in those suffering from acquired immunodeficiency syndrome (AIDS) 
(Rosso et al., 2009). Importantly, a non-invasive MEG study to monitor motor 
control demonstrated that HIV-infected patients have reduced beta responses 
indicative of a deficit in movement planning (Wilson et al., 2013). These motor 
	  142	  
dysfunctions are most likely the result of the loss of neurons within dopamine-rich 
regions such as the basal ganglia, substantia nigra, and striatum (Berger and 
Arendt, 2000). Loss of dopaminergic neurons results in decreased availability of 
dopamine, a neurotransmitter needed for movement-related signaling (Groger et 
al., 2014). For example, HIV-infected patients display up to a 53% decrease in 
dopamine availability within affected brain regions and when treated with anti-
retrovirals, they still experience a 45% decrease in dopamine levels (Kumar et 
al., 2011). Similarly, they also display decreases in the dopamine metabolite, 
homovanillic acid (HVA) (Kumar et al., 2009, Kumar et al., 2011). Thus, their 
movement and gait dysfunctions can be attributed to decreases in dopamine and 
dopamine metabolite availability.  
Due to the overlap of disease hallmarks and characteristics between viral 
infection and Parkinson’s-like symptoms, a direct association between the two is 
hypothesized. Likewise, several other viruses have already been shown to be 
associated with potential parkinsonism and Parkinson’s-like symptoms due to the 
neurotrophic character of viruses (Jang et al., 2009). To extend these findings, 
we tested whether viral infection impacts nigrostriatal degeneration by employing 
two mouse models of viral infection in parallel with MPTP intoxication.  
 
4.3 Materials and methods 
 
Animals, infections, and MPTP intoxication 
 
For HIV infection in humanized mouse studies, new-born NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NOD/scid-IL-2Rγcnull or NSG) mice (stock 005557, Jackson 
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Laboratories, Bar Harbor, ME) were transplanted with human CD34+ stem cells 
obtained from blood taken from the human umbilical cord, as previously 
described (Knibbe-Hollinger et al., 2015). Balb/cJ mice (stock 000651, Jackson 
Laboratories) served as non-humanized controls. After 15 weeks of 
reconstitution, humanized NSG mice were selected for study use based on 
human CD45+ cells numbers within peripheral blood. The selected animals were 
infected with HIV-1ADA via intraperitoneal injection at 104 tissue culture infective 
dose 50 (TCID50)/mouse. After four weeks of infection, mice received four s.c. 
injections of vehicle (DPBS, 10 ml/kg body weight) or MPTP-HCl (Sigma-Aldrich) 
at 14 mg MPTP (free base)/kg body weight in DPBS; each dose given at two 
hour intervals. Seven days post-MPTP intoxication, mice were sacrificed, brains 
harvested, and tissues processed for analysis. MPTP safety precautions were 
followed in accordance with determined safety and handling protocol (Jackson-
Lewis and Przedborski, 2007). All animal procedures were also in agreement 
with National Institutes of Health guidelines and approved by the Institutional 
Animal Care and Use Committee of the University of Nebraska Medical Center.  
Six- to eight-week old, male C57BL/6J mice (stock 000664) or B6.CB17-
Prkdcscid/SzJ (C57BL/6 scid) mice (stock 001913) (The Jackson Laboratory) were 
used in all EcoHIV studies. In order to achieve infection, mice were inoculated 
intraperitoneally using EcoHIV, kindly provided by the laboratory of Dr. David 
Volsky (Columbia University, New York), at a dose of 3x106 pg p24/mouse. 
EcoHIV virus stock was prepared as previously described (Potash et al., 2005). 
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After 4 weeks of infection, animals were intoxicated with MPTP in the same 
manner as the HIV studies. 
 
Plasma collection, flow cytometric assessment and T cell Profiling 
 
During the course of infection, peripheral blood was isolated using a maxillary 
bleed. Plasma was collected for analysis of viral load, and whole blood was 
stained with fluorescently-conjugated monoclonal antibodies to human CD45, 
CD3, CD4, CD25, CD8, and FoxP3 in order to quantify T cell frequencies. For 
intracellular staining, samples were permeabilized using the FoxP3 staining 
buffer set kit (eBioscience). Fluorescent staining was analyzed using a 
FACSCalibur flow cytometer.  
 
Perfusions and immunohistochemistry  
 
Following administration of terminal anesthesia (Fatal Plus, pentobarbital), mice 
were transcardially perfused with DPBS followed by 4% paraformaldehyde/DPBS 
(Sigma-Aldrich).  On day 7, to assess dopaminergic neurons in the substantia 
nigra (SN) and termini in the striatum, whole brains were isolated and 
cryosectioned. Frozen midbrain sections (30 µm) were immunostained for 
tyrosine hydroxylase (TH) (anti-TH, 1:2000, EMD Millipore) and counterstained 
for Nissl substance, as previously described (Benner et al., 2008). To determine 
the microglial reactivity, midbrain sections (30 µm) were immunostained for Mac-
1 (anti-CD11b, 1:1000, AbD Serotech), as previously described (Kosloski et al., 
2013). Within the SN, Stereo Investigator software (MBF Bioscicence) was 
utilized to determine, by stereological analysis, the total numbers of Mac-1+ 
	  145	  
cells/mm2, TH+Nissl+ (dopaminergic neurons), and TH-Nissl+ (non-dopaminergic 
neurons) within the substantia nigra. Density of dopaminergic neuronal termini in 
the striatum was calculated by digital densitometry using Image J software 
(National Institutes of Health).  
 
RNA isolations and polymerase chain reaction  
Following 4 weeks of infection and MPTP intoxication, fresh ventral midbrain 
tissue was isolated, and total RNA was harvested using an RNeasy Mini Kit 
(Qiagen), using RNAse-free conditions. cDNA was generated from RNA using 
the RevertAid First Strand cDNA Synthesis kit (Thermo Scientific) and pre-
amplification was performed using the appropriate primer mixes for RT2 PCR 
arrays for the mouse Inflammatory Response array (Qiagen). Quantitative RT-
PCR was performed on an Eppendorf Mastercycler realplex ep as per the 
manufacturer’s instructions (Eppendorf). Data analysis was performed using RT2 
Profiler PCR Array web-based data analysis software, version 3.5 (Qiagen), and 
gene networks were generated using Ingenuity Pathway Analysis (IPA, Qiagen). 
The resulting pathway was designed using the Pathway Designer Tool.  
 
Statistical Analysis 
All values are expressed as means ± SEM. Differences in between-group means 
were analyzed using ANOVA followed by Fisher’s least significant difference 





HIV infection does not exacerbate neurodegeneration in MPTP-intoxicated 
humanized mice.  
To determine the interplay between HIV infection and development of Parkinson-
like symptoms, we utilized humanized NSG mice that were either infected with 
HIV or uninfected, followed by MPTP intoxication. Following infection, mice were 
sacrificed and stereological analysis was used to quantify surviving neuron 
numbers. TH+Nissl+ dopaminergic neuron counts were decreased with MPTP 
intoxication, as expected from 9012 ± 679 to 6596 ± 580  (Figure 1A and 1B). 
However, co-infection with HIV did not increase the degree of degeneration 
observed, suggesting no effect on speed or amount of neurodegeneration 
associated with MPTP intoxication. Similarly, with MPTP intoxication alone or 
HIV infection + MPTP intoxication, TH density within the striatal termini 
decreased 49%, respectively compared to PBS controls (Figure 1C). There were 
no significant differences in microglial reactivity between treatments. Mac-1+ 
counts remained similar between groups (Figure 2A and 2B), indicating that the 
neuroinflammatory response had subsided by day 7. HIV infection did not 
enhance microglial reactivity above that observed with MPTP intoxication alone. 
Taken together, these results indicate that chronic and active HIV infection, as 
determined by viral loads in plasma, did not lead to enhanced nigrostriatal 
degeneration in the inflammatory mouse model of PD. These findings may either 
show either the lack of a synergistic effect causing neuronal loss or a lack of 
interaction between reconstituted human lymphocytes and murine microglia 
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within the humanized system. The small loss of dopaminergic neurons is most 
likely due to the initial neuronal toxicity of the toxic MPTP metabolite, MPP+, 
rather than the ensuing inflammatory cascade associated with immune 
activation. Thus, based on these confounds, we began to explore the use of 
EcoHIV as a model of HIV infection in order to utilize a less complicated and non-
humanized system. The EcoHIV virus has the ability to infect murine cells and 
exhibits neuroinvasiveness, allowing us to utilize non-humanized mouse models 
to test its effects on neurodegenerative disease (Potash et al., 2005).  
 
EcoHIV infection enhances MPTP-induced nigrostriatal degeneration.  
To determine a time course evaluation of EcoHIV infection in normal mice, male, 
C57BL/6 mice were inoculated with EcoHIV for 2, 3, or 4 weeks, followed by 
MPTP intoxication. At the time of sacrifice, brains were collected to assess 
neuronal survival and microglial reactivity following dual insult. Surviving neuron 
numbers were decreased with all treatments when compared to the control group 
(Figure 3A-C). EcoHIV infection alone resulted in a significant decrease at all 
time points decreasing neuron counts from 9556 ± 326 for PBS to 7450 ± 350 at 
2 weeks of infection, 7359 ± 364 at 3 weeks of infection, and 6836 ± 999 after 4 
weeks of infection (Figure 3C). Addition of MPTP intoxication lead to a further 
decrease in neuron numbers at all time points as well, resulting in 5404 ± 671 at 
2 weeks of infection + MPTP, 6238 ± 743 at 3 weeks of infection, and 4103 ± 103 
at 4 weeks of infection + MPTP. Striatal termini were also affected in all treatment 
groups (Figure 3D). At 4 weeks of infection and MPTP intoxication, numbers of 
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surviving dopaminergic neurons were decreased within the substantia nigra, 
when compared to mice treated with PBS, MPTP, or 3 weeks EcoHIV infection + 
MPTP, indicating a synergistic effect with longer periods of viral infection.  
Based on these findings, we sought to elucidate a mechanism for the 
increased neuronal degeneration observed at 4 weeks of infection followed by a 
second insult with MPTP. It was shown that microglial activation and increased 
reactivity are associated with neuronal cell death in the MPTP mouse model of 
PD, so we also quantified numbers of Mac-1+ reactive microglia within the 
ventral midbrain of mice treated with PBS, MPTP, EcoHIV, and EcoHIV + MPTP 
at varying time points (Figure 4A) (Kurkowska-Jastrzebska et al., 1999a). The 
numbers of reactive microglia observed were significantly increased compared to 
PBS controls in MPTP without infection and at 4 weeks of infection followed by 
MPTP intoxication (Figure 4B). The other experimental groups were similar to 
controls. Interestingly, 4 weeks of infection followed by MPTP intoxication 
increased reactive microglial counts nearly 10 fold, increasing counts from 3 ± 
0.3 cells/mm2 in PBS-treated mice to 29 ± 4.1 cells/mm2. These findings support 
the notion that EcoHIV infection exacerbates neuronal degeneration and 
enhances the neuroinflammatory response.  
Furthermore, T cells interact with microglial populations to elicit active 
immune responses (Brochard et al., 2009). Therfore, mice were bled and 
peripheral blood was collected for analysis of changes in lymphocyte populations  
following EcoHIV infection (Figure 5). Flow cytometric analysis indicates that 
CD3, CD4 (Figure 5A and 5D), CD8 (Figure 5B and 5E), and CD25 (Figure 5C 
	  149	  
and 5F) populations remained relatively unchanged over the course of infection 
and remained stable after MPTP intoxication, revealing the lack of a shift in 
number or frequency of T cell populations, suggesting that EcoHIV does not 
result in a diminution of CD4+ T cells as has been noted with HIV infection itself 
(Hong and Banks, 2015).  Also, these results indicate that sufficient levels of 
CD4+ T cells exist to support necessary immune reactions necessary for 
successful neurodegeneration following MPTP intoxication. Moreover, these data 
support the continued use of the EcoHIV infection model rather than HIV 
infection in a humanized model.   
Next, we investigated possible mechanisms for the increased neuronal 
loss and microglial reactivity observed at 4 weeks co-insult. We isolated the 
ventral midbrain of mice following infection at 4 weeks EcoHIV infection alone or 
4 weeks EcoHIV infection followed by MPTP intoxication and isolated total RNA 
to assess changes in inflammatory response gene expression (Figure 6 and 
Figure 7).  Although these results are not significant, they suggest a change in 
the inflammatory response pathway upon co-insult. When compared to EcoHIV 
alone, co-insult resulted in increased gene expression levels of the genes 
encoding for CCR7, CCL2, IFNγ, IL-10, IL-9, and NFκB and decreased levels of 
TLR4 and IL-5 (Figure 6 and 7B). Similarly, when compared to MPTP alone, co-
insult led to an upregulation of, CCL2, IFNγ, IL-10, IL-9, NFκB, TLR4, and IL-5 
(Figure 7A and 7B). These results suggest an interaction between two insults 
causing increased dysregulation in the inflammatory response pathway within the 
ventral midbrain.  
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EcoHIV infection does not affect MPTP-induced neuronal degeneration in 
immunodeficient mice.  
Next, in order to evaluate the role of T cell-mediated neurodegeneration in 
EcoHIV infection, we utilized immunodeficient, non-humanized NSG mice and 
C57BL/6 scid mice. Each set of mice was infected with EcoHIV for 4 weeks, 
followed by MPTP-intoxication. On day 7 post-MPTP, animals were sacrificed 
and brains were harvested. Neuronal survival and microglial reactivity was 
assessed and quantified using stereological analysis. In non-humanized NSG 
mice, when compared to PBS controls, MPTP intoxication lead to a 13% and 6% 
loss in TH+ dopaminergic neurons, indicating that this strain may not be readily 
susceptible to MPTP intoxication (Figure 8A and 8B). This is most likely due to 
the lack of lymphocytes needed for MPTP susceptibility (Benner et al., 2008, 
Brochard et al., 2009). However, EcoHIV infection alone significantly decreased 
neuronal numbers by 26% compared to PBS, suggesting that EcoHIV may have 
a direct effect on dopamine–producing neurons, which is similar to the results 
observed in the immune competent, C57BL/6 strain of mice (Figure 3). Likewise, 
in humanized NSG mice, dopaminergic neuron numbers diminished after 
infection with EcoHIV alone (Figure 8B), further supporting the idea that EcoHIV 
may be directly neurotoxic. However, even though the neuronal cell bodies 
remained intact following MPTP intoxication, striatal termini were not spared 
(Figure 8C). MPTP intoxication significantly deceased the relative TH+ density 
within the striatum compared to PBS controls, whereas EcoHIV infection alone 
did not result in a significant loss of termini. These findings support the idea that 
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striatal termini are more susceptible to MPTP-intoxication and degeneration may 
occur in cell termini prior to the degeneration of neuronal bodies (Burke and 
O'Malley, 2013).  To assess the presence of an inflammatory response, 
microglial populations were also stained and quantified in the same tissues, as 
previously performed. Reactive microglial numbers were significantly increased 
with MPTP intoxication when compared to PBS controls (Figure 9A and 9B); 
however, levels remained far below those observed in co-infection in C57BL/6, 
as shown in Figure 4.  
In studies using immunodeficient, C57BL/6 scid mice, the results observed 
were similar to non-humanized NSG mice. TH+ neuron counts indicate no 
significant decrease in cell number after MPTP intoxication (Figure 10A and 
10C). However, MPTP intoxication still resulted in an 8% and a 24% loss of 
dopaminergic neurons within the substantia nigra (Figure 10C). EcoHIV infection 
alone also led to a 7% loss in cell number, further supporting the concept that the 
virus causes dopaminergic cell death. Similarly, striatal termini in all treatment 
groups were significantly diminshed (Fig 10B and 10D). MPTP intoxication alone 
resulted in a 39% loss of striatal termini, and EcoHIV infection plus MPTP-
intoxication displayed a 52% loss, indicating increased susceptibility of striatal 
termini (Figure 10D). EcoHIV infection alone also resulted in a significant termini 
loss of 20%. The loss in both dopaminergic cell bodies and striatal termini were a 
result of direct MPP+ toxicity and viral neurotoxicity, rather than a resulting 
adaptive immune response generally associated with MPTP intoxication. 
Likewise, microglial populations remained unreactive (Figure 11A). There were 
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no significant changes in reactive microglia numbers among treatment groups 
(Figure 11B). In fact, virtually no inflammatory microglial response could be 
detected.  This is most likely due to the lack of functional T cell populations in 
scid mice. In order for the neuroinflammatory cascade to occur in MPTP, an 
adaptive immune response is necessary (Benner et al., 2008, Brochard et al., 
2009). Collectively, the data using two immunocompromised models help justify 
that an adaptive immune response is needed to achieve significant nigrostriatal 
degeneration in the MPTP model, and that EcoHIV infection alone exhibits a 





Viral infection, specifically HIV infection, affects the CNS and causes 
Parkinson’s-like symptoms (Navia et al., 1986). Post-mortem studies of HIV 
patients also indicate the presence of increased alpha-synuclein and decreased 
dopamine bioavailability, similar to that observed in PD (Kalia and Lang, 2015). 
However, in spite of these similarities, a paucity of scientific literature exists 
investigating the interplay of viral infection and development and/or progression 
of neurodegenerative disease using animal models.  Thus, we investigated the 
potential effects of viral infection on MPTP-induced neurodegeneration utilizing 
two different mouse models of infection, HIV and EcoHIV. Infection of humanized 
mice with HIV-1 prior to MPTP intoxication did not result in enhanced nigrostriatal 
degeneration. The speed or magnitude of degeneration was unaffected, as was 
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the inflammatory response associated with MPTP. These results suggest either 
the lack of a synergistic effect of viral infection with an MPTP-induced lesion or 
that resident mouse microglia and neurons do not successfully interact with the 
humanized immune system. In order to initiate the neurodegenerative cascade in 
MPTP intoxication, MPTP is converted into its neurotoxic form, MPP+. The 
resulting neurotoxicity from MPP+ uptake and binding to complex I of the electron 
transport chain accounts for approximately 10% of the observed neuronal cell 
death (Przedborski et al., 2001). Further death results from the induced pro-
inflammatory microenvironment induced by dying cells and subsequent activated 
microglial responses (Kurkowska-Jastrzebska et al., 1999a). For this response to 
occur, CD4+ cells must be present. Studies from Brochard et al indicate that 
mice lacking CD4+ cells are not susceptible to MPTP intoxication (Brochard et 
al., 2009). Therefore, we hypothesize that the lack of an accelerated 
neurodegenerative response in these studies is due to the lack of human CD4+ 
cell interaction with mouse microglial cells. The complexity and compounding 
effects of interspecies immune interaction make our findings difficult to interpret 
definitively. Our studies using immunodeficient models also help justify the 
importance of an adaptive immune response in the MPTP model of PD (Benner 
et al., 2008). In mice lacking a functional adaptive immune system, MPTP 
intoxication resulted in a minor loss in dopaminergic neuron number. This is 
presumably due to the effect of MPTP being metabolized into its toxic form, 
MPP+. MPP+ inhibits complex 1 of the electron transport chain causing cell 
death (Jackson-Lewis and Przedborski, 2007).  This accounts for the initial drop 
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in cell viability. The secondary inflammatory reaction due to reactive microglia 
that ensues following initial neuronal loss continues the neurotoxic cascade. 
Without CD4+ T cells, this cascade does not occur (Benner et al., 2004, 
Brochard et al., 2009). Likewise, if CD4+ T cells are not functional, as in NSG 
and scid mice, a successful secondary reaction is not engaged. This also was 
observed in the humanized system. The lack of interaction between mouse 
microglia and human lymphocytes may account for the lack of MPTP 
susceptibility.  Thus, taking these findings into account, we chose to utilize a less 
complex and species-specific model using EcoHIV infection in an 
immunocompetent, non-humanized system to address this question.  
 EcoHIV/NDK is a chimeric virus on the backbone of HIV-1 clade D, NDK, 
containing the gp80 envelope protein of murine leukemia virus instead of gp120 
(Potash et al., 2005). It has been shown to infect murine cells, replicate in murine 
lymphocytes and macrophages, induce antiviral immune responses, invade the 
CNS, and increase inflammatory mediators in the brain. Use of EcoHIV 
inoculation to mimic HIV infection in humans is efficient and reproducible, and 
offers a suitable testing paradigm to study the neurodegenerative effects of 
infection (Potash et al., 2005, Hadas et al., 2007).  Potash et al. showed that 
EcoHIV enters and establishes an infection in the mouse brain as early as 3 
weeks after inoculation. The infected brains also express inflammatory factors 
including C3, IL-1B, STAT-1, and IL-6 indicating an active infection and anti-viral 
response within the brain (Hadas et al., 2007). The mechanism of the observed 
neuroinvasiveness of EcoHIV lies in its ability to increase BBB permeability after 
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2 weeks of infection (Jones et al., 2016). EcoHIV infection results in decreased 
expression of tight junction proteins, ZO-1 and claudin-5, within the BBB, 
allowing virus to actively enter the brain. Similarly, increased BBB permeability 
through the weakening of tight junctions is a mechanism used by HIV, further 
supporting the use of EcoHIV infection to mimic HIV infection (Dallasta et al., 
1999).  In our findings, we did not observe a significant decrease in neuron loss 
until 4 weeks of EcoHIV infection. This finding is most likely due to the time it 
takes for virus to enter the brain, travel to vulnerable sites, and successfully 
replicate. It also appears that with co-insult, microglial reactivity is increased at 
this time point as well. Microglia have the capacity to be infected causing them to 
become reactive (He et al., 1997, Bissel and Wiley, 2004). Likewise, EcoHIV may 
also have the capacity to infect microglia or microglia may be engulfing viral 
particles and proteins such as p24 or tat. A second possibility would be the effect 
of direct neuronal death, causing resident microglia to become activated as they 
sample the microenvironment (Kreutzberg, 1996). A third possibility would be the 
infiltration of infected peripheral macrophages across the leaky BBB to areas of 
degeneration (McArthur et al., 2005). Increased numbers of infiltrating cells 
would yield higher numbers of reactive Mac-1+ cells, as we observed. Further 
studies should be performed utilzing co-staining for Mac-1+ and viral proteins 
such as p24 and/or isolation by laser capture microdissection to determine 
whether microglial populations are productively infected.  
 With the significant increase in both neuronal death and microglial 
reactivity at 4 weeks EcoHIV infection, followed by MPTP intoxication, we 
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assessed potential changes in the inflammatory response cascade. Although the 
changes observed did not reach statistical significance, small changes in gene 
expression can lead to large fluctuations in protein content, thus giving rise to a 
more profound response. Therefore, these changes may be important its 
mechanism of action. We observed changes in gene expression of both pro- and 
anti-inflammatory mediators with EcoHIV infection followed by MPTP-
intoxication, indicating a general dysregulation of the inflammatory response. 
Increases in pro-inflammatory mediators including CCL2, IFNγ, NFκB, TLR4, and 
IL-5 were observed, but increases in anti-inflammatory mediators, IL-9 and IL-10, 
were also detected. Previously, HIV-1 infection was linked to increases in the 
pro-inflammatory cytokines, IL-5 and IFNγ (Navikas et al., 1994, Resino et al., 
2000).  The observed increase in CCL2 here may be linked to BBB permeability. 
Studies show that CCL2 mediates the transmigration of HIV-infected leukocytes 
across the BBB, resulting in viral neuroinvasiveness (Eugenin et al., 2006). 
Likewise, this may indicate a potential mechanism of CNS invasion with EcoHIV 
infection. HIV infection also activates NFkB and TLR4, which correlates with 
increased expression observed in our EcoHIV study (Fiume et al., 2012, 
Hernandez et al., 2012). Increased expression and activation of the NFkB 
pathway would ultimately lead to increases in overall pro-inflammatory gene 
levels (Fiume et al., 2012). Similarly, changes in TLR4 levels could affect the pro-
inflammatory response by promoting viral replication and disease progression 
(Hernandez et al., 2012). Overall, changes in protein levels based on these gene 
changes may give rise to enhanced microglial reactivity observed after 4 weeks 
	  157	  
co-infection, as well as led to an enhanced inflammatory microenvironment, thus, 
further exacerbating neurodegeneration. On the other hand, the upregulation of 
anti-apoptotic and anti-inflammatory interleukins may result from counteracting 
the neuroinflammatory response associated with infection in order to maintain a 
homeostatic balance within the brain.  For instance, IL-9 has been linked to 
protecting cortical neurons and thymic lymphoma cells against apoptosis 
(Renauld et al., 1995, Fontaine et al., 2008). The upregulation of this interleukin 
would serve to decrease neuronal cell death associated with viral infection and 
MPTP intoxication.  Similarly, IL-10 is needed for an anti-inflammatory response 
and is often secreted to suppress an overactive pro-inflammatory response, like 
that observed in MPTP intoxication or viral CNS infection (Kwon and Kaufmann, 
2010).  
 Interestingly, EcoHIV viral infection alone yielded neuronal death in both 
immunocompentent and immunodeficient mice, indicating a direct effect of 
EcoHIV on the dopaminergic system that does not require cell-mediated immune 
responses. Until recently, in vivo and in vitro studies of neuronal infection have 
not yet yielded few compelling results. Some studies have shown that various 
neuronal subsets display the appropriate co-receptors for viral infection, such as 
CXCR4, CCR5, and CCR3 (Lavi et al., 1997, Rottman et al., 1997, Sanders et 
al., 1998). CD4 has also been detected on some neuron types (Funke et al., 
1987). Also, multiple studies have shown that neuronal exposure to gp120 
directly induces neuronal apoptosis (Brenneman et al., 1988, Xu et al., 2004). 
However, it should be noted that EcoHIV does express gp120, as it has been 
	  158	  
replaced by gp80, and the effect that gp80 on neuronal survival has not yet been 
tested. To our knowledge, no study has explored the effect of HIV or EcoHIV 
infection on neurons within the substantia nigra or ventral midbrain specifically. 
This brain region exhibits increased susceptibility to neuronal cell death itself, so 
the presence of virus or viral particles may lead to increased neuronal cell death 
that may not be presently observed in other regions of the brain (Naoi and 
Maruyama, 1999, Sulzer and Surmeier, 2013, Haddad and Nakamura, 2015). 
This neuronal susceptibility to viral infection could, in turn, lead to the likelihood 
of developing PD or Parkinson-like symptoms later.   
A second possibility for the neuronal death detected in this group is the 
presence of activated astrocytes within the lesioned region. Results utilizing in 
vitro models of astrocyte infection using cell lines indicate that they can be 
infected (Cheng-Mayer et al., 1987). In vivo findings show that cells with 
astrocyte morphology stain positive for p25, nef, and viral particles, indicating 
that they may be infected with HIV (Pumarola-Sune et al., 1987, Anderson et al., 
2003). Cells immunostained with GFAP also tested positive for HIV gag DNA, 
furthering supporting the notion that astrocytes may have the potential to be 
actively infected (Trillo-Pazos et al., 2003).  In these studies, we did not examine 
the astrocyte population, but this cell type may be important in the observed 
neuronal cell death. Astrocytes are important generators of neuroprotective 
mediators, such as nerve growth factor (NGF) and glial-derived neurotropic factor 
(GDNF), and infected and/or dying astrocytes could result in surrounding 
neurodegeneration (Belanger and Magistretti, 2009).     
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 As stated previously, MPTP intoxication helps to generate a 
neuroinflammatory response, similar to that observed in human PD (Kurkowska-
Jastrzebska et al., 1999a, Hirsch et al., 2012, Kalia and Lang, 2015). It also 
mimics dopaminergic neuronal loss associated with PD progression (Przedborski 
et al., 2001). However, it does not mimic all aspects of PD. For instance, this 
model of MPTP intoxication is acute and does not simulate the chronic and 
progressive nature of human disease (Kurkowska-Jastrzebska et al., 1999a, 
Przedborski et al., 2000, Przedborski et al., 2001). Thus, it should be appreciated 
that the dual effect observed using this model may not be observed in other more 
chronic and progressive disease models, such as chronic MPTP intoxication or 
alpha-synuclein overexpression models (Mochizuki et al., 2006, Meredith et al., 
2008). Nonetheless, these findings suggest a potential effect of HIV/EcoHIV 
infection on neuronal survival, especially those neurons within the dopaminergic 
system. This negative effect can be partially attributed to enhanced microglial 
reactivity and changes in the inflammatory response pathway. If viral infection 
can initiate neurodegeneration in areas primarily affected in PD, then it is likely 
that viral infection could potentially lead to formation of PD later in life or at least 







4.6 Figures  
 
Figure 1. Co-administration of HIV and MPTP intoxication does not affect 










Figure 1. Co-administration of HIV and MPTP intoxication does not affect 
neuronal degeneration in humanized mice. A. Representative images of the SN 
and STR of humanized NOD/scid-IL-2Rγc null mice treated with MPTP alone or 
inoculated with HIV for 3 weeks or 4 weeks followed by MPTP intoxication. B. 
Total numbers of surviving dopaminergic neurons (TH+Nissl+) and 
nondopaminergic neurons (TH-Nissl+) in the SN following MPTP intoxication, or 
HIV infection followed by MPTP intoxication. Percentages of spared 
dopaminergic neurons are displayed on the representative bar for each 
treatment. C. Relative TH+ density within striatal termini of dopaminergic 
neurons. Differences in means (± SEM, n = 3-6) were determined where P < 0.05 









Figure 2. HIV infection does not increase microglial reactivity after MPTP 















Figure 2. HIV infection does not increase microglial reactivity after MPTP 
intoxication in humanized mice. A. Representative images Mac-1+ microglia 
within the ventral midbrain of humanized NOD/scid/IL-2Rγc null mice treated with 
MPTP alone or inoculated with HIV for 3 weeks or 4 weeks followed by MPTP 
intoxication. B. Quantification of reactive microglia cells/mm2 located within the 











Figure 3. EcoHIV co-infection exacerbates MPTP-induced neurodegeneration. A. 
Photomicrographs of TH+Nissl+ neurons in the substantia nigra (SN) in C57/Bl6 
mice treated with PBS, MPTP, or EcoHIV infection at multiple time points prior to 
MPTP intoxication.  Sections were immunostained with anti-TH and HRP-
conjugated secondary antibody and visualized with DAB. B. Photomicrographs of 
TH+ striatal termini (STR) following PBS, MPTP or EcoHIV coinfection. C. Total 
numbers of surviving dopaminergic neurons (TH+Nissl+) and nondopaminergic 
neurons (TH-Nissl+) in the SN following MPTP treatment alone, EcoHIV infection 
alone, or EcoHIV infection followed by MPTP intoxication. Percentages of spared 
dopaminergic neurons are displayed on the representative bar for each 
treatment. Differences in means (± SEM, n = 8) were determined where P < 0.05 
compared to PBS (a), MPTP (b), 3 wk EcoHIV + MPTP (c), and 4 wk EcoHIV + 
MPTP (d). D. Relative TH density of striatal dopaminergic termini following 
infection. Differences in means (± SEM, n = 8) were determined where P < 0.05 

















Figure 4. EcoHIV infection leads to increased microglial reactivity. A. 
Representative photomicrographs of Mac-1+ microglia with the SN of C57/Bl6 
mice treated with PBS, MPTP, EcoHIV, or EcoHIV + MPTP over time (4x image, 
inset = 40x image). B. Quantification of reactive microglia within the SN 7 days 
post MPTP intoxication. Sections were stained using an anti-Mac-1 antibody, 
followed by an HRP-conjugated secondary antibody and DAB. Numbers of 
amoeboid microglia were assessed using stereological analysis. Differences in 
means (± SEM, n = 8) were determined where P < 0.05 compared with groups 






















Figure 5. EcoHIV infection does not affect peripheral T cell populations. C57/Bl6 
mice were inoculated with EcoHIV for 2-4 weeks and then intoxicated with 
MPTP. Mice were assessed for frequencies of CD3+CD4+ (A), CD3+CD8+ (B), 
and CD4+CD25+FoxP3+ (C). Differences in means (± SEM, n = 8) were 
determined where P < 0.05 compared with groups treated with PBS (a). D-F. 
















Figure 6. EcoHIV infection alone leads to changes in the inflammatory response.  
RT-PCR data shows gene expression changes in the ventral midbrains of 
C57BL/6 mice inoculated with EcoHIV followed by MPTP intoxication (n = 3-4). 
Fold changes were determined using SABioscience RT2 Profiler PCR Array Data 
Analysis software, version 3.5.  Changes in the inflammatory response pathway 
associated with EcoHIV infection alone vs EcoHIV + MPTP co-treatment. 
Resulting gene networks from each treatment group were analyzed using Qiagen 
Ingenuity Pathway Analysis. Pink coloration indicates a modest increase in 
expression and red indicates a profound increase in expression. Green coloration 
indicates a decrease in expression. Nodes lacking color indicate a molecule 




Figure 7. EcoHIV co-infection results in gene changes in the inflammatory 





Figure 7. EcoHIV co-infection results in gene changes in the inflammatory 
response pathway. Fold changes were determined using SABioscience RT2 
Profiler PCR Array Data Analysis software, version 3.5. A. Changes in the 
inflammatory response pathway associated with MPTP intoxication alone vs 
EcoHIV + MPTP co-treatment are shown in the above pathway. Resulting gene 
networks from each treatment group were analyzed using Qiagen Ingenuity 
Pathway Analysis. Pink coloration indicates a modest increase in expression and 
red indicates a profound increase in expression. Green coloration indicates a 
decrease in expression. Nodes lacking color indicate a molecule involved in the 
pathway, but not identified in the PCR data set. B. Fold changes for differentially 
regulated mRNA levels with EcoHIV + MPTP treatment normalized to either 




Figure 8. EcoHIV and MPTP co-administration does not exacerbate neuronal 










Figure 8. EcoHIV and MPTP co-administration does not exacerbate neuronal 
degeneration in non-humanized NSG mice. A. Photomicrographs of TH+Nissl+ 
neurons in the substantia nigra (SN) and striatum (STR) in non-humanized or 
humanized NOD/scid-IL-2Rγc null mice treated with PBS, MPTP, EcoHIV 
infection, or EcoHIV + MPTP co-administration. Animals were infected for 3 
weeks prior to MPTP intoxication. B. Total numbers of surviving dopaminergic 
neurons (TH+Nissl+) and nondopaminergic neurons (TH-Nissl+) in the SN 
following MPTP treatment alone, EcoHIV infection alone, or EcoHIV infection 
followed by MPTP intoxication. Percentages of spared dopaminergic neurons are 
displayed on the representative bar for each treatment. Differences in means (± 
SEM, n=3-4) were determined where P<0.05 compared to PBS (a). C. Relative 
TH density of striatal dopaminergic termini following infection and MPTP 
intoxication. Differences in means (± SEM, n = 3-4) were determined where P < 







Figure 9. Microglial reactivity following EcoHIV and MPTP co-administration is 
















Figure 9. Microglial reactivity following EcoHIV and MPTP co-administration is 
not enhanced in non-humanized NSG mice. A. Representative photomicrographs 
of Mac-1+ microglia within the midbrain following EcoHIV infection, MPTP 
intoxication, or EcoHIV infection and MPTP intoxication (4x image, inset = 40x 
image). B. Quantification of reactive microglia within the SN 7 days post MPTP 
intoxication. Differences in means (± SEM, n = 3-4) were determined where P < 














Figure 10. Immunodeficient C57BL/6 scid mice are not susceptible to MPTP 
intoxication. A. Photomicrographs of TH+Nissl+ neurons in the substantia nigra 
(SN) and striatum (STR) (B) in C57BL/6 scid mice treated with PBS, MPTP, 
EcoHIV infection, or EcoHIV + MPTP co-administration. Animals were infected 
for 3 weeks prior to MPTP intoxication. C. Total numbers of surviving 
dopaminergic neurons (TH+Nissl+) and nondopaminergic neurons (TH-Nissl+) in 
the SN following MPTP treatment alone, EcoHIV infection alone, or EcoHIV 
infection followed by MPTP intoxication. D. Relative TH density of striatal 
dopaminergic termini following infection and MPTP intoxication. Differences in 
means (± SEM, n = 5) were determined where P < 0.05 compared to PBS (a) or 









Figure 11. MPTP intoxication does not lead to an inflammatory response in 















Figure 11. MPTP intoxication does not lead to an inflammatory response in 
C57BL/6 scid mice. A. Representative midbrain images stained with Mac-1 
following PBS, MPTP, EcoHIV + MPTP, or EcoHIV treatment. B. Quantification 
of Mac-1+ microglial cells/mm2 within the substantia nigra. No significant 






















Collectively, the data presented in this dissertation delineate a link between viral 
infection and neurodegenerative disease progression, a potential therapeutic 
agent for combating disease progression, a mechanism to track immune-
modulating therapies in vivo using bioimaging techniques, and a shift in the 
current treatment paradigms for PD. First, PD has been associated with many 
risk factors, including male gender, aging, exposure to pesticides, and genetics 
(Kalia and Lang, 2015). It has also been suggested that viral infections may be 
linked to disease onset and progression (Jang et al., 2009, Moulignier et al., 
2015). However, this has not been extensively studied or definitively linked. 
Thus, the studies presented here indicate that viral infection can, in fact, act 
directly on susceptible brain regions involved in the development of PD. Our data 
show the idea that viral invasion into the CNS results in direct neurotoxicity of 
dopaminergic cell bodies along with their striatal termini following infection with a 
chimeric murine virus that simulates HIV infection in humans. This also indicates 
that active viral infection potentiates and/or accelerates neurodegeneration, as 
observed in dual insult studies. One possibility for these neurotoxic findings 
would be the direct infection of dopaminergic neurons themselves, as discussed 
previously. Other possibilities include viral effects on surrounding astrocytes and 
microglia, the BBB, or peripheral immune populations.  
Astrocytes are a glial subset that is normally involved in the maintenance 
of brain homeostasis and can also potentiate or mitigate neuroinflammatory 
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circuits. In the presence of hyper-activated microglia, astrocytes can directly 
participate in inflammatory reactions to secrete pro-inflammatory mediators such 
as IL-6 and TNFα, upregulate expression of FasL, and diminish trophic activities 
that eventually lead to the acquisition of a neurotoxic phenotype that exacerbates 
neurodegeneration (Dong and Benveniste, 2001). Similarly, while microglia that 
exist in an alternatively-activated (M2) state are generally considered 
neuroprotective and release anti-inflammatory cytokines as well as neurotrophic 
factors, under neuroinflammatory conditions, microglia can readily switch to an 
M1 cytotoxic phenotype. The phenotypic switch is accompanied with 
upregulation of oxidative stress-generating enzymes such as iNOS and NADPH 
oxidase; increased levels of ROS and RNS; and secretion of neurotoxic levels of 
proinflammatory cytokines including IL-1β, TNFα, and IFN-γ (Liao et al., 2012) 
that lead to secondary neuronal damage (Walsh et al., 2014). Similarly, apart 
from reactive glia, viral infection also has the capacity to increase BBB 
permeability, allowing both cellular and non-cellular immune mediators to enter 
the normally immune privileged site (Dallasta et al., 1999). Chronic viral infection 
causes uprgegulation of cytotoxic mediators as an anti-viral response, and 
progressive HIV disease is also associated with systemic and chronic immune 
activation, leading to B-cell activation, increased T cell turnover, increased 
frequencies of activated T cell phenotypes, and increased levels of 
proinflammatory cytokines and chemokines in peripheral blood and serum 
(Beltran et al., 2015). With a compromised BBB, these cytotoxic and neurotoxic 
mediators, such as CD8+ CTLs, activated CD4+ cells, activated macrophages, or 
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proinflammatory cytokines, may enter the brain, ultimately contributing to the 
neuroinflammatory microenvironment associated with both CNS viral infection 
and PD.  
The presence of T cells within the brain of PD patients is higher than those 
typically found in the CNS which suggests a role of T cells beyond normal 
surveillance (Stone et al., 2009). For instance, during viral infections and 
neuroinflammation, MHC II is upregulated by microglia, whereas MHC I is 
constitutively expressed by most cells including oligodendrocytes, neurons, 
microglia, and endothelia (Redwine et al., 2001). Therefore, neurons in a pro-
inflammatory environment, such as that associated with PD or other 
neurodegenerative diseases and viral infection, could serve as targets for CD8+ 
T cells with direct killing of neurons through antigen-specific interactions 
mediated by cytotoxic granzyme release. For instance, in animal models of MS, 
studies demonstrated that CD8+ CTLs form stable adhesions with neurites in an 
MHC I peptide-dependent fashion. Furthermore, MBP-specific CD8+ T cells 
induce direct tissue damage when injected into immunocompromised recipient 
mice (Neumann et al., 2002). Likewise, increased numbers of CD8+ T cells are 
found in close proximity to activated microglia in post mortem studies of PD 
patients (Brochard et al., 2009). However, their role in PD and PD animal models 
remains unknown. Based on past studies, the probability exists that, apart from 
CD4+ T cells, CD8+ Teffs may also play a role in inflammation-associated 
neurodegenerative disorders. However, in our studies, we did not focus on the 
potential detrimental roles of CD8+ CTLs in CNS viral infection and PD 
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progression. This cell types, along with chronically activated glia, may be 
potentiating some of the neuronal loss observed in the dual infection studies. 
Nonetheless, based on our findings, there is a synergistic effect of infection and 
MPTP-induced neuronal loss. The exact mechanism and/or mechanisms have 
not yet been deciphered, but our studies suggest a role for T cell-mediated 
neurodegeneration and a dysregulation in the neuroinflammatory response. 
Thus, in patients living with HIV and Parkinson’s-like symptoms, therapies aimed 
at suppressing the neuroinflammatory condition and over-activation of immune 
mediators may be of clinical benefit. 
Second, the studies discussed here point to a potential therapeutic agent 
that merits further study for both the treatment of PD alone and PD patients living 
with HIV comorbidities or vice versa. VIP is an endogenous peptide that is widely 
expressed and secreted by cells in the immune system, endocrine system, 
central nervous system, and peripheral nervous system (Delgado and Ganea, 
2003a, Gonzalez-Rey et al., 2007). It acts as a neuropeptide, exerting a wide 
variety of biological effects, including neurotransmission and neuroprotection 
(Gonzalez-Rey et al., 2007). However, it is difficult to harness its effects for 
clinical use due to its rapid degradation and short half-life in vivo (Domschke et 
al., 1978). Thus, we synthesized an analog of VIP, LBT-3627, with increased 
receptor selectivity and improved half-life. When utilized in an inflammatory 
model of PD, LBT-3627 resulted in significant dopaminergic neuron sparing, 
decreased microglial reactivity, decreased astrocyte reactivity, decreased pro-
inflammatory cytokine production, and a shift in inflammatory T cell phenotypes 
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to suppressive subsets. Each of these findings helps to strengthen its potential 
clinical utility for the treatment of neuroinflammatory and neurodegenerative 
disorders. Previously, our lab utilized another known immune modulator, GM-
CSF, in preclinical models, and observed similar effects (Kosloski et al., 2013, 
Kelso et al., 2015). Based on its pre-clinical efficacy and neuroprotective profile, 
a phase I clinical trial for its use in patients with PD was initiated (Gendelman et 
al., 2017). GM-CSF treatment yielded suggested improved motor function and 
cortical motor electrical activities, as well as modulated immune functions and 
changes in serum metabolites. GM-CSF treatment also corrected known PD-
associated Treg dysfunction, potentially contributing to the observed improved 
motor outputs.  However, these promising therapeutic results were paralleled by 
the development of multiple adverse events, including injection site reactions, 
increased white blood cell counts, upper torso and extremity bone pain, feelings 
of “chest tightening”, stroke, and vasculitis. Many of these reactions anticipated 
with extended use of GM-CSF, from studies in which GM-CSF is utilized to 
reconstitute the immune system following chemotherapy (Arellano and Lonial, 
2008).  From a clinical perspective, it would be beneficial to develop a treatment 
that utilizes similar immune-mediated mechanisms, but does not have these 
associated untoward side effects and does not require reconstitution of the entire 
immune system to achieve its neuroprotective effects. LBT-3627 meets these 
standards. Along with its neuroprotective potential, treatment with LBT-3627 
resulted in an increase in GM-CSF gene transcript within the entire CD4+ T cell 
population, yet it did not modulate the number of T cells observed. This suggests 
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that LBT-3627 has the potential to mediate the neuroprotective activities that may 
be associated with GM-CSF treatment, without having to treat with GM-CSF 
protein itself for an extended amount of time. Clinically, this may benefit PD 
patients and may result in decreased adverse events associated with current 
immunotherapy treatments.   
Previous studies utilized native VIP for neuroprotection from HIV toxicity 
(Brenneman et al., 1988, Brenneman et al., 1999, Brenneman et al., 2000, Zusev 
and Gozes, 2004). Various studies have shown that VIP treatment prevents HIV-
1-induced neuronal death (Brenneman et al., 1988, Brenneman et al., 1999). 
This protection is partially mediated through VIP-associated signaling within 
astrocytes. When astrocyte and cortical neuron cultures were treated with VIP, 
there was an increase in macrophage inflammatory protein-1α (MIP-1α), beta-
chemokine, and RANTES (Brenneman et al., 1999, Brenneman et al., 2000). 
This chemokine upregulation blocks receptor interactions that are needed for 
viral entry and toxicity, resulting in neuronal survival. Likewise, when VIP binds to 
the VIPR2 on astrocytes, it induces changes in activity-dependent 
neuroprotective protein (ADNP), which is associated with cell survival and 
development, further supporting the neuroprotective effects of VIP that could be 
achieved by targeting VIPR2, similar to our data with LBT-3627 treatment (Zusev 
and Gozes, 2004). Interestingly, activated CD4+ T cells in HIV infection also 
display elevated levels of VIPR2, thus, targeting this receptor may help to limit 
immune activation in the CD4+ T cell subset in a selective manner (Ipp et al., 
2014).  VIP-mediated signaling through VIPR2, rather than VIPR1, results in an 
	  188	  
immunosuppressive profile and shift in T cell phenotypes, as observed in our 
studies. Thus, use of LBT-3627 in our dual insult studies would be expected to 
counteract the enhanced neurodegeneration observed. LBT-3627 would likely 
lead to a neuroprotective phenotype in this case, making its clinical utilization 
more appealing.  
Along the same vein, VIP has been used in many other inflammatory and 
neurodegenerative conditions, including rheumatoid arthritis, inflammatory bowel 
disease, AD, MS, Huntington’s disease, endotoxin shock syndrome, and Crohn’s 
disease. Previous works show that VIP protects against neurotoxicity by 
decreasing microglial activation and degradation of neuronal cell bodies and 
termini in both MPTP- and 6-OHDA-induced injuries (Offen et al., 2000, Delgado 
and Ganea, 2003b, Reynolds et al., 2010, Korkmaz et al., 2012, Tuncel et al., 
2012). The protective mechanism arises from altering the cytokine response into 
an anti-inflammatory profile by downregulation of proinflammatory mediators 
such as TNFα, IL-6, and IL-12 (Vial and Descotes, 1995b, Delgado et al., 1999, 
Chen et al., 2008, Reynolds et al., 2010), and by protecting neuronal tissue 
against oxidative stress and apoptosis by reducing lipid peroxidation and DNA 
fragmentation (Tuncel et al., 2012). Likewise, as stated previously, it also 
mediates protective effects via modulation of astrocyte activity and neurotrophin 
secretion and through the induction of immunosuppressive Treg populations 
(Zusev and Gozes, 2004, Fraccaroli et al., 2015).  
Here, we propose the idea that VIP-induced transformation of T cell 
populations and enhanced Treg-mediated suppression are one of the main 
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mechanisms of its neuroprotective capacity. However, contrary evidence 
suggests that Tregs are detrimental to cell survival and can enhance 
neurodegeneration. Notably, this was shown during the acute phase of 
experimental stroke in which Treg expansion exacerbated brain injuries 
(Schuhmann et al., 2015). However, it should be noted that the acute phase is a 
relatively short span of time and is during a period consisting of an intense initial 
inflammatory response. Throughout this period, such an innate response in 
affected brain tissue is required to enhance phagocytosis of cellular debris, which 
may explain the coincident increase in inflammation associated with Treg 
infiltration. In contrast, another study demonstrated that IL-10-producing Tregs 
elicited a reduction in infarct size and attenuated the inflammatory response 
associated with ischemic stroke (Na et al., 2015). Likewise, another group 
showed that brain-derived neurotrophic factor (BDNF)-positive Tregs are 
increased in stroke patients, and this increase is associated with improved 
clinical outcomes (Chan et al., 2015). Further support of Tregs as 
neuroprotective cells is observed in tests using an experimental model of ALS 
and in human disease. Tregs were shown to modulate disease progression and 
to actively contribute to a neuroprotective cascade through their interactions with 
microglial populations (Beers et al., 2011, Zhao et al., 2012, Henkel et al., 2013). 
Similarly, a study was carried out using bee venom phospholipase A2 to protect 
dopaminergic neurons through the modulation of the inflammatory response 
associated with MPTP intoxication that occurred following Treg treatment 
transfer. When endogenous Tregs were blocked with anti-CD25 antibody, the 
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protective phenotype was no longer observed, indicating their specific 
involvement in neuroprotection (Chung et al., 2015). Collectively, these findings, 
along with our data, further support a direct neuroprotective role of Tregs in 
neurodegenerative disorders.  
However, it should be appreciated that induction of Treg subsets may 
simply be a primary endpoint in a cascade of beneficial immunological changes. 
Tregs are not the only suppressive cell type within the immune system. Other 
types of immunosuppressive agents include CD8+ regulatory T cells, regulatory 
B cells, myeloid-derived suppressor cells (MDSC), and tolerogenic DCs (McHugh 
and Shevach, 2002, Gabrilovich and Nagaraj, 2009, Wang and Alexander, 2009, 
Rosser and Mauri, 2015). VIP induces and mediates its actions via these cell 
types as well as though the induction of Tregs (Chorny et al., 2005, Chorny et al., 
2006, Gonzalez-Rey et al., 2006a, Li et al., 2015).  
DCs are a heterogeneous population of APCs that contribute to innate 
immunity and initiate the adaptive immune response associated with 
inflammation and autoimmunity. However, apart from this, DCs also play an 
important role in maintaining immune homeostasis and immune tolerance 
(Mildner and Jung, 2014). Unlike classical DC function, tolerogenic DCs should 
not stimulate T cell proliferation or inflammatory cytokine production. Instead, 
they should act by suppressing the immune response and the effector 
populations required for the response. In support of this, VIP treatment regulates 
DC differentiation by causing an upregulation of CD86 in immature DCs and a 
downregulation of CD80 and CD86 in LPS-stimulated DCs (Chorny et al., 2006). 
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Also, induced CD4+ T cells by VIP-treated immature DCs exhibit an anti-
inflammatory Th2 phenotype. Another study found that VIP induces tolerogenic 
DCs that cause surrounding CD4+ T cells to release anti-inflammatory cytokines 
such as IL-10 and TGFβ, indicating the formation of a regulatory subset rather 
than an effector population (Chorny et al., 2005). Likewise, in human studies, VIP 
treatment generated tolerogenic DCs that induced both CD4+ Tregs and CD8+ 
Tregs, further supporting the idea that signaling via VIPRs is involved in the 
generation of multiple immunosuppressive subsets (Gonzalez-Rey et al., 2006a).  
Additionally, VIP also has the capacity to induce and generate myeloid-
derived suppressor cells (MDSCs) (Li et al., 2015). MDSCs are an important 
population of regulatory cells within the innate immune system (Zhao et al., 
2016). They have been linked to cancer pathogenesis due to their 
immunosuppressive function (Hoechst et al., 2008, Fujimura et al., 2012). These 
functions are mainly mediated through increased production of arginase, TGFβ, 
IL-10, and IDO (Zhao et al., 2016), ultimately leading to the crosstalk between 
MDSCs and Tregs. Therefore, we suggest that the observed regulatory T cell 
induction and shift in inflammatory state following LBT-3627 treatment may also 
be linked to changes in MDSC and tolerogenic DC populations, as well as 
through a direct interaction with T cells. For that reason, it would be beneficial to 
evaluate other regulatory cell populations following treatment to obtain a better 
understanding of shifts in the immune cascade in response to VIPR agonism.  
Such studies could yield additional potential clinical targets for the treatment of 
PD and other neuroinflammatory conditions.  
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Third, clinical diagnosis of PD is mainly limited to the associated motor 
dysfunction linked to neuronal loss along the nigrostriatal axis (Olanow et al., 
2009). However, this aberrant motor read out does not present until 50-70% of 
the neurons are lost. The slowly progressive nature of the disease makes early 
detection difficult, and currently, diagnostic tests or clinical biomarkers for early 
recognition of the disease are lacking (Kalia and Lang, 2015). Therefore, the 
studies in Chapter 3 focused on utilizing bioimaging to track not only 
neuroinflammation associated with disease progression over time, but to 
evaluate treatment efficacy using LBT-3627 in a non-invasive manner. 
Collectively, our results confirm the ability of MEMRI to detect neurodegeneration 
in areas of brain inflammation, as well as to monitor the success of an anti-
inflammatory and immune-modulating therapy in vivo. MEMRI can be used to 
identify brain subregions where inflammation is active and may also be useful for 
longitudinal measurement of inflammation in rodent models of neuroinflammatory 
disease, providing measurement tools to evaluate putative neurotherapeutics. 
However, Mn2+ has been linked to neurotoxicity itself, potentially making it unsafe 
for use in humans (Olanow, 2004). Thus, further examination into bioimaging 
techniques suitable for human use needs to be carried out. Nonetheless, the use 
of MEMRI in animal models allows non-invasive tracking of glial and neuronal 
populations in response to treatment and neuroinflammatory insults, supporting 
the idea that bioimaging, such as MRI, PET/SPECT, or MEG, could potentially be 
used to diagnose disease, follow disease progression, or track treatment efficacy 
in the clinical setting.  
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Lastly, progressive neurodegenerative disorders, such as PD, present a 
major challenge for developing treatments because onset of the disease may be 
unknown, and the exact mechanism of disease initiation is poorly understood. 
However, neuroinflammation associated with activated microglial responses and 
adaptive immune aberancies are widely considered to participate in the 
pathogenesis of PD, making them potential suitable targets. The pro-
inflammatory cytokines, chemokines, ROS, and RNS secreted by reactive 
microglia trigger neurotoxic cascades that have detrimental effects within the 
CNS by exacerbating neuronal lesions. Thus, therapies targeting 
neuroinflammation either directly or indirectly should be explored. Many anti-
inflammatory agents and immune modulating compounds discussed in the 
introduction share this commonality and have shown promising results in 
experimental models of the disease. However, even with their success in animal 
models, clinical advances using these agents are limited. This may be due to the 
fact that no animal model of PD encompasses all aspects of PD. Although some 
therapies have shown the potential to be translated into a clinical setting, they 
may not be as successful in treating patients with progressing PD. In acute, 
inflammatory models of PD, targeting inflammation specifically using anti-
inflammatory agents has been shown to be neuroprotective, but with the multi-
factorial and slowly progressing nature of PD in humans, simply targeting one 
aspect may not be effective. Perhaps a combinatorial approach that targets many 
aspects of the disease and modifies disease microenvironment may be better 
suited for PD therapy.  
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One potential way of achieving this is by modulating the innate and 
adaptive immune system, as well as shifting peripheral T cell populations from 
pro-inflammatory, activated Teffs to anti-inflammatory phenotypes by utilizing 
agents that enhance Treg-mediated suppression of the immune response, such 
as LBT-3627. The data presented here, using a Treg-mediated therapy, 
document considerable progress toward improving disease outcomes in models 
of nigrostriatal degeneration. Some of the mechanisms by which the immune 
system can be used to target and control neuroinflammation are now realized. 
The therapeutic potential of immunomodulating therapies is an exciting advance 
and raises real possibilities for successfully combating disease and changing the 
course of PD pathogenesis. Thus, further pre-clinical exploration into the 
development of LBT-3627 as a neuroprotective agent should be carried out, with 
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